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Nitric oxide (NO) is a gaseous signaling molecule that plays a role in cardiac contraction 
and relaxation. One of the pathways of NO signaling is through S-nitrosylation, which is 
the covalent attachment of a NO moiety to the thiol side chain of a cysteine residue. One 
downstream target of NO via S-nitrosylation is the calcium handling protein calcium-
calmodulin dependent protein kinase II (CaMKII). There is evidence that the S-
nitrosylation of CaMKII promotes calcium mishandling in cardiomyocytes, which is the 
precursor of cardiac arrhythmias. The role of CaMKII in the whole heart during NO 
exposure is yet to be understood. Therefore, the aim of this thesis was to determine how 
CaMKII modification by NO and β-adrenergic stimulation can affect cardiac contractility 
and arrhythmias.  
With the use of echocardiography, cardiac function was compared between wild type 
(WT) mice and transgenic mice lacking cardiac CaMKIIδ (KO), and loss of CaMKIIδ did 
not severely alter cardiac structure and function. To determine if NO and CaMKIIδ did 
affect cardiac function, the hearts were isolated from the mice and treated with different 
concentrations of a NO donor (GSNO). GSNO reduced contractility measured as left 
ventricular (LV) developed pressure and increased heart rate in WT mice whereas KO 
mice showed no response to GSNO treatment. WT mice were susceptible to arrhythmias 
and the number of arrhythmic events increased with increasing GSNO concentration. 
There was no change in the number of arrhythmic events in the KO mouse hearts with 
GSNO treatment compared to baseline. Therefore, CaMKIIδ removal was 
cardioprotective, as it prevented arrhythmias during acute GSNO treatment.  
Having established a role for CaMKII in determining the effects of acute NO treatment 
on cardiac function, I then focused on a model of chronically elevated NO. Chronic 
GSNO treatment of WT and KO mice involved a 5-week supplementation with GSNO in 
drinking water, followed by measurement of cardiac function in isolated hearts from these 
mice with and without GSNO. Echocardiographic data from WT and KO mice showed 
no effect of GSNO treatment after 5-week GSNO supplementation. The isolated hearts 
showed no difference in cardiac function at baseline. Following subsequent GSNO 
treatment, the LV developed pressure and rates of contraction and relaxation decreased 
compared to baseline in WT and KO hearts. Both animal models showed a trend towards 
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increased number of arrhythmic events, suggesting that knocking out CaMKIIδ from the 
heart did not prevent the KO hearts from developing arrhythmias in the chronic treatment 
compared to the acute treatment. 
β-adrenergic stimulation using the β-adrenergic receptor agonist (ISO) enhanced cardiac 
contractility and arrhythmias in both WT and KO hearts. However, ISO induced an 
increase in arrhythmic events in WT hearts, but not in KO hearts, suggesting that the 
presence of CaMKII enhanced the susceptibility of WT hearts to ISO-induced cardiac 
stress. To determine the effect of NO treatment and β-adrenergic stimulation on cardiac 
function, WT hearts were treated with ISO and GSNO. There were two groups, ISO-
GSNO (ISO before GSNO treatment) and GSNO-ISO (GSNO before ISO treatment). In 
both groups, ISO increased contraction and relaxation. GSNO did not alter cardiac 
contractility compared to baseline except in the ISO-GSNO group. ISO-GSNO induced 
cardiac arrhythmias, and GSNO treatment prolonged the arrhythmias. Interestingly, in the 
GSNO-ISO group, there was no increase in arrhythmic events compared to baseline. This 
finding provided evidence of a differential role of NO in the heart. 
Overall, the findings in this thesis show, for the first time, CaMKII plays a role in the 
development of arrhythmias in the whole heart during NO signaling. Additionally, this 
thesis highlights the dual role of NO in preventing or prolonging cardiac arrhythmias 
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CHAPTER 1: INTRODUCTION 
1.1 Regulation of cardiac contraction 
1.1.1 Autonomic regulation of the heart 
The heart is a vital organ in the body which contracts and relaxes in order to pump 
deoxygenated blood to the lungs and oxygenated blood to the body through blood vessels.  
The heart is controlled by the autonomic nervous system (ANS), which consists of the 
parasympathetic nervous system (PNS) and sympathetic nervous system (SNS), which 
act complementarily with each other. The SNS has a wide variety of cardiovascular 
actions which include increase in cardiac contractility, acceleration of heart rate, 
reduction of venous capacitance and constriction of resistance vessels (Triposkiadis et al., 
2009). It is known to be responsible for the “fight or flight” response as it controls the 
body’s reaction to stress. The PNS is required for the rest state and does the contrary by 
slowing the heart rate (Kishi, 2012; Gordan et al., 2015) and it is also known as “rest and 
digest”. In physiologic conditions, there is always a net balance between the actions of 
the SNS and PSNS therefore in autonomic dysregulation which is a main feature of CVD, 
there is an imbalance between both systems. Certain circulating and hormonal factors like 
angiotensin II, aldosterone, atrial natriuretic peptide, reactive oxygen species (ROS) and 
nitric oxide (NO) also contribute to the modulation of sympathetic outflow at several sites 
in the central nervous system (Kishi, 2012). The stimulation of the SNS leads to increase 
myocardial contractility which is caused elevation of intracellular Ca2+ in the 
cardiomyocytes (Gordan et al., 2015). The autonomic regulation of the heart is usually 
propagated through cardiac excitation and contraction coupling (ECC). ECC is the 
process from electrical excitation of the myocyte to contraction of the heart to cause 
ejection of blood (Bers, 2002). Calcium ion (Ca2+) plays a role in activation of 





1.1.2 Action Potential in cardiac cell 
The cardiac action potential is the waveform that occurs in response to changes in 
electrical potential across the cell membrane in the cardiac cell during contraction and 
relaxation. In cardiac cells, action potential is composed of 5 phases (Figure 1.1). Prior to 
influx of Ca2+ into the cell, there is resting membrane potential of  -90 mV, here the Na+ 
and Ca2+ channels remain deactivated, as K+ leak out of the cell. This is known as Phase 
4. Resting membrane potential is the electrical potential difference across the cell 
membrane under resting conditions. The next phase is Phase 0, which is known as the 
depolarisation phase. Here, there is rapid transient influx of Na+ as the membrane 
potential rises from -90 mV to approximately +20 mV. As the Na+ channels are 
deactivated, the K+ channels open and there is an efflux of K+, this makes up Phase 1, 
which is a brief phase characterised by a rapid initial repolarisation. This brings the 
membrane potential to 0 mV. Phase 2 is the plateau phase, a stable period where is a slow 
opening of voltage-gated L-type calcium channels (LTCCs) and high influx of Ca2+ ions. 
Slow Na+ channels are also opened, and the entry of Na+ and Ca2+ ions allows the 
membrane potential to remain at 0 mV leading to prolonged depolarisation which forms 
a plateau. Phase 3 is the final repolarisation phase where there is efflux of K+, and Ca2+ 
channels become inactivated. As the K+ exiting the cell exceeds the amount of Ca2+ 
entering the cell, this creates a negative current. This also brings the cell back to its resting 
potential at -90 mV. In this phase also, excess Ca2+ is pumped out through the Na+/Ca2+ 
exchanger (NCX) and the activated Na+/K+ pump allows influx of K+. This is to allow for 





Figure 1.1 Action potential in ventricular myocyte. Time course showing different 
phases of action potential in ventricular myocyte at 37oC. Phase 0 is rapid depolarisation, 
Phase 1 is early rapid depolarisation, Phase 2 is plateau, Phase 3 is final rapid 
depolarisation and phase 4 is resting membrane potential. Black line is action potential. 
Blue line is Ca2+ transient during action potential. Red line is contraction and relaxation 










1.1.3 Excitation Contraction Coupling in cardiomyocytes 
For the myocardium to contract, there is a series of events that must occur between 
excitation and contraction (Figure 1.2). Ca2+ is critical for ECC because it is the effector 
that acts on the myofilaments in cardiomyocytes for contraction to occur (Bers, 2002). 
Action potentials spread over the sarcolemma through the transverse tubules, which have 
LTCCs. During the plateau phase of action potential, there is Ca2+ influx into the 
cardiomyocyte through LTCCs that triggers the release of Ca2+ release from the 
intracellular stores in sarcoplasmic reticulum (SR) through the ryanodine receptor type 2 
(RyR2). This mechanism is known as calcium-induced calcium release (CICR) (Fabiato 
& Fabiato, 1978). The SR releases Ca2+ into the cytosol and increases free intracellular 
Ca2+ concentration. The cytosolic Ca2+ transient then activates myofilaments when Ca2+ 
binds to myofilament protein troponin C. A change in position of troponin occurs, pulling 
the tropomyosin complex away from actin to expose the binding site. Myosin binds to 
actin, the filaments form a cross-bridge which causes a shortening of the sarcomere and 
myofilament contraction is initiated (Gordan et al., 2015; Beckendorf et al., 2018). This 
concept is known as cross-bridge cycle. Relaxation occurs when there is a decline in Ca2+ 
current (Ica) and there is dissociation of Ca2+ from troponin C. Ca2+ declines as there is 
re-uptake of Ca2+ into the SR through the Phospholamban (PLB)-regulated Sarcoplasmic 
Reticulum Calcium ATPase 2 (SERCA2a), out of the cytosol. There is also extrusion of 
Ca2+ through the sarcolemmal Na+/Ca2+ exchanger (NCX) into the extracellular space 
(Rokita & Anderson, 2012; Dobrev & Wehrens, 2014). The re-acquired Ca2+ are then 
stored in the SR in preparation for the influx of Ca2+ through the LTCCs, for the next 






Figure 1.2 Excitation contraction coupling in cardiac cells. Action potential spreads over the sarcolemma through the transverse tubules. (2) LTCCs opens 
to allow influx of Ca2+ into the cell. (3) Calcium-induced calcium release (CICR) mechanism triggers the release of Ca2+ release from the sarcoplasmic reticulum 
(SR) through the ryanodine receptor type 2 (RyR2). The SR releases Ca2+ into the intracellular space and increases free intracellular Ca2+ concentration. (4) The 
cytosolic Ca2+ transient then activates myofilaments to initiate contraction. Relaxation occurs when there is a decline in Ca2+ initiates relaxation. (5) There is 
re-uptake of Ca2+ into the SR through the Phospholamban (PLN)-regulated Sarcoplasmic Reticulum Calcium ATPase 2 (SERCA2a) and extrusion of Ca2+ 
through the sarcolemmal Na+/Ca2+ exchanger (NCX) and Ca2+ ATPase  (6) The mitochondrial Ca2+ uniporter takes up the Ca2+ and  also extrudes Ca2+ from the 





1.2 Cardiac arrhythmias 
Cardiovascular diseases (CVDs) are caused by disorders of the heart and blood vessels, 
that affect the circulatory system of the body (D’Andrea et al., 2015). They are highly 
prevalent and include cerebrovascular diseases (stroke), peripheral arterial diseases, 
rheumatic heart diseases, deep vein thrombosis and pulmonary embolism, congenital 
diseases, coronary heart diseases (heart attack), cardiomyopathies and arrhythmias 
(D’Andrea et al., 2015; World Health Organisation, 2017). CVD is the leading cause of 
death worldwide. In 2015, 17.7 million people died from CVDs (World Health 
Organisation, 2017) and annually, over 7 million people die from cardiac arrhythmias 
(Ramanathan et al., 2004). In New Zealand, CVDs account for 32% of deaths annually 
and approximately 35,000 New Zealanders are known to suffer from a type of cardiac 
arrhythmia (Ministry of Health, 2017).  
Arrhythmia is the deviation of the heart rhythm from the regular sinus rhythm. It is caused 
by disruptions in the orderly propagation of electrical impulses through the heart muscles 
(Ramanathan et al., 2004; Tse, 2016). Arrhythmias are often an indication of high-risk 
cardiovascular diseases such as heart failure, myocardial infarction, coronary artery 
disease, and valvular heart disease, all of which can lead to cardiac arrest. An alteration 
in the myocardium or in the autonomic system can lead to arrhythmias. Arrhythmias can 
be classified according to its effect on heart rate; when the hearts beats too fast 
(tachycardia) or too slow (bradycardia). They can also be classified based on part of the 
heart where it originates; the upper part (supraventricular arrhythmias) or the lower part 
(ventricular arrhythmias) of the heart (Lindberg, 2017). This thesis will focus on 
ventricular arrhythmias. 
In physiological conditions, electrical stimulus from the sinoatrial (SA) node located in 
the wall of the right atrium depolarises the cardiac cells causing atrial contraction. The 
electrical impulses are then transmitted to the atrioventricular (AV) node causing the 





AV node travel through the left and right branches of bundle of His into the purkinje 
fibres located in the muscular walls of the ventricles, which causes the ventricles to 
contract. Contraction of the ventricles allows the right ventricle to push blood out into the 
pulmonary system while the left ventricle pushes blood out into the systemic circulation.  
One of the known mechanisms of arrhythmia is triggered activity, which results from 
afterdepolarization during abnormal pulse initiation (Wit & Boyden, 2007). 
Afterdepolarisations are spontaneous depolarisations which interrupt phases of the action 
potential in cardiomyocytes. They are of two types; early afterdepolarisation (EAD) and 
delayed afterdepolarisation (DAD). EAD is defined as the secondary voltage oscillations 
that occur before full repolarisation of action potential in ventricular cardiomyocytes. 
They correspond to phase 2 and 3 of the cardiac action potential (Qu et al., 2013; Tse, 
2016; Huang et al., 2018). DAD occurs after repolarisation has been completed. They 
correspond to the phase 4 of the cardiac action potential. Afterdepolarisations are known 
to be related to increase in diastolic Ca2+ (Gaztañaga et al., 2012). 
Untreated arrhythmias can lead to serious complications and become life threatening, and 
as such can lead to sudden cardiac death or damage other body organs. Anti-arrhythmic 
drug therapies that target electrolyte imbalance and triggered activity are used in clinical 
settings. Aside from the contribution of autonomic activation to the development of 
arrhythmias, one of the mechanisms that is known to alter cardiac function and trigger 
arrhythmias is impaired intracellular Ca2+ cycling by cardiac proteins during excitation 
contraction coupling (ECC) (Qu et al., 2013). The role of impaired Ca2+ cycling in 
triggered rhythm activities is complex. Further understanding of this mechanism at the 
cellular level is required, in order to design new therapies that target cardiac arrhythmias 





1.3 Nitric oxide in the heart 
Nitric Oxide (NO) is a ubiquitous gasotransmitter molecule involved in many 
physiological processes throughout the cardiovascular system. It is a well-known 
vasodilator which plays a role in overall cardiac homeostasis. Aside from the vascular 
response pathway, it is also involved in neuronal and immune response pathways (Kojda 
& Kottenberg, 1999; Bishop, 2012). It also regulates blood pressure, as well as 
myocardial contraction and relaxation, making it a key regulator of ECC (Massion et al., 
2003; Houston & Hays, 2014; Vielma et al., 2016). Previous studies focused on NO 
signaling have provided great insight about its involvement in complex 
pathophysiological conditions such as myocardial infarction, heart failure, diabetic heart 
disease and pulmonary hypertension (Katz et al., 1999; Phillips et al., 2009; Liu, 2017; 
Ling et al., 2018).  
1.3.1 Nitric oxide synthesis 
NO is produced in the cardiomyocytes from the cleavage of L-arginine into L-citrulline 
by nitric oxide synthase (NOS) enzyme isoforms. The neuronal (nNOS/NOS1) isoform 
is localized to the sarcoplasmic reticulum while the endothelial (eNOS/NOS3) isoform is 
localized to the plasmalemmal caveolae (Ziolo et al., 2008). The NOS1 and NOS3 are 
expressed constitutively in cardiomyocytes (Lima et al., 2010; Moosavi et al., 2014); 
(Đorđević et al., 2012). The inducible isoform (iNOS/NOS2) is a cytosolic protein (Ziolo 
& Bers, 2003) expressed in response to inflammation or injury as seen in heart failure and 
ischemia-reperfusion injury (Balligand et al., 1994; Wildhirt et al., 1999; Ziolo et al., 
2004). The eNOS and nNOS control fluctuating low levels of NO to ensure normal 





1.3.2 Nitric oxide donors 
The role of NO has been extensively studied in cardiac function using different NO 
donors, which store NO in a stable form and spontaneously release NO or require 
enzymatic reaction to generate NO (Ignarro et al., 2002; Herman & Moncada, 2005). 
Some of the NO-releasing compounds (NO donors) used in studying physiological 
processes include sodium nitrite, sodium nitroprusside (SNP), S-nitroso-N-
acetylpenicillamine (SNAP) and S-nitroso-glutathione (GSNO). For example, NO release 
from sodium nitrite reduced the number of arrhythmic episodes in anaesthesised dogs 
after a 25-min period of coronary artery occlusion and reperfusion (Kovács et al., 2015). 
For measurement of quantitative release of NO, the decomposition of SNAP triggered by 
Cu+ has been used for calibration of electrochemical NO microsensors (Zhang et al., 
2000). SNP exhibited direct positive chronotropic effect by increasing heart rate of rabbits 
in vivo and in vitro (Hogan et al., 1999). In a study by Poluektov et al. (2019), GSNO 
was found to accelerate recovery of contractility of isolated perfused rat hearts after 
ischaemia-reperfusion. Exposure of cardiomyocytes to GSNO has also been found to 
induce positive inotropic response in cardiomyocytes (Sarkar et al., 2000). 
1.3.3 Nitric oxide signaling 
NO signaling in the heart involves two pathways (Figure 1.3). One is the guanylate 
cyclase (GC) pathway which is dependent on cyclic guanosine monophosphate (cGMP) 
where NO activates GC and leads to formation of cGMP and the activation of protein 
kinase G (PKG). This causes inhibition of phosphoinositide hydrolysis and reduction of 
intracellular Ca2+ concentration. Another signaling pathway for NO is through S-
nitrosylation, which is the covalent attachment of NO to cysteine sulphyldryls on the thiol 
side chain of a protein. S-nitrosylation leads to further activation of downstream protein 
targets such as LTCC, RyR2 and PLN. This affects Ca2+ handling in cardiomyocytes, 
which makes NO a key regulator of ECC (Vielma et al., 2016). NO can also activate 





Superoxide radicals can also react with NO to form reactive nitrogen species such as 







Figure 1.3 NO signaling pathways and the biphasic effect in cardiomyocytes. A, Low concentration of NO activates guanylate cyclase (GC) 
which leads to increase production of cyclic guanosine monophosphate (cGMP) and inhibits phosphodiesterase III (PDE III) which prevents cyclic 
adenosine-3’,5’-cyclic monophosphate (cAMP) hydrolysis. Low NO concentration also activates adenylyl cyclase (AC) which leads to increase 
in cAMP. Activation of protein kinase A (PKA) fosters the opening of voltage gated Ca2+ channels (VGC) and RyR2, which allows increase in 
Ca2+ and results in increased contractility.  B, High concentration of NO leads to increase in cGMP, activation of protein kinase G (PKG) which 





1.3.4 Biphasic effect of nitric oxide 
NO is involved in dilation of blood vessels. However, several studies have showed that 
NO exerts a biphasic effect in the heart which is dependent on concentration. Low 
concentration of NO induces vasoconstriction and positive inotropic effects in the heart, 
while high concentration promotes vasodilation and negative inotropy. A study by 
González et al. (2008), showed that low concentrations of the NO donor SNAP increased 
cardiac contractility and pressure development in isolated rat heart, and a high 
concentration of SNAP induced an opposite effect by increasing cGMP, leading to 
reduced cardiac contractility. The mechanism for positive inotropic effect of NO could 
be the role of eNOS and nNOS derived NO which mediates calcium handling proteins, 
LTCC and RyR2 during ECC and also S-nitrosylation (Campbell et al., 1996). The 
mechanism underlying the negative inotopic is suggested to be cGMP dependent, by 
reducing calcium sensitivity in the myofilaments (Cotton et al., 2002). Müller‐Strahl et 
al. (2000) also found that reduced endogenous NO release during NOS inhibition 
increased myocardial contractility in the rat heart.  
1.3.5 Cardioprotective effect of nitric oxide 
Oxidative stress, an imbalance between reactive oxygen species and cellular antioxidant 
production, is the hallmark of major pathophysiological conditions in the heart. NO has 
antioxidant properties that prevent pathophysiological consequences of tissue damage 
through various mechanisms (Wink et al., 2001) and this can be achieved endogenously 
and exogenously. Kruzliak et al. (2014) suggested that NO acts as a radical scavenger but 
the mechanism is not well defined. However, NO could also prevent production of 
superoxide. Increase in cGMP, upregulation of ferritin production and expression of 
hemoxygenase has been observed as the mechanisms by which NO prevents peroxide 
injury in hepatocytes (Kim et al., 1995). According to Clancy et al. (1992), NO inhibits 
neutrophil oxygen generation and assembly of the nicotinamide adenine dinucleotide 





injury, there was evidence that administration of NO donor, molsidomine prevented 
against depletion of antioxidant levels suggesting that NO production inhibits oxidative 
stress pathways (Chander & Chopra, 2005). 
During ischemia and reperfusion (I/R), there is interruption of blood supply which can 
exacerbate cellular dysfunction and tissue injury/death, dependent of the duration and 
magnitude of ischemia (Kalogeris et al., 2012). In the human heart of patients who 
underwent coronary artery bypass grafting, transcardiac production of pro-inflammatory 
substances such as Interleukin-6 (IL-6), Tumour necrosis factor – alpha (TNF-α), 
activated leucocytes and platelets were reduced after SNP treatment in the first 60 minutes 
of reperfusion, thereby protecting against I/R injury (Massoudy et al., 2000). NO 
protected against hemorrhagic shock and liver injury in rats by improving hemodynamic 
response, scavenging reactive oxygen species, and blocking the effect of inflammatory 
cytokines (Anaya-Prado et al., 2003). L-arginine, a precursor of NO, protected against 
I/R induced hepatocyte injury in rats by preventing increase in lipid peroxidation and 
reducing neutrophil infiltration (Chattopadhyay et al., 2008). In a pathway independent 
of cGMP, NO can also protect rat cardiac cells against metabolic inhibition-induced 
cellular injury by preventing increase in lactate dehydrogenase levels, which is an 
indicator of tissue damage (Garreffa et al., 2006). Another mechanism by which NO 
protects the heart from I/R  injury is by stimulation of cyclooxygenase-2 (COX-2) 
activity, which in turn leads to production of cytoprotective prostanoids (Kruzliak et al., 
2014). Even though the precise mechanism of cardio-protection is complex, NO plays a 
role in immune response by acting as an anti-inflammatory and antioxidant agent by 
reducing the expression of pro-inflammatory cytokines (Rodriguez‐Peña et al., 2004; 
Webb et al., 2004; Phillips et al., 2009; Strijdom et al., 2009).  
During stress conditions that require fight or flight response, the heart requires increased 
blood perfusion to tissues and organs. The response of the heart to this increase in demand 
is a determinant of cardiac performance. NO plays a critical role in the stretch of cardiac 





showed that endogenous NO release in cardiac cells was able to influence how 
cardiomyocytes responded to stretch response. They suggested that the localization of 
eNOS, which is close to the SR T-tubule and also regulation of the RyR2 channels by S-
nitrosylation during ECC, could be responsible for this effect. Therefore, NO may act as 
an amplifier of Ca2+ signaling and possibly regulate the response of cardiomyocyte to 
increase in preload (Prendergast et al., 1997). 
NO modulates basal heart rate and induces positive chronotropic effect in cardiac 
myocytes. Knocking out NOS isoforms in animal models has resulted in reduced heart 
rate (Yang et al., 1999; Rakhit et al., 2001; Massion & Balligand, 2003). Mice lacking 
eNOS gene displayed bradycardia and mild hypertension while treatment of C57BL/6 
wild-type mice with a NOS inhibitor, L-NAME also induced bradycardia (Kojda et al., 
1999) suggesting that other NOS isoforms were involved in heart rate regulation. A study 
by Liu et al. (2002) observed that basal heart rate was lower in eNOS deficient mice 
compared with their control group. A contrary finding was observed by Kennedy et al. 
(1994) who reported that NO had no chronotropic effect in rat atrial preparation. They 
attributed the different observations to the difference in tissues and role of the currents 
contributing to pacemaker activity. Administering NO donors to isolated guinea pig atrial 
preparations increased spontaneous beating rate and pharmacologically blocking 
hyperpolarization activated inward current (If) prevented an increase in the beating rates 
with exposure to NO donors. This suggests that HR control by NO is through the cGMP 
pathway by modulation of If (Musialek et al., 1997). In summary, eNOS and nNOS are 
involved in regulating heart rate (Barouch et al., 2002) and could be therapeutic targets 
in pathophysiological conditions involving overactivation of the sympathetic nervous 
system. 
1.3.6 Nitric oxide and regulation of intracellular calcium during ECC 
Exogenous NO can modulate the opening of Ca2+ channels as shown in a study involving 





GSNO (100 µM) increased basal Ica. However, lowering cGMP levels by inhibiting 
guanylyl cyclase blocked the effect of NO on Ica, suggesting that NO signaling modulates 
intracellular calcium levels through cGMP. Furthermore, blocking Protein Kinase A 
(PKA) and phosphodiesterases (PDEs) failed to inhibit the stimulatory effect of GSNO, 
showing that this pathway is dependent on phosphorylation of PKG and not PKA or 
PDEs. Therefore, NO signaling leads to PKG phosphorylation which directly mediates 
the opening of LTCCs involved in regulating basal Ica. Another finding demonstrated at 
100 µM GSNO, PKG activation prevented opening of voltage-gated calcium channels 
and decreased myofilament calcium sensitivity through troponin I phosphorylation, 
independent of cGMP (Hu et al., 1997). The disparity in findings suggest that the effect 
of NO on Ica is both inhibitory and stimulatory, dependent on both cGMP and post 
translational modification signaling pathway, which further confirms its biphasic effect 
(Campbell et al., 1996). 
1.3.7 Nitric oxide and ß-adrenergic signaling 
In a previous study, it has been observed that ß-adrenergic signaling increases endogenous 
NO which leads to S-nitrosylation of Ca2+-handling proteins (RyR2, SERCA2a, LTCC). 
It is also known that the isoform that plays a role in this ß-adrenergic responsiveness is 
NOS1 (Vielma et al., 2016) and not NOS3 (Wang et al., 2008). In the study by Vielma et 
al. (2016), exposing cardiomyocytes to selective NOS1 blocker led to decreased inotropic 
effect and results also showed that NOS1 was responsible for nitrosylation following ß-
adrenergic stimulation. The mechanism of ß-adrenergic response attenuation by NO was 
a reduction in Ica (Wang et al., 2008), which also prevents pro-arrhythmic signaling. 
Furthermore, acute nitrosative stress and overactivation of sympathetic stimulation can 
be deleterious to the heart (Gutierrez et al., 2013; Curran et al., 2014). The relationship 





1.3.8 Nitric oxide and arrhythmias 
Increase in NO release is known to induce Ca2+ leak in cardiac myocytes and this could 
be a trigger for arrhythmias. In autonomically denervated dogs, NG-monomethyl-L-
arginine (endogenous NO precursor) infusion reduced the incidence of ventricular 
arrhythmias during sympathetic stimulation (Fei et al., 1997). Kubota et al. (2000) 
observed that cardiomyocytes deficient of eNOS exhibited oubain-induced arrhythmias 
and exposure of these cells to NO donor, S-nitroso-N-acetylcysteine (SNAC), attenuated 
transient inward current, which is a predictor of digitalis-induced arrhythmias. These 
studies suggest that inhibiting NOS pathway may exacerbate proarrhythmic stimulation. 
Wang et al. (2008) also demonstrated that NOS3-defecient cardiomyocytes were 
susceptible to arrhythmias in response ß-adrenergic receptor stimulation. Therefore, 
blocking NOS pathway during sympathetic stimulation could aggravate 
arrhythmogenesis.  
However, some experimental studies have contrary findings and have shown that NO is 
not totally cardioprotective but stimulates pro-arrhythmic signaling by mediating increase 
in Ca2+ spark frequency, a predictor of cardiac arrhythmias. Gutierrez et al. (2013) found 
that 150 µM GSNO (NO donor) could directly induce an increase in Ca2+ spark frequency 
independent of ß-AR stimulation and this pathway involved nitrosylation of cardiac 
proteins. Furthermore, they found that an inhibitor of Ca2+/calmodulin dependent protein 
kinase II (CaMKII) attenuated the pro-arrhythmic effect of GSNO. NO donor, SNAP 
increased SR Ca2+ leak in rabbit cardiomyocytes, in the absence of ß-AR stimulation 
(Curran et al., 2014). The CaMKII inhibitor also prevented SR Ca2+ leak, suggesting that 
the effect of NO in cardiomyocytes was primarily through CaMKII activation. 
The contradictory findings about the beneficial and deleterious effects of NO in the heart 
have been reported in literature, and this makes the function of NO in the heart somewhat 
controversial. In summary, the actions of NO are dependent on concentration, the NOS 





makes the role of NO also complex. These are important when considering the role of 
NO in health and disease. This thesis will highlight the effects of NO and identify a 
CaMKII-dependent pathway through which NO could be contributing to cardiac 
dysfunction. 
1.4 Ca2+/calmodulin dependent protein kinase II  
CaMKII is a multifunction protein which is expressed as a multimer comprising of 12 
subunits in most commonly observed physiological conditions (Figure 1.4) (Braun & 
Schulman, 1995). CaMKII is a mediator of calcium linked signaling and regulates a broad 
range of cellular functions. Basal activity of CaMKII is responsible for calcium handling 
during excitation-contraction (coupling between membrane excitability and cell 
contraction) and excitation-transcription (coupling between cardiomyocyte activity and 
gene transcription) coupling in the myocardium (Mohler & Hund, 2011; Daniels et al., 
2015). However, research has also shown that aberrant activation of CaMKII is the 
underlying cause of pro-rhythmic signaling and heart failure (Sag et al., 2009; Zhong et 
al., 2017). 
1.4.1 Structure of CaMKII 
CaMKII consists of 6-12 subunits or monomers that form a dodecameric holoenzyme. 
The structure of CaMKII is said to resemble a “wagon wheel” because of the way it is 
arranged, having each of the monomers form each spoke of the wheel around a central 
core (Erickson, 2014). Each monomer is comprised of three domains, an association 
domain, a catalytic domain and a regulatory domain. The carboxy-terminal (C-terminal) 
association domain directs the assembly of the dodecameric holoenzyme by associating 
the subunits. The amino-terminal (N-terminal) catalytic domain is responsible for the 
serine/threonine kinase function of CaMKII and it contains substrate binding pockets, 1 
for ATP and 1 for the target protein which lies close to ATP to allow for transfer of 





regulatory domain contains the binding site for Ca2+/calmodulin (Ca2+/CaM), the various 
sites of post-translational modification and also mediates the function of the catalytic 
domain via autoinhibition (associating with the C-terminal) in the baseline state (Hoelz 
et al., 2003; Erickson et al., 2015). 
 
Figure 1.4 Structure of CaMKIIδ A, CaMKIIδ monomer showing the three domains; 
C-terminal association domain which directs the assembly of the dodecameric 
holoenzyme, N-terminal catalytic domain which binds to potential substrates and 
regulatory domain which has the binding site for Ca2+/CaM. B, An assembled CaMKIIδ 





1.4.2 Isoforms of CaMKII 
CaMKII is a serine/threonine kinase widely expressed in muscle, nerve and immune 
tissues. It is a regulatory node in the heart and brain, and exists in four main isoforms 
produced by four different genes; alpha, beta, delta and gamma (α, β, δ and γ,) (Erickson 
et al., 2013; Hund & Mohler, 2015). The neuronal isoforms, CaMKIIα and CaMKIIβ are 
important for learning and memory. The predominant cardiac isoform is CaMKIIδ, with 
a secondary expression of CaMKIIγ and both isoforms play a role in Ca2+ handling 
(Zhang & Brown, 2004; Erickson et al., 2015). This delta isoform exists in two major 
splice variants in the adult heart, CaMKIIδB and CaMKIIδC. δB and δC are known to have 
similar sensitivity to Ca2+/CaM binding and catalytic activity (Edman & Schulman, 1994; 
Gray & Brown, 2014), however in the variable domain of δB, there is insertion of an 11 
amino acid sequence. The expression of the splice variant, δB is localised to the nucleus, 
as it contains a nuclear localization signaling (NLS), while the cytosolic δC lacks NLS 
and is expressed in the cytosol (Edman & Schulman, 1994). There are other splice 
variants (δ5-11) but have been found to be expressed during neonatal development (Mayer 
et al., 1994; Hoch et al., 1999) and CaMKIIδA which localises to the T-tubules and nuclear 
membranes is expressed in neonatal and adult models (Xu et al., 2005; Li et al., 2011). 
Both δB and δC are known for their opposing roles in apoptosis, while δB is anti-apoptotic, 
δC promotes apoptosis (Peng et al., 2010; Daniels, 2017). The difference in subcellular 
localisations suggests difference in Ca2+-CaM sensitivity and distinct functions (Bers & 
Guo, 2005). δB signaling leads to the activation of several transcription factors that 
regulate gene expression and therefore over expression can induce cardiac hypertrophy 
(Zhang et al., 2002). Over-expression of δC can cause severe cardiac dysfunction, heart 
failure and premature death (Zhang et al., 2003). This thesis will focus on the CaMKIIδC 





1.4.3 Activation and Function of CaMKII in the Heart 
Under basal conditions, the regulatory domain and the catalytic domain remain in close 
association preventing the binding of substrates, this ensures that the kinase is inactive or 
is in an autoinhibitory state (Figure 1.5) (Erickson, 2014). Influx of Ca2+ leads to the 
binding of Ca2+/CaM to the regulatory domain of CaMKII, which causes a conformational 
change that disrupts the interaction of the regulatory domain with the ATP and protein 
substrate binding sites of the catalytic domain. This action exposes the catalytic domain 
for substrate binding and distorts the autoinhibition of the kinase. However, in 
pathophysiological conditions, where CaMKII is activated by prolonged Ca2+ cycling, the 
kinase is susceptible to post translational modifications, rendering the protein 
autonomously active. 
Research has shown that CaMKII is also responsible for the mediation of the heart’s fight 
or flight response to ß-AR stimulation (Mohler & Hund, 2011; Wu & Anderson, 2014) 
and there is evidence that autonomous activation or dysfunction of CaMKII activity has 
adverse effects in heart function. Therefore, CaMKII is also thought to play a key role in 
development of cardiac hypertrophy and dilated cardiomyopathy (Hoch et al., 1999; 
Kirchhefer et al., 1999; Zhang et al., 2003), heart failure (Zhang et al., 2003; Ai et al., 
2005; Ling et al., 2009; Rajtik et al., 2017), progression of diabetes (Erickson et al., 2013; 






                          
Figure 1.5 Activation of CaMKIIδ in the heart. In basal conditions, the regulatory and catalytic domains remain in close association and renders 
the kinase inactive. Elevation in intracellular Ca2+ leads to binding of Ca2+/CaM to the regulatory domain which exposes the catalytic domain for 
substrates to bind. PTMs can occur when ATP, H2O2, O-GlcNac and/or NO residues bind to the regulatory domain. This prevents re-association 





1.5 CaMKII and ECC 
Protein kinases serve as intermediary between upstream and downstream signaling 
pathways and are responsible for functions like gene expression, ion transport, cell cycle 
activity and metabolism (Bayer & Schulman, 2001; Mollova et al., 2015). Several studies 
have shown that CaMKII can modulate ECC in cardiomyocytes through the 
phosphorylation of several important Ca2+ regulatory proteins like RyR2, PLN, 
SERCA2a (Wehrens et al., 2004; Abiria & Colbran, 2010; Grimm et al., 2015). CaMKII 
can phosphorylate the LTCC subunits and mediate Ica to cause myocyte mishandling of 
Ca2+ and lead to contractile dysfunction, development of early after-depolarisation and 
arrhythmias (Bers, 2002; Zhang & Brown, 2004). 
For propagation of Ca2+ in ECC, voltage-gated channels such as LTCCs serve as the main 
entry point for Ca2+ in cardiac cells (Bers & Grandi, 2009). CaMKII phosphorylation of 
LTCC subunits is important for Ca2+ dependent facilitation of the channel (Hudmon et 
al., 2005; Grueter et al., 2008). This interaction increases the opening probability of 
LTCCs and facilitates Ica which increases cytosolic Ca2+ concentration and strengthens 
contraction (Gordan et al., 2015). Hudmon et al. (2005) showed that CaMKII can 
associate with the regions pore-forming alpha-1C subunit of LTCCs responsible for 
modulating the channel function. This phosphorylation leads to upregulation of Ca2+ 
influx during action potential, and this mechanism is called Ca2+-dependent facilitation 
(CDF). Using a ‘site specific’ CaMKII inhibitor, Xiao et al. (1994) was able to determine 
the role of CaMKII in Ca2+ influx via LTCCs in cardiomyocytes, as Ca2+ influx was 
required due to the correlation between activation of the kinase and change in Ica. 
CaMKII also phosphorylates voltage-gated sodium channel, NaV1.5 at several sites 
within the I-II linker loop (Ashpole et al., 2012; Marionneau et al., 2012; Grandi & 
Herren, 2014). The S516 site is most efficiently phosphorylated by CaMKII, and in heart 
failure, CaMKII phosphorylation of S571 site is increased (Wagner et al., 2006; Koval et 





responsible for regulating the activation of the channel and increasing the voltage-
dependent Na+ current, leading to re-entrant arrhythmias (Herren et al., 2013), DADs 
(Gonano et al., 2011) and prolonged EADs as seen in ventricular cardiomyocytes of mice 
over expressing CaMKIIδC (Edwards et al., 2014). 
During ECC, CaMKII has a direct effect on RyR2. The role of RyR2 is to 
facilitate/mediate Ca2+ release from the calcium stores in the SR and direct it into 
excitable cells. It is known to play a role in CICR (Wehrens et al., 2004). RyR2 
phosphorylation by CaMKII occurs at Ser2809 and Ser2815 sites.  This phosphorylation 
promotes RyR2 activity in cardiomyocytes, and inhibiting CaMKII blunts this effect 
(Currie et al., 2004; Grimm & Brown, 2010). In cardiomyocytes with over expression of 
CaMKIIδC, Maier et al. (2003) found enhanced diastolic Ca2+ leak and increased 
frequency of Ca2+ sparks, which indicated spontaneous Ca2+ release in diastole. They 
inferred that this process increases RyR2 phosphorylation due to CaMKII overexpression. 
Conversely, inhibition of CaMKII decreased Ca2+ spark frequency in ventricular 
cardiomyocytes, and the suggested mechanism was the inhibition of RyR2 
phosphorylation by CaMKII (Li et al., 1997). The pathological effect of RyR2 
phosphorylation by CaMKII is also seen in heart failure due to increase SR Ca2+ leak into 
the cytosol (Ai et al., 2005; Respress et al., 2012).  
PLN, which is also a target of CaMKII, acts as the regulator of SERCA2a (Li et al., 1998). 
CaMKII phosphorylates PLN at Thr 17 to inactivate it and relieve its inhibition of 
SERCA2a. This action facilitates more pumping of Ca2+ into the SR through the 
SERCA2a, thereby restoring Ca2+ content levels in the SR (Gordan et al., 2015). CaMKII 
is known to decrease SR Ca2+ uptake as seen in heart failure, it was shown that ablation 
of PLN in CaMKIIδC TG mice normalised SR Ca2+ levels, restored Ca2+ transients and 





1.6 Post-translational Modification of CaMKII 
CaMKIIδ is susceptible to many forms of post-translational modifications (PTMs) 
(Figure 1.6), which prevent re-association of the catalytic and regulatory domains of the 
active kinase. PTM is a biochemical process in which amino-acid residues in a protein 
are covalently modified, during or after protein biosynthesis. PTM is important for several 
physiological and cellular processes including cellular differentiation, protein 
degradation, regulation of gene expression, protein-protein interactions, signaling and 
regulatory processes (Mollova et al., 2015; Marquez et al., 2016). PTMs have a number 
of roles, including stimulating or suppressing protein functions that can have an impact 
on downstream signaling (Mollova et al., 2015). Thus, PTMs of CaMKIIδ can induce an 
autonomously active form of the kinase, a process that has been associated with 
pathological cardiac signaling (Cutler et al., 2012; Erickson et al., 2015). While this thesis 
will focus on one specific PTM of CaMKIIδ, S-nitrosylation, I will briefly describe three 






                        
Figure 1.6 Post-translational modification sites of CaMKIIδ. CaMKII is susceptible to PTMS that can bind on the regulatory domain. 
Nitrosylation (Cys 273 and Cys 290 residues), O-GlcNAcylation (Ser 280 residue), Oxidation (Met 281 and Met 282 residues) and phosphorylation 




When CaMKIIδ activation is extended due to prolonged Ca2+/CaM association, it 
undergoes autophosphorylation and a phosphate group is added at Thr287, resulting in 
autonomous activity (Erickson et al., 2008). Autophosphorylation is important because 
the resultant effects foster the binding affinity of CaM to the regulatory domain of 
CaMKII and also prohibits the autoinhibition of the kinase independent of a fall in Ica and 
dissociation of CaM from CaMKII. Autophosphorylation of CaMKII contributes to a 
number of cellular processes. For example, nuclear targeting of CaMKII is mediated by 
autophosphorylation, which could affect both transcriptional regulation and downstream 
signaling of CaMKIIδ (Mollova et al., 2015). Autophosphorylation of CaMKII is known 
to be downstream effect of ß-adrenergic signaling which contributes to the progression 
of cardiac hypertrophy and dilated cardiomyopathy (Zhang et al., 2003; Erickson, 2014).  
1.6.2 Oxidation 
Oxidative stress is defined as an imbalance between the production of ROS and 
antioxidant defences which could cause injuries in the tissues (Betteridge, 2000). Ca2+ 
elevation in pro-oxidant conditions leads to facilitation of Ca2+/CaM activity by ROS. 
Oxidation can activate CaMKII through aldosterone- and angiotensin II-dependent 
increase in ROS (He et al., 2011).  
Elevated levels of reactive oxygen species (ROS) facilitate the development of 
cardiovascular diseases. Erickson et al. (2008) showed that CaMKII activity can be 
sustained by oxidation of paired regulatory domain methionine residues (Met281/282), 
and that this process could lead to myocardial apoptosis, electrical remodelling, impaired 
cardiac function and increased mortality after myocardial infarction (Rajtik et al., 2017). 
Diabetic mice which were also CaMKII oxidation-resistant were found to be protected 
against myocardial infarction and fibrosis compared to WT diabetic mice, suggesting that 
oxidation of the methionines 281/282 sites on the regulatory domain of CaMKII plays a 
role in myocardial infarction (Luo et al., 2013). 
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1.6.3 O-GlcNAcylation  
This is a type of glycosylation that involves attachment of single O-linked N-
acetylglucosamine (O-GlcNAc) moieties to Ser and Thr residues on the regulatory 
domain of CaMKII. CaMKII is autonomously activated by O-GlcNAc modification of 
CaMKII at Ser279 during physiological stress as seen in acute hyperglycemic conditions. 
This process alters protein function and contributes to cardiac mechanical function and 
arrhythmias in diabetes (Erickson et al., 2013; Daniels et al., 2018). Erickson et al. (2013) 
found that CaMKII modification by O-GlcNAc was greater in hearts of patients with heart 
failure and diabetes compared to patients with only heart failure but not diabetic. 
Spontaneous Ca2+ release, which is enhanced by CaMKII activation, leads to cardiac and 
neuronal pathophysiology in diabetes. Mesubi et al. (2020) showed that CaMKII 
contributed to increase susceptibility of diabetic mouse hearts to atrial fibrillation via 
elevated protein O-GlcNAcylation. 
1.6.4 S-nitrosylation of CaMKII  
One of the signaling pathways of NO involves a PTM called S-nitrosylation. S-
nitrosylation is the covalent and reversible attachment of nitric oxide-related species to a 
thiol side chain of a cysteine residue in order to form S-nitrosothiol (Bradley & Steinert, 
2016; Marquez et al., 2016). S-nitrosylation sites have been observed in the neuronal and 
cardiac isoforms of CaMKII. Recently, in the delta isoform of CaMKII found in the heart, 
two sites on the regulatory domain, C273 and C290 have been confirmed to be involved 
in S-nitrosylation (Erickson et al., 2015). Further details on how CaMKII S-nitrosylation 
may affect cardiac function will be discussed in this Section 1.7.1. 
1.7 CaMKII and arrhythmias 
Post-translational modification of CaMKII is known to contribute to arrhythmia in 
cardiac disease animal models. Calcium mishandling by Ca2+ handling proteins in 
cardiomyocytes during hyperactivation of CaMKII is the cause of proarrhythmic 
electrical modelling (Erickson et al., 2011). Some studies have shown links between 
CaMKII and arrhythmias, as seen in diabetic hyperglycaemia, ß-AR stimulation and 
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oxidative stress (Sag et al., 2009; Erickson et al., 2013; Lebek et al., 2018; Neef et al., 
2018). 
CaMKII-dependent regulation of diastolic SR Ca2+ release is the important cellular 
mechanism that enables the kinase to promote arrhythmias (Vincent et al., 2014). 
Intracellular Ca2+ release is enhanced by opening probability of the RyR2 during  CaMKII 
phosphorylation (Wehrens et al., 2004). CaMKII phosphorylation of RyR2, increased SR 
Ca2+ leak and reduction in SERCA2a activity can result in Ca2+ overload in the 
mitochondria, potentially leading to diastolic dysfunction, arrhythmias and even cardiac 
death (Curran et al., 2007; Lim et al., 2017; Mohamed et al., 2018).  
A study by Curran et al. (2007) showed that ß-AR activation can upregulate SR Ca2+ leak 
in rabbit cardiomyocytes via CaMKII and this was prevented by inhibiting CaMKII. 
Cardiac arrhythmias can be enhanced by ß-AR stimulation and inhibition of CaMKIIδ 
activity by knocking out CaMKIIδ prevented the induction of SR Ca2+ leak by 
isoproterenol. 
Another mechanism that can lead to arrhythmia is inappropriate atrial depolarization that 
occurs during action potential. Development of early after depolarisations (EADs) and 
delayed afterdepolarisations (DADs) can be initiated by continuous CaMKII activation 
(Daniels, 2017). EADs occur before complete repolarisation and can be found in heart 
failure and arrhythmic conditions such as torsades des pointes (TdP), polymorphic 
ventricular tachycardia (PVT) and ventricular fibrillation (VF) (Weiss et al., 2010). DADs 
occur after complete repolarisation and in conditions of elevated intracellular Ca2+ due to 
SR overload (Daniels, 2017). In mice with heart failure and overexpressing CaMKIIδ, 
inhibition reduced the EAD arrhythmia events thereby preventing CaMKII-dependent 
effects on RyR2 (Sag et al., 2009). 
As described earlier, oxidation is one of the several mechanisms that can prolong the 
activation of CaMKII. It was found that the animal model of Duchenne muscular 
dystrophy was more susceptible to DADs and triggered ventricular arrhythmias was 
observed even in isolated hearts from same mouse model. Genetic inhibition of oxidative 
CaMKII prevented DAD incidence and prevented ventricular arrhythmias (Wang et al., 
2018). Genetically modified mice which was resistant to CaMKII oxidation were treated 
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with angiotensin II and found to be resistant to atrial fibrillation, a form of arrhythmia 
compared to wild-type mice infused with angiotensin II, suggesting that CaMKII 
oxidation increases AF susceptibility in response to angiotensin II in mice (Purohit et al., 
2013). 
In diabetic heart dysfunction, Erickson et al. (2013) reported O-GlcNAc-induced and 
glucose-dependent increase in Ca2+ sparks frequency in WT cardiomyocytes but not in 
CaMKIIδ-KO cardiomyocytes. This was suggested to occur through a CaMKII pathway 
as pharmacological inhibition using a CaMKII inhibitor reduced Ca2+ sparks in intact 
isolated cardiomyocytes.  Elevated CaMKII activity has been confirmed in diabetic rat 
hearts, and treatment of these hearts with caffeine/dobutamine made them more 
susceptible to arrhythmias. This effect was blunted by an O-GlcNAc inhibitor. Taken 
together, these suggest arrhythmic events in diabetes are CaMKII and O-GlcNaC-
dependent (Erickson et al., 2013). In pre-diabetic animal model, it was demonstrated that 
CaMKII-dependent phosphorylation of RyR2 promoted SR Ca2+ leak and led to increase 
in Ca2+ spark frequency, CaMKII inhibition in same mouse model, ablated this effect 
(Sommese et al., 2016). However, there has been no study that fully elucidates how NO 
triggers arrhythmias via CaMKIIδ signaling pathway in the whole heart.  
1.7.1 CaMKII S-nitrosylation and arrhythmias 
A few studies have shown that NO-mediated CaMKII signaling contributes to cardiac 
arrhythmias. Curran et al. (2014) showed that NO-dependent increased in SR Ca2+ leak 
led to spontaneous Ca2+ waves. Inhibition of NOS activity with N-omega-nitro-L-
arginine methyl ester (L-NAME), a non-selective NOS inhibitor, led to reduction of SR 
Ca2+ leak when compared to myocytes stimulated with isoproterenol (ISO), a ß-AR 
agonist, in the absence of L-NAME. Specific inhibition of NOS1 in the presence of ISO 
also showed a reduction in active myocytes while inhibition of NOS3 had no effect. The 
NOS1 isoform also plays a role in NO-mediated CaMKII signaling as shown by Curran 
et al. (2014), that ß-adrenergic stimulation did not increase Ca2+ leak in ventricular 
myocytes from NOS knockout (NOS1-/-) mice. Their study showed that ISO treatment of 
NOS1-/- mouse myocytes did not increase SR Ca2+ leak above control levels and inhibition 
of CaMKII did not facilitate the leak. However, in the presence of an NO donor, S-
nitroso-N-acetyl-D,L-penicillamine (SNAP), SR Ca2+ leak increased in NOS1-/- mouse 
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myocytes. This showed that NOS1-dependent CaMKII activity mediates SR Ca2+ leak. 
Therefore, there is a relationship between NO-dependent activation of CaMKII and 
increased SR Ca2+ leak. ISO increased CaMKII phosphorylation in wild- type C57BL/6 
mouse myocytes, but this was absent in NOS1-/- mouse myocytes. However, there was no 
difference when oxidised CaMKII was stimulated by ISO in WT and NOS1-/- mice. In 
conclusion, ISO dependent increase in SR Ca2+ leak was dependent on NO signaling and 
CaMKII activation (Curran et al., 2014).  
Another study showed that CaMKII was responsible for modulation of Ca2+ spark 
frequency during ß-AR stimulation. This study involved inhibiting CaMKII activity in 
Guinea pig ventricular myocytes, it was observed that the CaMKII inhibitors, KN93 and 
Autocamtide-2-Related Inhibitory Peptide (AIP) prevented increases in Ca2+ spark 
frequency in the presence of ISO while SR Ca2+ content was unchanged. This finding was 
similar to that of Curran et al. (2014). This study demonstrated that NO donor, GSNO, 
reproduced increases in Ca2+ spark frequency induced by ß-AR stimulation. On inhibition 
of CaMKII with AIP, it was observed that Ca2+ spark frequency was not significantly 
elevated by GSNO. This was further confirmed by in vitro quantification of NO-
dependent CaMKII activation and concluded that nitrosylation of CaMKII modulated 
spark frequency even in the absence of Ca2+ signals (Gutierrez et al., 2013).  
Taken together, these results show that autonomous activation of CaMKII by NO induced 
an increase in frequency of spontaneous SR Ca2+ release (Ca2+ sparks) which is a predictor 
of arrhythmias. 
1.8 CaMKII Inhibition in the heart 
1.8.1 Pharmacological Inhibitors 
Considering the deleterious effects of CaMKII in pathophysiological conditions, 
pharmacological inhibition of CaMKII has offered positive outcomes as seen in diabetic 
heart disease, heart failure, arrhythmias and myocardial infarction (Zhang et al., 2005; 
Vila-Petroff et al., 2007; Sag et al., 2009; Erickson et al., 2013; Daniels et al., 2018; Neef 
et al., 2018). 
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There are numerous CaMKII inhibitors used to elucidate the physiological effects of 
CaMKII in cells. However, KN93 and AIP are the widely used CaMKII inhibitors. KN93 
acts by selectively and competitively binding to the Ca2+/CaM thereby preventing its 
interaction with the binding site on the regulatory domain of CaMKII (Johnson et al., 
2019; Wong et al., 2019). In a study by Sag et al. (2009), CaMKII inhibition with 20 
µmol/L/kg of KN93 reduced the incidence of in vivo cardiac arrhythmias in mice 
overexpressing CaMKIIδC. However, there is also evidence that KN93 has a CaMKII-
independent effect which involves its direct interaction with a variety of ion channels and 
potentially, other kinases (Anderson et al., 1998; Tessier et al., 1999; Wu et al., 1999; 
Wong et al., 2019). A drawback in the use of KN93 is its effect on delayed rectifier 
potassium current (IKr) which plays a role in cardiac repolarisation. KN93 can inhibit IKr 
through a pathway independent of CaMKII and result in cardiac arrhythmias (Hegyi et 
al., 2015). Therefore, the use of KN93 to inhibit CaMKII may interfere with the outcomes 
of studies investigating CaMKII inhibition and arrhythmias.   
AIP is a peptide-competitive and highly specific CaMKII inhibitor which acts by blocking 
the catalytic domain and is more effective in inhibiting the kinase in an autonomous state 
compared to KN93 (Ishida et al., 1995; Daniels et al., 2018). In a study investigating the 
role of CaMKII activation in cardiac function using trabeculae of rat model of type 2 
diabetes, AIP fully restored developed force, and rates of contraction and relaxation 
compared to KN93 which partially restored the myocardial function parameters (Daniels 
et al., 2018). 
1.8.2 CaMKII knockout mouse models 
In addition to CaMKII inhibitors, transgenic mouse models with global deletion of one 
or more CaMKII isoforms have been developed. CaMKIIδ-deficient mice as generated 
by Ling et al. (2009) did not have any significant impairment in cardiac function 
compared to the C57BL/6 wild-type (WT) mice. CaMKIIδ deletion did not cause any 
increase in mortality and the mice did not exhibit any abnormality in their basal cardiac 
function measured via echocardiography (Backs et al., 2009; Grimm et al., 2015). 
According to Backs et al. (2009), CaMKIIδ-KO mice were protected against hypertrophy 
and fibrosis, when induced with pressure load via thoracic aortic constriction. Knocking 
out CaMKIIδ did not alter the response of CaMKIIδ-KO mice hearts to ß-AR stimulation 
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in comparison with WT mice hearts, however they were protected from fibrosis induced 
by chronic ß-AR stimulation (Grimm et al., 2015). In order to prevent off target effects 
of CaMKII inhibitors, CaMKIIδ-KO mouse model is preferred for investigating the role 
of CaMKIIδ in the heart. 
1.9 Conclusion 
Consistent with other studies, PTMs like S-nitrosylation can lead to cardiovascular 
diseases. Since the improvement in survival of CVDs is likely to have a great impact on 
the health system, it is important that the mechanism underlying this is understood. Even 
though previous studies have shown that NO can modulate CaMKII function via S-
nitrosylation and contribute to pathological signaling, the mechanism of this process is 
elusive. According to Erickson et al. (2015), nitrosylation of CaMKIIδ happens at two 
key sites, Cys-273 and Cys-290. Depending on which of them becomes nitrosylated, 
CaMKII activity can either be activated or inhibited. They showed that nitrosylation at 
Cys-290 site increases CaM-binding and nitrosylation at Cys-273 site appears to reduce 
CaM-binding, therefore ablates the effect of CaMKIIδ autonomous activity. This 
evidence suggests that the activation state of CaMKII is important when considering the 
possibility of nitrosylation of the kinase.  
Therefore, further understanding is required as to how S-nitrosylation affects cardiac 
function to cause arrhythmias, how the role of the two nitrosylation sites, Cys-273 and 
Cys-290 contribute to the alteration of whole heart function, and also how targeted 
permanent inhibition of CaMKIIδ can help attenuate the outcomes of autonomous 
activation of CaMKIIδ in the heart. 
1.10 Overview and scope of thesis 
This thesis assessed the effects of NO-mediated CaMKIIδ activity in pathological cardiac 
signaling. The main aim of this study was to determine the role of NO in the modulation 
of CaMKII and how this contributes to development of cardiac arrhythmias. Firstly, I 
determined the effect of acute NO treatment on contractile parameters in isolated hearts 
from 3 mouse models; a model with intact CaMKII, a model without CaMKIIδ, and a 
model lacking both cardiac isoforms CaMKIIδ and CaMKIIγ (Chapter 3). I also assessed 
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the effect of ß-adrenergic signaling and NO treatment on cardiac function of isolated 
mouse hearts with intact CaMKIIδ (Chapter 4). Finally, I investigated the effects of 
chronic NO treatment on cardiac function in isolated hearts from mouse models with and 
without CaMKIIδ (Chapter 5). 
1.10.1 Aims and Hypotheses 
The three key aims of this project were: 
Aim 1. Effects of acute NO-mediated CaMKII activation on cardiac function.  
This was to determine the acute effects of NO on the cardiac contraction and relaxation 
in mice lacking cardiac isoforms of CaMKII. I hypothesized that NO could alter cardiac 
contraction and relaxation and will prevent cardiac arrhythmias in mice lacking the 
cardiac isoforms of CaMKII. To test this hypothesis, I performed echocardiography to 
determine the baseline cardiac function of 12-week old C57BL/6 wild type mice and 
CaMKIIδ-KO mouse models. Subsequently, I isolated the hearts from these mouse 
models and treated the hearts with different concentrations of a NO donor, S-
nitrosoglutathione (GSNO), using Langendorff isolated heart perfusion technique. Then 
I measured the contractile parameters and quantified the arrhythmias in the isolated hearts 
from this setup. I did gel electrophoresis and western blotting to determine expression 
levels of CaMKII in the stored heart tissues. 
Aim 2. Effect of ß-adrenergic stimulation and NO treatment on cardiac function in WT 
mice. 
This was to determine how NO-mediated activation of CaMKII and ß-adrenergic 
signaling affects cardiac function in mice with intact cardiac CaMKII.  I hypothesized 
that treating mouse hearts with a NO donor, GSNO and a non-selective ß-AR agonist, 
isoproterenol (ISO) will cause S-nitrosylation of CaMKII and enhance cardiac 
arrhythmias. To test this hypothesis, I isolated hearts from 12-week old C57BL/6 mice 
and perfused them with GSNO and ISO. During the perfusion, I measured cardiac 
contraction and relaxation, and counted the number of arrhythmias. I alternated the order 
of the drug treatment, ISO before GSNO and GSNO before ISO. The aim was to 
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determine if the timing of NO-mediated CaMKII activation may influence ß-adrenergic 
induced arrhythmias in the heart. The tissues were then saved for determination of protein 
expression and activity levels (phosphorylated and nitrosylated proteins). 
Aim 3. Cardiac alterations associated with chronic NO treatment in mouse hearts.  
In this aim, I measured the chronic effects of NO on the cardiac function of wild type and 
CaMKIIδ-KO mice. I hypothesized that NO may alter cardiac function and mice lacking 
CaMKIIδ will be resistant to NO-induced cardiac arrhythmias. I administered GSNO to 
13-week old mice for 5 weeks and performed echocardiography before and after the 
treatment. The mice hearts were isolated at the end of the treatment protocol and perfused 
with GSNO while the cardiac function parameters were measured. Plasma samples from 
the mice were obtained and analysed for NO concentration. I also determined expression 
levels of total, phosphorylated and nitrosylated CaMKII. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Animal Models 
2.1.1 Wild-type C57BL/6 Mouse 
The wild-type C57BL/6 mouse is an inbred laboratory genotype of mice. It is a non-
pathological model that has normal expression of the δ and γ cardiac isoforms of CaMKII. 
It will be referred to as WT throughout this thesis.  
2.1.2 CaMKIIδ-KO Mouse 
I used a genetically modified genotype of mouse with the C57BL/6 background,  but 
deficient of the predominant cardiac isoform of CaMKII, δ (Ling et al., 2009). It will be 
referred to as knockout (KO). 
2.2 Animal Husbandry 
The mice were housed and maintained in University of Otago’s animal facility (Hercus 
Taieri Resource Unit), in a controlled environment of 12-hour light/dark cycle and 
temperature of 21 ± 1 oC. The mice were fed standard chow diet (Teklad Diet, Wisconsin, 
USA) and water was available ad libitum. All experimental protocols were carried out 
according to procedure guidelines approved by the University of Otago Animal Ethics 
Committee (Dunedin, New Zealand) (AUP – 9/15) and in accordance with New Zealand 
Animal Welfare Act (1999). The mice were weighed at the commencement of each 
experiment, and the body weights and ages were recorded. The age or weight of the 
animals is specified in each chapter. 
2.3 Echocardiography 
This is a non-invasive imaging technique used to view the anatomical structures of the 
the heart and assess cardiac function (Gao et al., 2000). Transthoracic echocardiography 
procedures in all mouse models were performed with a high-resolution ultrasound 
echocardiogram machine (Vivid E9, General Electric Vingmed Ultrasound, Norway). 
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The mouse was placed in a closed chamber and anaesthetised by continuous inhalation of 
2% isoflurane gas and 0.5 L/min of 100% O2. As soon as loss of righting reflex was 
observed, the mouse was taken out of the chamber and placed in a supine position, with 
the limbs partially taped to the board, on a warm heating pad to maintain body 
temperature at 37oC. The mouse was then placed in a nose cone to ensure continuous 
inhalation of the isoflurane gas maintained at 1.5%. The chest hair was shaved using a 
hair removal cream. Ultrasound probe with the frequency of 11-MHz was coated with gel 
and placed on the thoracic area of the mouse to obtain images along the long and short 
axes of the heart (see Figure 2.1). All captures were obtained at the level of the papillary 
muscles. The images were analysed offline and each measurement was obtained from an 
average of 15 cardiac cycle measurements. To prevent bias, I was blinded by another 
researcher before echocardiography data analysis. 
2.3.1 Left ventricle structure and systolic function 
Two-dimensional (2D) echocardiographic parameters were obtained from the parasternal 
short-axis in M-mode (see Figure 2.2). The measurements obtained include, LV 
interventricular septal thicknesses at diastole and systole (IVSd, IVSs), LV internal 
dimension at diastole and systole (LVIDd, LVIDs), and posterior wall thicknesses at 
diastole and systole (LVPWd, LVPWs) and R-R Interval. End diastolic volume (EDV), 
end systolic volume (ESV), ejection fraction (EF), fractional shortening (%FS), stroke 
volume (SV), cardiac output (CO) and heart rate (HR) were calculated from the obtained 
measurements.  
2.3.2 Left Ventricular diastolic function 
Using pulse wave doppler, trans-mitral inflow doppler in the long-axis measured the peak 
velocities of early (E wave) and late (A wave) filling of mitral inflow, and E/A ratio. 
Deceleration time (DT) of early filling of mitral inflow was also obtained by measuring 
the peak of E wave to the baseline (Figure 2.3). 
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Figure 2.1 Echocardiography setup. Animal under anaesthesia placed in a supine position on a heat pad to maintain body temperature at 37 oC. 
Probe connected to echocardiograph machine placed on the shaved area of the chest. Anaesthesia was maintained through the nose cone with 0.5 
L/min 100 % oxygen and 1.5 – 2 % isoflurane. Original Figure by Esther Asamudo. 
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Figure 2.2 A sample M-mode image capture for assessment of left ventricular 
structure and systolic function. LV interventricular septal thicknesses at diastole and 
systole (IVSd, IVSs), LV internal dimension at diastole and systole (LVIDd, LVIDs) and 
Posterior wall thicknesses at diastole and systole (LVPWd, LVPWs) and R-R interval. 
 
 
Figure 2.3 A representative pulse wave doppler image for assessment of left 
ventricular diastolic function. Peak velocities of early (E) and late (A) filling of mitral 
flow. 
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2.4 Langendorff isolated heart perfusion 
This is a perfusion system that provides information on cardiac function, including 
inotropy and chronotropy without the interference of other body systems or hormones 
(Reichelt et al., 2009; Bell et al., 2011; Liao et al., 2012). It is designed in a way that even 
though the heart is outside the body, it still receives adequate oxygenation and nutrient 
delivery to maintain its viability and optimal function in order to aid the experiment ex 
vivo. 
The Langendorff rig setup (see Figure 2.4) consisted of a 23-guage cannula, a 
thermostatically controlled water bath (Lauda, Germany), peristaltic pump (Gilson, 
France), flow meter (Transonic systems Inc., USA) and pressure pump controllers, 
coronary pressure and LV pressure transducers (ADInstruments, Australia), intra 
ventricular (LV) balloon, bubble trap/heat chamber, compliance chamber, double-
jacketed organ bath, oxygenators for carbogen, Powerlab data acquisition system and 
LabChart software (ADInstruments, Australia). 
The heart was perfused with a modified Krebs-Henseleit Buffer (KHB) containing the 
following salts and concentrations: NaCl 118.5 mM, KCl 4.7 mM, MgO4S.7H2O 1.2 mM, 
KH2PO4.H2O 1.2 mM, NaHCO3 25 mM, Glucose 11 mM, Pyruvate 2 mM, CaCl2.2H2O 
2 mM. To arrest the heart after dissection, the KHB solution was modified to KCl 18.8 
mM and did not contain pyruvate and CaCl2.2H2O. The perfusion solution was stored in 
a cylinder and placed in the water bath heated to 37oC. The solution was continuously 
gassed with carbogen (95% O2 and 5% CO2) for oxygenation and maintenance of pH at 
7.4 and then delivered to the isolated heart through tubes controlled by a peristaltic 
perfusion pump. The compliance chamber was a 50 ml syringe filled partly with air and 
about 10 ml of KHB, this was to act in the way the compliant walls of the aorta would in 
vivo to allow for consistency in systolic and diastolic cycles and consistent perfusion. The 
arresting solution for the heart was in a beaker placed on ice and gassed with carbogen 
(95% O2 and 5% CO2) prior to excision of the heart.  
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2.4.1 Heart Excision 
Under anaesthesia with isoflurane (5% at 0.5 L/min of oxygen), the mouse was injected 
intraperitoneally with anticoagulant, heparin (10,000 U/kg). Five minutes after the 
heparin injection, the fur was pulled up and cut, the peritoneum was cut to the left and 
right, to expose the thoracic cavity. The rib cage was cut on both sides, raised and clipped 
back. Once the beating heart was exposed, the aorta was identified and clipped. The heart 
was excised and placed in a beaker containing the gassed ice-cold high KCl KH buffer 
solution (arresting solution) before being transferred to the petri-dish for cannulation. The 
excision and cannulation was performed in less than 5 minutes to ensure viable heart 
function. 
2.4.2 Cannulation 
The aorta was identified and picked up with tweezers on the edge. Using another set of 
tweezers, the other edge of the aorta was clipped and pulled up like a sock on the cannula 
(a blunt-ended grooved 23-guage needle). Using a fine edged clip, the aorta was secured 
on the cannula temporarily, and then tied with a thin suture, the flow from the buffer was 
increased to begin perfusion and restart the heartbeat. A second suture was knotted. 
Excess tissues surrounding the aorta were carefully trimmed off. The cannula with the 
heart was hung vertically and placed in the warmed perfusate which was passed through 
a 0.45 µm GVS filter (GVS, USA) before entering the coronary circulation via the aorta 
(see Figure 2.5). The coronary pressure was maintained at an average of 75 mmHg and 
coronary flow rate range of 1.5 ml/min – 4.5 ml/min. The heart was allowed to stabilize 
for 5 minutes. Flow rate was determined by pressure pump controller to maintain constant 
perfusion pressure. Coronary flow was measured in real time using an in-line flow probe 
in the perfusion line. Hearts with coronary flow greater than 4.5 ml/min were excluded 
as that could be indication of a tear in the aorta and hearts with flow rate lower than 1.5 
ml/min were also excluded as it indicated that there could be an air bubble in the coronary 
circulation therefore inadequate perfusion.  
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2.4.3 Pressure measurements 
Coronary pressure was measured by a line connected via the sidearm of the cannula to 
the pressure transducer. The coronary pressure transducer was calibrated using a 
sphygmomanometer. LV systolic and diastolic pressures were measured using a custom-
made balloon attached to a pressure transducer. The balloon was made from saran wrap 
and a polyethylene PE-50 tube. One end of the tube was connected to a syringe filled with 
~20 µl of Milli-Q water. A small square was cut out from the saran wrap and attached to 
the other end of the tube, then tied loosely with a thin suture to form a balloon (see Figure 
2.6). The balloon was then inflated gently with the Milli-Q water via pressure on the 
syringe to slowly expel air bubbles. Once it was ensured that air bubbles were expelled, 
the knot was then tired securely. The balloon was then inspected for leaks, and a second 
suture was to prevent any leaks. The LV balloon was connected to a pressure transducer. 
The left atrium was cut and removed to expose the atrioventricular (AV) valve. The 
balloon was deflated and carefully pushed into the LV and secured in place with a tape 




                                           
Figure 2.4 Langendorff isolated heart setup. The mouse heart cannulated and immersed in the organ bath with a temperature probe to ensure 
that temperature of 37oC is maintained. The gassed KHB flowed through the tubes and was pumped by the peristaltic pump into the system, it 
passed through the filter, compliance chamber, the in-line flow probe, the bubble trap/heat chamber and then into the isolated heart. The transducers 
were connected to a powerlab which generated signals that were recorded using LabChart software to determine coronary perfusion pressure and 
LV pressure (connected to the balloon in the left ventricle of the heart). Original figure by Esther Asamudo. 
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Figure 2.5 Representative image of an isolated mouse heart on a Langendorff rig. 
The balloon is inserted into the left ventricle of the heart via the left atrioventricular valve 
and secured by taping it to the top part of the cannula. 
 
 
Figure 2.6 Mouse ventricular balloon. 
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The balloon was custom made in the laboratory using a polyethylene tube, saran wrap 
and thread. Deflated before inserting into the left ventricle and inflated when it is in the 
left ventricle.  
2.4.4 Experimental Protocol 
The balloon was inflated with 5 – 15 µL of Milli-Q water in order to stretch the 
myocardial fibres and achieve a left ventricular end-diastolic pressure (LVEDP) of 5 – 10 
mmHg. The heart was then immersed in the temperature-controlled organ bath filled with 
pre-warmed buffer. The LV pressure trace was monitored for consistent steady-state 
pressure development and normal heart rhythm before obtaining basal heart function 
parameters. The transducers measured coronary pressure, coronary flow rate and LV 
pressure. At the end of the experiment, the left and right ventricles were dissected off the 
cannula and snap frozen in liquid nitrogen and stored at -80oC. The recorded trace (Figure 
2.7) was saved for offline analysis.  
2.4.5 Offline analysis 
Using Labchart 7.0 software (ADInstruments, Australia), the following parameters were 
obtained; left ventricular developed pressure (LVDP), heart rate (HR), maximum and 
minimum rate of developed pressure (Max dP/dt and Min dP/dt). LVDP is the change in 
peak systolic pressure and diastolic pressure. Heart rate is the number of beats per 60 
seconds, calculated from the systolic and diastolic cycle duration. Max dP/dt is the 
steepest slope during the upstroke of the LV pressure curve, indicating rate of contraction 
and min dP/dt is the steepest slope during the downstroke of the LV pressure curve, 
indicating rate of relaxation. Pressure-Time integral is the index of average pressure 
developed by the cardiac muscle per beat and is derived from the product of average 
developed pressure and systolic time. The last 3 minutes of the recorded trace (Figure 
2.8) per protocol was selected and analysed to obtain the average for each parameter. The 
abnormal beats (arrhythmia events) were counted individually in the last 3 minutes of 
each protocol to obtain an average. The data from the software was exported for 
processing and analysis.  
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Figure 2.7 A sample trace recording from LabChart during Langendorff isolated 
heart Perfusion, showing the traces of a full experiment, indicating LV pressure, 
coronary pressure, coronary flow, temperature and heart rate of the isolated heart.  
 
                   
Figure 2.8 Representative image from LabChart showing analysis parameters; 
Developed pressure (maximum pressure – minimum pressure), Max dP/dt (Rate of 
contraction), Min dP/dt (Rate of relaxation) and End diastolic pressure (EDP). 
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2.4.6 Determination of arrhythmias  
Arrhythmia count was done according to the method of Huggins et al. (2008). The 
different types of arrhythmias identified in the isolated mouse hearts included; ventricular 
premature beats (VPBs), bigeminy, trigeminy, potentiated contraction and ventricular 
tachycardia (VT) (Figure 2.9). VPBs were defined as an early contraction prior to 
relaxation and is often succeeded by a larger subsequent beat (Figure 2.9B). Bigeminy 
was defined as paired beats occurring in repetition (Figure 2.9C). Trigeminy was defined 
as a triplet beat occurring in repetition with every third beat as a premature beat (Figure 
2.9D). Potentiated contraction was referred to as normal sinus rhythm then a slight delay 
before an increased single contraction and followed by resumption of sinus rhythm 
(Figure 2.9E). Ventricular tachycardia was defined as a run of four or more ventricular 
premature beats in quick succession (Figure 2.9F).  
To determine severity, each heart was also evaluated by a 5-point arrhythmia score 
adopted from Curtis and Walker (1988). Score E from this previous study, was modified 
to include the following characteristics; 
Table 2.1 Arrhythmia score classification 
Arrhythmia        Characteristics 
    Score 
      0                 0 – 5 VPBs (no arrhythmias or isolated VPBs) 
      1                 6 – 20 VPBs (very occasional bigeminy and trigeminy) 
      2                 21 – 100 VPBs (frequent bigeminy, trigeminy and PCs) 
      3                 > 100 VPBs or 1 – 2 episodes of VT 
      4                 ≥ 3 VT 
      5                 VF or death 




The arrhythmias were counted from the start to the end of each protocol, characterized 
according to the arrhythmia scores and then recorded against the time (8, 16, 24, 32 
minutes) and different doses depending on the group. 
 
Figure 2.9 Sinus rhythm and arrhythmia events identified in isolated hearts. 
Representative traces showing (a) sinus rhythm (b) ventricular premature beats (c) 
bigeminy (d) trigeminy (e) potentiated contraction, and (f) ventricular tachycardia. 
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2.5 Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
and Western Blotting 
2.5.1 SDS-PAGE  
To determine protein expression in mice heart tissues, acrylamide gels of 6% or 10% were 
made in gel casting plates with 1.5 mm spacers (BioRad) depending on the protein of 
interest. A resolving gel (see Table 2.2) was cast and topped up with Milli-Q water to 
prevent an uneven layer and achieve a flat-topped gel solution. The resolving gel was left 
to polymerise for 1 hour. This process was followed by discarding the Milli-Q water 
overlaying the resolving gel and loading of the stacking gel (see Table 2.2). This was 
immediately followed by inserting a 15-well comb to create wells for loading samples. 
The stacking gel was allowed to polymerise for 1 hour.  
2.5.2 Homogenisation of cardiac tissue 
Ventricular heart samples were obtained from perfused isolated hearts tissues and used 
for Western blotting . The frozen tissues were thawed and placed in 2 ml micro centrifuge 
tubes. Magnetic beads (Advance Inc., USA) were added to the centrifuge tubes with 
Radio Immunoprecipitation Assay (RIPA) buffer including phosphatase and protease 
inhibitors (see Table 2.3). The tubes were placed carefully in a bullet blender and the 
tissues were blended for 4 minutes at speed 8 after which samples were taken out and 
visually inspected for complete homogenization. The samples were left to cool on ice for 
15 minutes, then centrifuged at a speed of 15,000 rcf at 4oC for 15 minutes. The 
supernatant was taken and stored in 1.5 ml tubes. The total protein concentrations of the 
homogenates were measured using the protein A280 method (Simonian & Smith, 2006), 
RIPA buffer was used as blank. The homogenates were aliquoted, snap-frozen in liquid 






Table 2.2 Constituents of resolving and stacking acrylamide for 10% gel 
Chemicals Resolving (µl) Stacking (µl) Supplier 
Milli-Q water 3832 2516 Merck 
Millipore 
1.5 M Resolving buffer (375 
mM Tris) 
2000 - Biofroxx 
0.5 M Stacking buffer (375 
mM Tris) 
- 1000 Biofroxx 
40 % Acrylamide 2000 400 Merck 
10 % SDS 80 40 Merck  
10 % Ammonium Persulfate 
(APS)  
80 40 Sigma 
Tetramethylethylenediamine 
(TEMED) 
8 4 Merck  
 
 
Table 2.3 Constituents of RIPA Buffer 
Chemical Concentration Supplier 
Triton X-100 1 % (w/vol.) Applichem 
SDS 0.1 % Merck  
Tris-HCL (pH 7.4) 50 mM Biofroxx 
NaCl 150 mM Applichem 
EDTA 1 mM Applichem 
Phosphatase and Protease Inhibitors 
PMSF (Phenylmethane 
sulfonyl fluoride) 
1 mM  Sigma 
PhosSTOP 1X Roche 




2.5.3 Gel Electrophoresis 
For gel electrophoresis, Milli-Q water was added to sample tubes, followed by 20 µg of 
protein homogenates and sample buffer (Tris 0.31 M pH 6.8, Glycerol 50 %, SDS 10 %, 
Dithiothreitol 0.5 M, Bromophenol blue 0.05 %). The diluted samples were then 
incubated on the heat block for protein denaturation. The temperature of the heat block 
and length of time was dependent on the protein of interest (Table 2.4). After protein 
denaturation, the sample combination was centrifuged at 13,500 rpm for 30 seconds at 
room temperature. When samples were ready to be loaded into the wells, the gel was 
placed in a vertical electrophoresis tank (BioRad) filled with running buffer (Glycine 1.92 
M, Tris 0.25 M, SDS 1 %). Precision protein plus dual colour standard (4 µl; BioRad) 
was added to the first well to serve as molecular weight marker. The aim was to monitor 
the protein migration and also to help determine the size of protein of interest on the 
membrane. The subsequent wells were loaded with 5 µl of the prepared protein samples. 
Electrophoresis was then performed using the voltage and running times specified in 
Table 2.4. 
2.5.4 Western blotting 
A wet tank transfer of the proteins from the acrylamide gel to a polyvinyl difluoride 
(PVDF) membrane with porosity of 0.22 – 0.45 µm (BioRad) was used. To begin, the 
PVDF membrane was activated in 2 ml of 20% methanol (Merck Millipore). The sponge, 
filter paper, PVDF membrane, gel, filter paper and sponge were soaked in transfer buffer 
(Glycine 1.92 M, Tris 0.25 M, SDS 10 %, methanol 20 %) and placed in the cassette in 
the same order. Attention was placed on the orientation of the membrane and the gel; the 
former was placed towards the anode and the latter towards the cathode. The sandwich 
was made in a cassette, rolled after each layer to prevent air bubbles existing between the 
gel and the membrane, thereafter, sealed tightly and placed in a tank filled with transfer 
buffer (Transfer time specified in Table 2.4).  
At completion of the transfer process, the membrane was removed from the cassette and 
blocked by incubating with 5% skimmed milk in Tris-buffered saline (Tris 0.5 M, NaCl 
1.5 M) containing 0.5 % Tween-20 (TBS-T) for 2 hours. After this, the membrane was 
washed twice in quick succession and allowed to sit in TBS-T for 1 minute at room 
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temperature. Subsequently, depending on the protein of interest, the membranes were 
incubated with their corresponding primary antibodies (see Table 2.5). The antibody 
concentrations for Western blotting were based on optimization from pre-established 
laboratory protocols. Thereafter, the membranes were washed four times in TBS-T (5 
minutes between each wash). The membranes were further incubated with secondary 
antibodies (see Table 2.5) for 1 – 2 hours at room temperature. This was followed by 
washing with TBS-T four times after every 10 minutes. 
2.5.5 Blot analysis 
The membranes were incubated in freshly prepared Clarity Western ECL substrate (Bio-
Rad) for 5 minutes at room temperature. Each membrane was placed between two 
transparent plastic sheets and placed in the SynGene Imager Pxi 4 (Cambridge, UK) for 
visualization and detection of chemiluminescent signal via the GeneSys image acquisition 
software. To test for total and phosphorylated proteins on the same blot, the membrane 
was stripped of antibodies and re-probed. The membrane was incubated in low pH (2.0) 
stripping buffer (Glycine 25 mM, SDS 1 %, distilled water 400 ml) for 10 minutes at 
room temperature and washed in TBS-T 3 times for 10 minutes each time and finally 
once in TBS for 5 minutes. The membrane was imaged to confirm completion of 
stripping. To re-probe with different antibody, the membrane was blocked in 5% milk in 
TBS-T and incubated in primary and secondary antibodies.  
The blot images were analysed with Genetools 1.0, a SynGene image analysis software. 
The densitometry values of total protein were normalized to that of GAPDH 
(housekeeping protein). The ratio of phosphorylated to total proteins was then calculated.  
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Table 2.4 Specific SDS-PAGE and Western blotting protocols for each protein 
 Protein of interest 
CaMKII CaMKII Thr 287 GAPDH 
Molecular weight (kDa) 50  50 37 
% Gel 10 10 10 
Heat block temperature (oC) 95 95 95 
Heat block duration (minutes) 5 5 5 
Protein loading (µg) 20 20 20 
Gel running duration (minutes) 100 100 100 
Running voltage (V) 120 120 120 
Membrane type PVDF PVDF PVDF 
Transfer duration (minutes) 180 180 180 
Transfer voltage (V) 100 100 100 
Primary antibody incubation 
duration (minutes) 
overnight overnight 60 
Secondary antibody incubation 
duration (minutes) 
60 120 60 
    
Table 2.5 Western Blotting Antibodies 
Protein Primary antibody Secondary antibody 
Concentration Species Supplier Concentration Species Supplier 
















All antibodies were diluted in Tris-buffered saline containing Tween-20. 
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2.6 Statistical analyses 
All numerical data were exported to Microsoft Excel 2016 and statistical analysis was 
done with GraphPad Prism (version 8.4.0). All data are presented as mean ± standard 
error of the mean (S.E.M). Shapiro-Wilk normality test was carried out to determine 
statistical distribution of data. Mean comparison of normally distributed data was 
performed using parametric test. Unpaired t-test was used to compare two population 
means that did not belong to the same sample group. One-way analysis of variance 
(ANOVA) was used to compare variance between group means of three or more 
categorical groups with one independent factor and two-way ANOVA was used to 
compare between group means with two independent factors. Three-way ANOVA was 
used to compare three independent variables and one dependent variable. Repeated 
measures ANOVA was used in analysis of data that involved repeated measurements, for 
example, drug concentration. ANOVA analyses were followed by multiple comparisons 
using uncorrected Fisher’s LSD test. Data that did not pass normality test were subjected 
to non-parametric Mann-Whitney test (for unpaired t-test) or Kruskal Wallis test (for 
ANOVA). Correlation between two variables was determined by correlation. Pearson 
correlation coefficient was used for normally distributed and Spearman correlation was 
used to data that did not pass the normality test. Statistical significance was indicated as 
p < 0.05.  
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CHAPTER 3: EFFECTS OF ACUTE GSNO TREATMENT 
AND LOSS OF CAMKII ON CARDIAC FUNCTION 
3.1 Introduction 
NO plays a role in pro-arrhythmic signaling in cardiac cells, and the pathway for this 
action is mediated by CaMKII (Gutierrez et al., 2013). Currently, how CaMKII 
contributes to arrhythmias in the whole heart is not fully understood. This chapter is 
focused on assessing the acute effects of GSNO on cardiac function in the presence and 
absence of CaMKIIδ, using C57BL/6 wild-type (WT) and CaMKIIδ-KO mice. 
It is well known that ECC involves the propagation of electrical signaling in 
cardiomyocytes, which leads to Ca2+ release from the SR into the cytoplasm via a CICR 
mechanism. Ca2+ binds to myofilaments to initiate contraction and dissociation of Ca2+ 
from troponin C which is facilitated by Ca2+. Reuptake via Ca2+ transporters leads to 
relaxation (Bassani et al., 1994). The amount of Ca2+ flux through the cardiomyocyte 
during ECC determines the inotropic and lusitropic response (the contractile force and 
the rate of relaxation) (Dibb et al., 2007; Landstrom et al., 2017). Since Ca2+ is the critical 
ion that mediates this process, it is important to have a balance between SR Ca2+ release 
and uptake. A disruption in intracellular Ca2+ handling can result in cardiac dysfunction. 
Research has shown that reactive nitrogen species including NO can play a role in 
dysregulation of ECC, leading to calcium mishandling and arrhythmogenesis (Gutierrez 
et al., 2013; Curran et al., 2014).  
NO is widely known for its protective role in the cardiovascular system by preventing 
hypertension and arrhythmias (Rees et al., 1996; Shesely et al., 1996; Kubota et al., 2000; 
Rakhit et al., 2001; Gonzalez et al., 2007). However, novel evidence has emerged 
showing that NO can induce spontaneous Ca2+ release events (known as Ca2+ sparks) 
from the SR via RyR2 channels during diastole in cardiomyocytes. Increased Ca2+ spark 
frequency is an indicator of SR Ca2+ leak (Bers, 2014) due to RyR2 phosphorylation 
(Wehrens et al., 2004; Zima et al., 2010). When these Ca2+ sparks build up with 
synchronisation in space and time, they evolve into Ca2+ waves (Shiferaw et al., 2012). 
The Ca2+ waves release Ca2+ ions, which activate Ca2+ sensitive currents and result in 
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afterdepolarisations, the underlying mechanism of triggered arrhythmias (Shiferaw et al., 
2012). Using isolated NOS1 knockout hearts, Wang et al. (2010) demonstrated a decrease 
in Ca2+ spark frequency associated with decreased opening rate of RyR2 channels, and 
this effect was reversed with exposure to a NO donor. These results suggested that 
increased SR Ca2+ leak associated with NO signaling does not occur via direct action on 
RyR2 rather through CaMKII phosphorylation of RyR2. Gutierrez et al. (2013) found that 
NO caused an increase in Ca2+ spark frequency in cardiomyocytes and confirmed that this 
was primarily due to CaMKII activity.  
NO-induced spontaneous Ca2+ waves in cardiomyocytes result in part from nitrosylation 
of CaMKII leading to its aberrant activation, which can cause deleterious effects 
including arrhythmias (Gutierrez et al., 2013). There is limited knowledge from previous 
studies about how NO modulates CaMKII activity to affect whole heart function as all 
studies investigating the relationship between NO, CaMKII and arrhythmias have been 
carried out using cardiomyocytes. In cardiomyocytes, according to Curran et al. (2014), 
NO exposure induced Ca2+ leak, and this effect was ablated with a CaMKII inhibitor. This 
suggests that CaMKII activation was required to facilitate SR Ca2+ leak during NO 
signaling. At the cellular level, there is evidence that NO activates CaMKII inducing 
spontaneous Ca2+ leak and this could result in cardiac arrhythmias. Erickson et al. (2015) 
reported that NO could directly regulate the activity of the primary cardiac isoform of 
CaMKII (CaMKIIδ). They demonstrated that activation of CaMKIIδ with Ca2+/CaM 
followed by addition of a NO donor (GSNO) induced Ca2+ sparks in mouse ventricular 
myocytes.  
These studies show that CaMKII plays a role in mediating NO-induced arrhythmogenesis 
in cardiac cells, and that CaMKII inhibition protects against spontaneous Ca2+ release. 
Taken together, it suggests this protein is a potential therapeutic target in preventing 
arrhythmias associated with NO signaling. As described in Chapter 1, pharmacological 
inhibitors of CaMKII have shown promising results in preventing cardiac arrhythmias; 
however, they also have off target effects when compared to the knockout models of 
CaMKIIδ where there is loss / reduction of protein expression.  The use of the CaMKIIδ 
knockout model could provide a clearer understanding about how NO alters CaMKII 
signaling pathway and the downstream effects on cardiac function.  
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3.1.1 Objectives and hypotheses 
The aim of the study described in this chapter was to determine the influence of NO on 
CaMKII signaling in isolated perfused hearts and how this contributes to cardiac 
dysfunction. The following objectives were outlined to determine the effect of GSNO on 
CaMKII activity and how this affects cardiac function: 
1) To determine total CaMKII expression levels in WT and CaMKIIδ-KO mouse models 
using Western blotting. I hypothesised that WT mouse hearts would have a relatively 
higher expression of total CaMKII compared to KO mouse hearts.  
2) To measure the in vivo basal cardiac function of WT and CaMKIIδ-KO mouse models 
via echocardiography. Based on the knowledge of basal CaMKII activity, I 
hypothesised that loss of CaMKIIδ would not alter cardiac function at baseline. 
3) To determine the effect of GSNO treatment on cardiac function using Langendorff 
isolated heart perfusion technique. I hypothesised that treating the isolated hearts with 
a NO donor would alter heart rate and contractility in WT and CaMKIIδ-KO mouse 
hearts. 
4) To investigate how loss of CaMKIIδ affects arrhythmias with GSNO treatment. I 
hypothesised that GSNO would trigger arrhythmias in WT mouse hearts but not in the 
CaMKIIδ-KO mouse models. 
3.2 Experimental Design 
To test the first hypothesis, I determined CaMKIIδ expression levels in the WT and KO 
mice using Western blotting in frozen cardiac tissues. 
I performed echocardiography (protocol described in chapter 2, section 2.3) to determine 
the in vivo baseline cardiac function of 12-week-old WT and CaMKIIδ-KO mice. After 
echocardiography, I randomly assigned the animals into 4 groups and subsequently used 
Langendorff isolated heart perfusion technique to isolate the hearts and treat with a NO 
donor, GSNO. The WT and KO animal models had treatment and control groups. The 
control groups served as time control to account for variations in the isolated hearts during 
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the experiment (Appendix 1). The treatment groups received different concentrations of 
GSNO (100 µM, 600 µM, 1600 µM). 
The hearts were isolated from the mice (described in Chapter 2, section 2.4). After initial 
stabilisation and achieving LVEDP of 5 – 10 mmHg (see Figure 3.1), each heart was 
allowed to stabilise for another 20 minutes, a total of 30 minutes. The first 8 minutes after 
that was considered baseline, then depending on the group (control or treatment), the heart 
was perfused with vehicle for 24 minutes or increasing concentrations of GSNO (100 µM, 
600 µM and 1600 µM) were added every 8 minutes.  
The arrhythmias were counted individually from the start to the end of each protocol and 
then recorded against the duration (8, 16, 24, 32 minutes) or different GSNO 
concentrations, depending on the group. 
 
Figure 3.1 A time course protocol for Langendorff isolated heart perfusion 
experiment 
 
3.2.1 Statistical Analyses 
Data was represented as mean ± standard error of mean (SEM). Normality of the data was 
determined with Shapiro-Wilk normality test. Unpaired t-test was used to compare 
baseline WT and KO contractile parameters. To determine the difference in GSNO effect 
and animal genotype effect, two-way ANOVA with repeated measures, followed by 
uncorrected Fisher’s LSD test was used. All data from the isolated heart protocols was 
imported from Lab chart 8 and analysed on GraphPad Prism (version 8). Data was 
accepted as statistically significant if p<0.05. 
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3.3 Results 
3.3.1 Animal Characteristics 
Table 3.1 shows the body weight of 12-week-old male and female WT and KO mice used 
for Langendorff isolated heart perfusion experiments. Overall, the KO mice had similar 
body weight with WT mice at the same age (p = 0.15).  
Table 3.1 Animal characteristics of the WT and KO mice 




Body Weight (g) 26.81 ± 1.11 30.06 ± 1.92 0.15 
Ratio M:F 9:3 3:8  
WT = Wild Type; KO = CaMKIIδ-knockout; M = Male; F = Female. Data are expressed 
as mean ± SEM. Independent t-test was used to compare between WT (n = 12) and KO 
(n = 11) values. 
3.3.2 CaMKIIδ expression 
Ventricular cardiac tissues from WT and KO mice was used to determine total CaMKII 
expression (Figure 3.2). As expected, the KO mice had significantly lower CaMKII 
expression compared to the WT mice (5.25 ± 0.94 vs 1.82 ± 1.12).  
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Figure 3.2 Western blot for total CaMKII expression. A, Representative immunoblot 
of total CaMKII expression in WT and KO heart tissues and GAPDH as loading control. 
B, Quantification of total CaMKII levels in WT (n = 8) and KO (n = 8). Data represented 
as mean ± SEM. Unpaired t-test was used to compare WT and KO, p = <0.05 
 
3.3.3 Echocardiographic measurements 
There was no significant difference in IVSd, IVSs, LVIDd, LVIDs, LVPWd, LVPWs, 
LVESV, FS, EF, CO, HR, R-R interval for the WT and KO (Table 3.2). There was a 
significantly lower SV in the KO compared to the WT (p = 0.04). There was also a trend 
towards reduced LVEDV in the KO (p = 0.05) but this was not significant. Altogether, 
these results reflect that the KO had very mild systolic dysfunction, which is seen in the 
reduced SV. However, the KO mice have a comparable systolic function to the WT mice 
and there was no evidence of severe cardiac dysfunction in the healthy KO mice at 
baseline. 
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Table 3.2 Echocardiography parameters in WT and KO mice at 12 weeks 
Parameter WT KO Genotype effect 
(P value) 
IVSd (mm) 1.07 ± 0.07 0.90 ± 0.04 0.06 
IVSs (mm) 1.32 ± 0.08 1.12 ± 0.06 0.07 
LVIDd (mm) 3.03 ± 0.09 2.82 ± 0.06 0.07 
LVIDs (mm) 1.65 ± 0.07 1.58 ± 0.06 0.50 
LVPWd (mm) 1.00 ± 0.04 0.96 ± 0.02 0.40 
LVPWs (mm) 1.37 ± 0.05 1.25± 0.04 0.08 
LVEDV (ml) 0.07 ± 0.01 0.06 ± 0.00 0.05 
LVESV (ml) 0.01 ± 0.00 0.01 ± 0.00 0.45 
FS (%) 45.77 ± 1.29 43.79 ± 1.81 0.38 
EF (%) 82.50 ± 1.25 80.19 ± 1.67 0.27 
SV (ml) 0.06 ± 0.00 0.05 ± 0.00   0.04* 
CO (ml/min) 26.31 ± 0.00 20.75 ± 0.00 0.10 
HR (beats/min) 429.30 ± 18.09 421.60 ± 14.75 0.75 
R-R Interval (ms) 143.20 ± 6.36 144.2 ± 5.12 0.90 
HR, heart rate; FS, Fractional shortening; EF, Ejection Fraction; IVSD, interventricular 
septum diastolic thickness; IVSS, interventricular septum systolic thickness; LVIDD, left 
ventricular internal dimension at diastole, LVIDS, left ventricular internal dimension at 
systole; LVPWD, left ventricular posterior wall thickness at diastole; LVPWS, left 
ventricular posterior wall thickness at systole. Data are expressed as mean ± SEM. 
Independent t-test was used to compare between WT (n = 12) and KO (n = 11) values, * 
= P< 0.05 WT vs KO 
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3.3.4 Cardiac contraction and relaxation parameters in isolated WT and KO 
mouse hearts at baseline. 
I analysed the cardiac function in both mouse models at baseline after Langendorff 
isolation prior to drug treatment. Figure 3.3 shows the average baseline contractile 
parameters; LVDP, HR, max dP/dt and min dP/dt in in isolated WT and KO hearts. As 
seen in Figure 3.3A-D, there was no significant difference in LVDP (p = 0.07), HR (p = 
0.12), max dP/dt (p = 0.63) and min dP/dt (p = 0.44). Arrhythmias (Figure 3.3E-F) were 
grouped according to the number of events and severity. Arrhythmic events were also 
expected; however, there was no difference in the number of arrhythmias (p = 0.68) or 
severity (p = 0.91) between the WT and KO hearts.  
The isolated hearts were perfused with buffer containing 2 mM Ca2+, which is higher than 
physiological Ca2+ concentration of 1.35 mM  (Reichelt et al., 2009) to mimic a high 
intracellular Ca2+ concentration condition. The isolated WT and KO hearts had similar 
baseline cardiac function. These data suggest that ex vivo cardiac function was not 
severely impacted in the KO mouse hearts, highlighting once again that removal of 
CaMKIIδ did not affect baseline cardiac function. 
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Figure 3.3 Basal contraction and relaxation parameters and quantification of 
arrhythmias in WT and KO mouse hearts. A, LV Developed Pressure. B, Heart rate. 
C, Maximum rate of contraction (Max dP/dt). D, Minimum rate of relaxation (Min dP/dt). 
E, Arrhythmic events F, Arrhythmia scores. Data are means ± SEM. WT, blue bar, n = 7 
hearts; KO, red bar, n = 5 hearts. Unpaired t-test was used to compare between animal 
models.  
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3.3.5 Effect of GSNO treatment on cardiac contraction and relaxation in isolated 
WT and KO mouse hearts 
Previous studies showed that NO has a dual role of increasing or reducing contractility 
depending on concentration (Vila-Petroff et al., 1999; González et al., 2008). I 
hypothesised that low concentration of GSNO would increase force of contraction, and 
there would be reduced contractility with increased GSNO concentration. To test this 
hypothesis, I examined the response of isolated WT and KO hearts to increasing GSNO 
concentrations (100 µM, 600 µM and 1600 µM) in the presence of 2 mM Ca2+.  
GSNO treatment did not significantly affect LV pressure development when WT and KO 
hearts were compared (p = 0.39) (Figure 3.4A). There was no difference in the slope of 
LV pressure in WT hearts compared to KO hearts (p = 0.07). However, there was a 
significant difference between LVDP at 100 µM and 1600 µM (p = 0.03) in WT hearts. 
There was no change in LVDP in the KO hearts with increased GSNO concentration. 
Interestingly, GSNO treatment significantly sped up the heart rate (Figure 3.4B) in WT 
hearts at 1600 µM GSNO compared to KO hearts at same concentration (p = 0.002). The 
slope of the line for heart rate in the WT hearts was significantly different than zero (p = 
0.01), suggesting that heart rate changed in response to GSNO concentration but this 
effect was not observed in the KO hearts (p = 0.11). Overall, GSNO induced a 
significantly faster heart rate in WT hearts compared to KO hearts (p < 0.05). For all 
concentrations of GSNO tested, there was no significant difference in rate of contraction 
(max dP/dt) (Figure 3.5A) between the WT and KO hearts (p = 0.4). There was a trend 
towards reduced max dP/dt in the WT hearts in comparing 100 µM and 1600 µM GSNO 
concentrations but this was not statistically significant (p = 0.06). In the KO hearts, the 
slope of the line (p = 0.54) showed that there was no GSNO-dependent change in max 
dP/dt. There was no GSNO-dependent significant change in rate of relaxation (min dP/dt) 
(Figure 3.5B) in WT and KO hearts (p = 0.22). 
In summary, GSNO treatment did not induce significant alteration in contractile function 
in WT and KO mouse hearts but increased chronotropy in WT hearts. The data in this 
section were presented as fold change to account for the variation in baseline developed 
pressure. Absolute values for all parameters can be found in Appendix 1. 
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Figure 3.4 LV pressure and heart rate in WT and KO mouse hearts with GSNO 
treatment (100 µM, 600 µM and 1600 µM). A, LV developed pressure B, Heart rate. 
Data are means ± SEM. WT, blue line, n = 7 hearts; KO, red line, n = 5 hearts. Two-way 
ANOVA (uncorrected Fisher’s LSD test) was used to compare between groups. * = P < 
0.05, ** = P < 0.01 treatment effect (100 µM vs 1600 µM), # = P <0.05 genotype effect 
(WT vs KO). 
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Figure 3.5 Rates of contraction and relaxation in WT and KO mouse hearts with 
GSNO treatment (100 µM, 600 µM and 1600 µM). A, Rate of Contraction (Max dP/dt) 
B, Rate of Relaxation (Min dP/dt). Data are means ± SEM. WT, blue line, n = 7 hearts; 
KO, red line, n = 5 hearts. Two-way ANOVA (uncorrected Fisher’s LSD test) was used 
to compare between groups. 
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3.3.6 Effect of GSNO on coronary flow and pressure-time integral in isolated WT 
and KO mouse hearts 
The effect of GSNO on vascular flow was not evident in this Chapter. Overall, there was 
no significant difference in coronary flow during GSNO treatment between WT and KO 
hearts (p = 0.90) (Figure 3.6a). In the KO hearts, 100 µM GSNO significantly elevated 
coronary flow compared to baseline (p = 0.008). The effect of heart rate on pressure 
development was measured through pressure-time integral. Pressure-time integral was 






Figure 3.6 Cardiac response to GSNO treatment (100 µM, 600 µM and 1600 µM) in 
WT and KO mouse hearts. A, Coronary flow (ml/min) B, Pressure-time integral 
(mmHg.s). Data are means ± SEM. WT, blue line, n = 7 hearts; KO, red line, n = 5 hearts. 
Two-way ANOVA (uncorrected Fisher’s LSD test) was used to compare between groups. 
** p < 0.01 vs baseline 
 
 69 
3.3.7 CaMKIIδ knockout prevents cardiac arrhythmias in isolated hearts from 
WT and KO mice treated with GSNO 
I hypothesised that GSNO would increase arrhythmias, but would be reduced in the 
absence of CaMKIIδ. To test this hypothesis, I quantified arrhythmic events and grouped 
them according to frequency and severity. 
Figure 3.6A shows the number of arrhythmic events in WT and KO hearts at different 
concentrations of GSNO. GSNO did induce arrhythmic events in the WT hearts. The 
slope of the regression line for WT hearts was significantly different from zero (p = 0.02) 
meaning that an increase in GSNO concentration corresponded with increase in 
arrhythmic events. There was a significant difference in the number of arrhythmic events 
at 100 µM GSNO compared to 1600 µM GSNO in the WT hearts. In the KO hearts, there 
was no significant change in arrhythmia count with increase in GSNO concentration (p = 
0.23).  There was also no significant difference in arrhythmic events between the WT and 
KO hearts (p = 0.68). 
There was a trend towards higher severity of arrhythmias as measured by arrhythmia 
score in WT at the highest concentration of GSNO compared to the lowest concentration 
(Figure 3.6B). However, this was not statistically significant (p = 0.06). In the KO hearts, 
there was no significant effect of GSNO on arrhythmia scores (p = 0.16). At 1600 µM 
GSNO, there was no significant difference in arrhythmic severity between the WT and 
KO hearts (p = 0.16). GSNO treatment did not induce any overall significant difference 
in arrhythmic scores between the WT and KO (p = 0.71). 
There was no relationship between heart rate and arrhythmia score in WT hearts (r = -
0.09, p = 0.67) and KO hearts (r = - 0.53, p = 0.06) (Figure 3.8). 
Taken together, GSNO induced arrhythmias in the WT hearts, and this effect was 
dependent on the concentration. The GSNO concentration-effect suggested that increase 
in GSNO in the presence of CaMKIIδ contributed to a significant increase in arrhythmic 
events in WT and this was no observed in the KO hearts. This finding is similar to the 
observation in cardiomyocytes and is consistent with the hypothesis that loss of CaMKIIδ 
can prevent GSNO-induced cardiac arrhythmias (Gutierrez et al., 2013). 
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Figure 3.7 Arrhythmias during GSNO treatment (100 µM, 600 µM and 1600 µM) in 
WT and KO mouse hearts A, Arrhythmic events B, Arrhythmia scores. Data are means 
± SEM. WT, blue line, blue bar, n = 7 hearts; KO, red line, red bar, n = 5 hearts. Two-
way ANOVA (uncorrected Fisher’s LSD test) was used to compare between groups. ** 
= P < 0.01 treatment effect (100 µM vs 1600 µM). 
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Figure 3.8 Effect of heart rate on arrhythmia severity during GSNO treatment in 
WT and KO mouse hearts A, Wild-type hearts B, CaMKIIδ hearts. Data are means ± 




The main aim of this chapter was to investigate the effects of NO and CaMKIIδ on cardiac 
function. To accomplish this, I determined basal cardiac function in WT and CaMKIIδ-
KO mice. The hearts were then isolated and treated with NO donor GSNO. I examined 
the effect of GSNO on cardiac contraction, relaxation and arrhythmias. The main findings 
were: (a) WT and KO mice had similar basal cardiac function (b) GSNO treatment did 
not alter pressure development in the isolated hearts. (c) high concentration of GSNO 
treatment increased chronotropy in WT mouse hearts but not in KO hearts. (d) GSNO 
treatment induced cardiac arrhythmias in the isolated WT hearts and CaMKIIδ loss 
prevented arrhythmias. 
3.4.1 Basal cardiac function is not severely altered with CaMKIIδ loss  
Studies have reported that even though presence of CaMKII is of physiological 
importance, the loss of CaMKIIδ does not impact basal cardiac function (Backs et al., 
2009; Ling et al., 2009; Grimm et al., 2015; Mohamed et al., 2018). Data from Western 
blotting in my study confirmed a reduction in CaMKII expression in KO mouse hearts 
due to knocking out CaMKIIδ. There is still some level of CaMKII expression in KO 
mouse hearts which is attributed to the presence of the secondary cardiac isoform, 
CaMKIIγ. Consistent with previous studies (Ling et al., 2009; Grimm et al., 2015), 
echocardiography data of WT and KO mice from my study showed comparable cardiac 
structure and function of both animal models at 12 weeks (Table 3.2). I also examined 
baseline function prior to GSNO treatment and observed that isolated and perfused WT 
and KO hearts showed no difference in contractile function (Figure 3.3), which is similar 
to a finding by Grimm et al. (2015) where they measured baseline isovolumetric cardiac 
performance in isolated WT and KO hearts prior to isoproterenol treatment. CaMKII is 
activated by stress conditions and at basal conditions in healthy unconscious WT mice, it 
was expected that CaMKII is mostly inactive. This would be comparable to the KO mice 
which have about 80% reduction in CaMKII expression and therefore less activity. Thus, 
there would be the possibility that basal cardiac parameters are not severely impacted in 
vivo and ex vivo with CaMKIIδ loss. 
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3.4.2 Impact of GSNO on contractile performance of the heart 
It was surprising to find that overall, GSNO had no effect on LV pressure development 
in isolated WT and KO hearts (Figure 3.4A). Previous studies have tested the effect of 
NO donors on contractility in different animal models (Wyeth et al., 1996; Chesnais et 
al., 1999; Vila-Petroff et al., 1999; Paolocci et al., 2000). González et al. (2008) reported 
that SNAP concentrations of 0.1 – 10 µM increased cardiac inotropy in isolated rat hearts 
while 100 µM led to reduced contractility, which indicated that the dual effect of NO in 
the heart was concentration-dependent. This is due to the ability of NO to activate two 
signaling pathways. High NO concentration activates the cGMP pathway and low NO 
concentration activates the S-nitrosylation pathway. According to my findings, GSNO 
did not improve cardiac contractility in isolated WT or KO mouse hearts regardless of the 
concentration, even when both were compared. This was not consistent with my 
hypothesis that NO would significantly alter cardiac contraction and relaxation. In the 
WT hearts, there was a significant negative inotropic effect at the highest concentration 
of 1600 µM compared to lowest concentration of 100 µM. With a different NO donor, it 
was found that 100 µM of SNAP depressed contractile amplitude in rat cardiomyocytes 
(Kojda et al., 1996; Vila-Petroff et al., 1999). It appears that NO donor concentrations 
less than 100 µM cause increase in inotropic effect or no change in contractility while 
concentrations greater than 100 µM produce negative inotropic effect in the heart (Sarkar 
et al., 2000). González et al. (2008) suggested that reduction in contractility induced by 
NO donors at high concentration was due to activation of guanylyl cyclase and cGMP-
PKG pathway due to increased cardiac cGMP production.  
Müller‐Strahl et al. (2000) showed that low concentrations (< 100 µM) of exogenous NO 
can increase chronotropy induced in isolated rat hearts. A similar finding was observed 
by Musialek et al. (1997) in spontaneously beating sinoatrial node/atrial preparations of 
isolated guinea pig hearts. The findings from this chapter showed a significant difference 
in HR in KO hearts during GSNO treatment compared to WT hearts (Figure 3.4B). 
Increased concentration of GSNO (1600 µM) elicited a positive chronotropic response in 
WT hearts, however this effect was not observed in KO hearts. According to Müller‐
Strahl et al. (2000), chronotropic effect induced by a NO donor, was suggested to be due 
to stimulation of hyperpolarisation-activated inward current (If) via the cGMP pathway 
activated by NO, however this was at a NO donor concentration lower than in my 
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protocol. In contrast to the increased chronotropic effect associated with high GSNO 
concentration that I observed. Kennedy et al. (1994) found that 300 µM of NO donor 
(SIN-1) induced negative chronotropic effect in right atria from isolated rat heart and an 
increase in concentration of SIN-1 to 3000 µM led to a further 27% decline in spontaneous 
beating rate. The observation was that chronotropic effect of SIN-1 was not induced by 
NO-cGMP pathway but could possibly be mediated by other compounds including 
reactive oxygen species (Kennedy et al., 1994). As observed in the isolated WT and KO 
hearts, it is possible that the presence of CaMKII contributed to the cardiac excitation and 
increase in HR, and the absence of CaMKIIδ in the KO hearts prevented that positive 
chronotropic effect. The specific mechanism underlying this effect is unknown. With 
literature suggesting that NO donors can mediate either increase or decrease chronotropic 
effect depending on the concentration and signaling pathway (Hogan et al., 1999), the 
effect of GSNO on heart rate could either be mediated by S-nitrosylation, cGMP 
activation targetting If. The release of NO from GSNO is spontaneous and literature has 
shown that GSNO can induce S-nitrosylation of CaMKII (Curran et al., 2014; Erickson 
et al., 2015). Therefore, S-nitrosylation of CaMKII could also be playing a role in the 
effect of NO observed in the WT hearts. In this chapter, I was unable to measure S-
nitrosylation levels and cGMP levels in the preserved hearts, and this was a limitation to 
the aim because there is not enough evidence to prove that the observed effects are 
primarily due to CaMKII S-nitrosylation and not via another NO-dependent mechanism, 
such as activation of guanylyl cyclase. 
No significant change in speed of contraction and relaxation with GSNO treatment was 
observed in the WT and KO hearts (Figure 3.5 A-B). Inotropic effects of NO donor 
concentrations higher than 100 µM is yet to be studied in isolated hearts. However, 
published literature has shown that NO can alter cardiac contractility by facilitating 
myocardial contraction and relaxation in isolated working rat hearts (Müller‐Strahl et al., 
2000). 10 µM SIN-1 (NO donor) was seen to induce positive lusitropic effects in isolated 
crystalloid perfused hearts and attributed this effect to S-nitrosylation (Paolocci et al., 
2000). The absence of changes in rates of contraction and relaxation in WT and KO hearts 
in this study could be attributed to a difference in concentration and type of NO donor, 
and not CaMKIIδ.  
 75 
NO is widely established as a vasodilator therefore NO donors would ideally increase 
coronary flow rate in isolated hearts. However, the change in coronary flow rate during 
GSNO treatment was not pronounced in the isolated hearts in my study (Figure 3.6A). 
Since coronary flow remained largely unchanged, any change in the number of 
arrhythmic events was unlikely to be as a result of GSNO on the coronary circulation. 
There was also no change in PTI in WT and KO hearts during GSNO exposure (Figure 
3.6B). This suggests that GSNO had no effect on the average work of contraction in the 
heart. 
3.4.3 CaMKIIδ loss attenuates arrhythmogenic effect of nitric oxide-induced 
cardiac arrhythmias 
I analysed arrhythmic events and severity in WT and KO isolated hearts treated with 
GSNO. These data shows for the first time that high concentration of NO contributes to 
a higher number of cardiac arrhythmias in WT mice compared to KO mice (Figure 3.7A), 
suggesting that CaMKIIδ could be responsible for this deleterious effect of NO. Results 
from this study also showed no difference in arrhythmia severity between WT and KO 
mice (Figure 3.7B) and arrhythmia was unrelated to change in heart rate (Figure 3.8). 
This was a striking observation, considering that NO is a vasodilator known for its 
cardioprotective function in the cardiovascular system, as studied in animals (Shesely et 
al., 1996; Preckel et al., 1997) and humans (Haynes et al., 1993; Sander et al., 1999). This 
data now unveils a more complex role for NO involving arrhythmias. Previous work on 
NO and arrhythmias has been performed in cardiomyocytes where it was found that in 
the absence of β-AR stimulation, 150 µM GSNO caused an increase Ca2+ spark frequency 
due to SR Ca2+ leak via RyR2 (Gutierrez et al., 2013). In the same study, acute CaMKII 
inhibition using AIP prevented the GSNO-induced Ca2+ sparks. This finding suggested 
that NO may directly modulate the activity of CaMKII through nitrosylation. This was 
confirmed in a different study which involved treating rabbit cardiomyocytes with 100 
µM SNAP, and it was found that SNAP independently induced higher SR Ca2+ leak 
(Curran et al., 2014). This was compared to treatment with SNAP and the CaMKII 
inhibitors AIP and KN93. Taken together, this provides a compelling evidence that 
CaMKII inhibition could be a potent way to prevent arrhythmias during increased NO 
production in the heart. It is also critical to understand the mechanism underlying 
arrhythmogenesis associated with exogenous NO treatment. In this chapter, CaMKII 
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nitrosylation levels were not measured; however, the KO mouse model provides a clue 
that loss of CaMKII can prevent NO-mediated CaMKII arrhythmias. 
3.4.4 Limitations 
These experiments were performed in isolated hearts, which can spontaneously beat for 
several hours while perfused with buffer at optimal temperature. However, there is a 
tendency for the contractility of the isolated heart to deteriorate with time, about 5-10% 
per hour depending on several factors (Sutherland & Hearse, 2000). To account for this, 
there was a time control group for each animal model, and no significant change was 
observed compared to the GSNO treatment groups. The drug in the buffer was delivered 
through long perfusate lines to the heart, and this may have affected the time of drug 
delivery and effect. To account for this, the time of delivery was pre-established through 
pilot experiments to be 2 – 3 minutes, while each protocol ran for 8 minutes. Future 
studies could employ the use of a drug infusion pump closer to the isolated heart. The 
isolated hearts were unpaced in order not to mask the incidence of arrhythmias, and 
therefore HR was below physiological range of 400 – 600 beats/minute in mice. Also, 
there was individual-to-individual variability in LV developed pressure due to variability 
in HR and the need to use different balloons which could have affected the contractility. 
However, all cardiac parameters in the isolated hearts were normalised to the baseline 
established for that heart before analysis.  
3.4.5 Conclusion 
The observations from this chapter support the hypothesis that CaMKIIδ could be 
responsible for pro-arrhythmic signaling associated with NO exposure. The results from 
this chapter highlight a possible mechanism involving NO and CaMKII regarding 
impaired cardiac function. This provides some information towards CaMKIIδ being a 
potential candidate, as a therapeutic target for cardiac arrhythmias. Since NO production 
is increased with β-AR signaling, there is a possibility that adrenergic stress could 
exacerbate cardiac arrhythmias mediated by NO and CaMKII. Future studies will assess 
the effect of adrenergic stress and NO treatment on cardiac function in animal models 
with intact CaMKIIδ. Based on the findings in this chapter, arrhythmias will be analysed 
and nitrosylation levels will also be assessed. 
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CHAPTER 4: CARDIAC RESPONSE TO CHRONIC 
NITRIC OXIDE TREATMENT 
4.1 Introduction 
CaMKII is a critical calcium-handling protein that is important for enhancing Ca2+ flux 
through the cardiomyocyte during contraction and relaxation (Komukai et al., 2010). 
Aberrant activation of CaMKIIδ due to post translational modifications in pathological 
conditions has contributed to deleterious effects in the heart (Erickson et al., 2013; 
Gutierrez et al., 2013; Federico et al., 2017; Daniels et al., 2018). In Chapter 3, data 
showed that acute exogenous nitric oxide (NO) exposure increased arrhythmias in wild-
type (WT) mouse hearts with intact CaMKIIδ, while CaMKIIδ-knockout (KO) mouse 
hearts were protected against arrhythmias. NO treatment did not alter cardiac contraction 
or relaxation in WT and KO hearts, and enhanced cardiac chronotropy in WT hearts but 
not in KO hearts. These results suggested that loss of CaMKIIδ in the presence of 
upregulated NO signaling prevents arrhythmogenesis. This chapter explores the long-
term effects of NO treatment on cardiac function of WT and KO mice. 
4.1.1 Nitric oxide and the cardiovascular system 
NO plays a vital role in the cardiovascular system by enhancing vasodilation. The action 
of nitric oxide synthase (NOS) is responsible for platelet aggregation and leukocyte 
activation in the cardiovascular system (Lefer et al., 1999). In the heart, NO is essential 
for regulating blood pressure, maintaining vascular tone and mediating cardiac 
contractility (Dietz et al., 1994; Mohan et al., 1996; Prendergast et al., 1997; Müller‐
Strahl et al., 2000). Disruption in NO signaling, which leads to an imbalance in NO levels, 
is a marker of cardiac dysregulation. For example, inhibition of NOS resulted in a 
reduction in basal endogenous NO release in patients with congestive heart failure (Mohri 
et al., 1997). The onset of myocardial infarction in spontaneously hypertensive rats was 
marked by decreased NO availability (Wiemer et al., 2001). Reports have confirmed that 
reduced NO release due to NOS1 inhibition in the presence of increased intracellular Ca2+ 
can promote ventricular arrhythmias, suggesting that increased NO levels can prevent 
arrhythmias (Cutler et al., 2012). Enhanced NO bioavailability has been found to prevent 
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stroke, myocardial infarction and congestive heart failure (Ruschitzka et al., 2000; Jones 
et al., 2003). In contrast to the known protective role of NO, studies have also revealed 
that NO can promote arrhythmias in cardiomyocytes (Curran et al., 2014; Erickson et al., 
2015). Currently, there is a debate surrounding the role of NO in the heart and the pathway 
by which it could be mediating cardiac arrhythmias. One suggested mechanism is through 
CaMKII S-nitrosylation (Gutierrez et al., 2013). 
4.1.2 Regulation of CaMKII activity by NO 
NO signaling can activate Ca2+-handling proteins by modifying them via addition of NO 
molecules to their cysteine residues. This process, called S-nitrosylation, enhances Ca2+ 
cycling and thereby contraction and relaxation. S-nitrosylation is important for regulation 
of many biological processes. For example, increased S-nitrosylation of RyR2 can impair 
Ca2+ handling (Gonzalez et al., 2009). Gonzalez and colleagues (2007) showed in NOS1 
deficient mouse cardiomyocytes that deficient S-nitrosylation of RyR2 promotes SR Ca2+ 
leak and pro-arrhythmic spontaneous Ca2+ waves. This suggested that S-nitrosylation of 
RyR2 can prevent Ca2+ mishandling in cardiomyocytes and, potentially, cardiac 
arrhythmias. This finding was in contrast to what has been observed in CaMKII 
nitrosylation. Experimental evidence has shown that increased CaMKII S-nitrosylation 
can be detrimental to cardiomyocytes due to its tendency to increase SR Ca2+ leak. 
Previous studies also support the concept that CaMKII could be responsible for 
arrhythmogenesis as a result of increase NO bioavailability by exogenous NO donors 
(Gutierrez et al., 2013; Curran et al., 2014; Erickson et al., 2015). 
Low bioavailability of NO has been associated with impaired cardiac function (Shesely 
et al., 1996; Jones et al., 2003). In clinical settings, NO donors are administered to control 
blood pressure in hypertensive patients (Houston & Hays, 2014), and also in pathological 
conditions associated with increased CaMKII expression, such as heart failure (Chirinos 
et al., 2016). Given what is known about GSNO and proarrhythmic signaling, there could 
be a possibility that increased NO levels and overexpression of CaMKII can jointly 
promote cardiac arrhythmias. Long-term GSNO treatment is known to improve insulin 
signaling and also play a role in neuroprotection (Rauhala et al., 2005; Giri et al., 2014; 
Jiang et al., 2014; Aggarwal et al., 2018; Khan et al., 2019; Khan & Singh, 2019). 
However, the effect of chronic GSNO exposure on cardiac arrhythmias is unknown.  
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In Chapter 3, I found that acute GSNO treatment can induce cardiac arrhythmias. This 
raised a question as to whether constant elevation of NO levels in the blood would alter 
cardiac function and promote arrhythmogenesis in mouse hearts. Based on this, it was 
important to determine how chronic NO exposure would affect cardiac function and the 
potential role of CaMKIIδ. The aim of this Chapter was to investigate the role of 
CaMKIIδ signaling during chronic NO treatment in isolated WT and KO hearts. 
4.1.3 Aims and hypotheses 
This chapter addressed the effect of chronic GSNO treatment on cardiac function in WT 
and KO mice. The aims were as follows: 
1) Measured nitrosylated CaMKII expression levels in mice after GSNO treatment. I 
hypothesised that there will be an increase in protein nitrosylation after chronic GSNO 
treatment. 
2) Investigated the effect of GSNO on cardiac function in vivo and ex vivo after chronic 
treatment. I hypothesised that GSNO would alter cardiac structure and function in 
mice. 
3) Determined the effect of GSNO on cardiac arrhythmias in WT and CaMKIIδ-KO mice 
chronically treated with GSNO. I hypothesised that KO mice would be protected 
against cardiac arrhythmias induced by chronic GSNO treatment. 
4.2 Experimental methods 
4.2.1 Administration of GSNO in drinking water 
12-week old WT and KO mice were randomly assigned into 4 experimental groups: WT 
and KO control groups, and WT and KO treatment groups. The treatment groups received 
50 mg/L of the NO donor (GSNO) in drinking water, refreshed every other day for 5 
weeks (Figure 4.1). This method of administration was adopted from previous studies that 
showed that long-term oral NO therapy using NO donors can increase NO production in 
the body. Chronic oral administration of 50 mg/L sodium nitrite in drinking water was 
found to increase plasma nitrite levels in healthy and hypertensive rats (Ling et al., 2018). 
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100 mg/L nitrite in drinking water restored depleted NO levels in diabetic rats to normal 
(Khalifi et al., 2015). Sindler et al. (2015) showed that there was increase in plasma nitrite 
concentration in mice after a 5-week treatment of sodium nitrite in drinking water. 
Together, these studies confirm to an extent, the effectiveness of NO donor delivery in 
animals.  
The experimental animals were housed in their usual cages (two mice per cage) and 
allowed to acclimatise for 7 days. Their water bottles were filled with 250 ml of water 
and weighed using digital scale to 0.1 g accuracy. To determine the average 24-hour water 
consumption per cage prior to the start of the experiments, the water bottles were weighed 
every day at the same time of the day for one week.  
During GSNO treatment experiment, Fluid intake was documented daily throughout the 
treatment. After 5 weeks, the hearts were isolated from the mice and treated again ex vivo 
with different concentrations of GSNO (100 µM, 600 µM, 1600 µM), while cardiac 
function was measured (Chapter 3, Section 3.1.2). Cardiac tissue was saved for Western 
blotting to determine protein expression levels. 
 
 
     
Figure 4.1 Timeline for GSNO treatment protocol in mice. 
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4.2.2 Biotin switch assay 
A biotin switch assay is used to measure the level of S-nitrosylated proteins in cells or 
tissues. The process involves blocking free thiol sites on protein of interest with methyl 
methanethiosulfonate (MMTS), followed by reducing the S-nitrosylated sites with 
ascorbate. The S-nitrsoyalted sites on the protein are then labelled with biotin. Gel 
electrophoresis followed by Western blotting can be performed to measure the S-
nitrosylation levels.  
In this Chapter, biotin switch assay was carried out using an S-nitrosylated protein 
detection kit (Cayman Chemical). Left ventricular cardiac tissues were homogenized in 
0.1 g/ml lysis buffer (50 mM Tris-HCl – pH 7.5; 3% SDS) using a bullet blender 
homogeniser and left on ice for 10 minutes. The sample was subjected to centrifugation 
and supernatant was aliquoted and stored in -80oC. 
The following steps were performed in the dark. 100 µl DMF and add 900 µl of buffer A 
was added to 1 vial of blocking reagent to form Buffer A reconstituted blocking reagent. 
Buffer A reconstituted blocking solution was added to samples as 1:9 (1µl per 9µl) to 
sample. Samples were placed on a shaker/rocker at a lowest speed for 30 min at 4oC. 
Lysate was clarified by centrifugation for 10 min at 4oC in table top microcentrifuge. 
Supernatants were transferred into separate cold pre-labelled 15 ml conical polypropylene 
tubes and 4 volumes of ice-cold acetone were added to each sample. Initial volume plus 
buffer A volume. The samples were mixed by inversion and incubated at -20oC for 1 hr. 
Samples were removed from -20oC and centrifugation was done at 3,000 x g for 10 min 
at 4oC. During centrifugation, 1 vial of S-NO reducing agent was reconstituted with 1 ml 
buffer B. 1 vial of S-NO labelling reagent was dissolved with 100 µl DMF followed by 
900 µl Buffer B. When each reagent is fully dissolved, 0.5 ml of Reducing Agent and 0.5 
ml of Labelling Reagent were mixed in a graduated cylinder and the dissolved S-NO 
labelling agent was added alongside 4 ml of Buffer B. This mixture was labelled Buffer 
B containing reducing and labelling reagents. Samples were removed from centrifuge and 
supernatants (mostly acetone) were carefully decanted without disturbing the protein 
pellets. Protein pellet tubes were placed on ice. Excess residue of acetone was removed 
with pipette. Each pellet was resuspended with 0.5 ml Buffer B containing reducing and 
labelling reagents. For control, cell pellet was resuspended in Buffer B alone. 
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The subsequent steps were performed outside the dark room. The mixture of protein pellet 
and Buffer B containing reducing and labelling reagents and incubated for 1 hr at RT. 
Afterwards, 4 volumes of ice-cold acetone was added to each sample, mixed by inversion 
and incubated for 1 hr at -20oC. Samples were removed from -20oC and spun in a 
centrifuge at 3,000 x g for 10 min at 4oC. Supernatant containing acetone was decanted 
and tubes containing the pellets were placed on ice. Pellets were resuspended in a minimal 
volume (100 µl) of cold wash buffer. 10 µl was used for protein estimation using the 
A280 method. The samples were aliquoted and stored at -20oC for Western blotting.  
For Western blotting (Chapter 2, section 2.5.3), sample was added to sample buffer and 
Milli-Q water. 20 µg of each sample were loaded on a fast cast 4-15% gel (Bio-Rad), and 
the gel was run for 45 minutes at 200 V. Gel was visualised on ChemiDoc MP Imaging 
System (Bio-Rad) to confirm protein load. The proteins were transferred onto a PVDF 
membrane at 30V overnight. Membrane was blocked in 2% BSA in PBS. The membrane 
was incubated in 1:100 dilution of Detection Reagent 1 (HRP) in Milli-Q water for 1 hour 
at RT, followed by a 10-minute wash, four times in TBS. The membrane was incubated 
in freshly prepared Clarity Western ECL substrate (Bio-Rad) and developed on 





This section describes data from echocardiography in WT and KO mice prior to GSNO 
treatment at 13 weeks and at 18 weeks post treatment with GSNO. Functional parameters 
in the isolated hearts with and without GSNO treatment in all groups are also reported 
here. 
4.3.1 Animal Characteristics 
Body weight and sex ratio from WT and KO mice at 18 weeks of age post treatment with 
GSNO are shown in Table 4.1. In the control group that did not receive GSNO, KO mice 
had a significantly higher average body weight compared to WT mice at 13 and 18 weeks 
(p < 0.05). In the GSNO treatment groups, WT and KO mice had similar body weights (p 
> 0.05). There was no difference between WT control and GSNO treatment groups at 13 
weeks (p = 0.98) or 18 weeks (p = 0.96). A similar observation was seen in the KO control 
and GSNO treatment groups at 13 (p = 0.54) and 18 weeks (p = 0.56). The average daily 
water intake per mouse in WT and KO mice is shown in Table 4.1. WT and KO mice 
control groups had similar initial and final daily water intake (p = 0.81; p = 0.44). There 
was also no significant difference in the average daily water consumption in the GSNO 
treatment groups of the WT mice compared to KO mice before commencement of 




Table 4.1 Animal characteristics of WT and KO mice at 13 and 18 weeks 









Body weight (g) at 
13 weeks 
24.41 ± 1.37 27.40 ± 1.56* 24.30 ± 1.51 26.03 ± 1.70 
Body weight (g) 
at 18 weeks 
26.45 ± 1.39 32.05 ± 1.75* 26.38 ± 1.59 30.06 ± 1.81 
Initial average 
daily water intake 
per mouse (ml) 
5.26 ± 0.32 5.35 ± 0.19 4.65 ± 0.33 4.75 ± 0.19 
Final average 
daily water intake 
per mouse (ml) 
5.64 ± 0.58 6.26 ± 0.26 6.04 ± 0.70 5.85 ± 0.91 
Ratio (M:F) 4:4 4:4 3:3 3:3 
WT = Wild Type; KO = CaMKIIδ-knockout. Data are expressed as mean ± SEM. Two 
way-ANOVA was used to compare between animal genotypes and GSNO treatment 
effect between groups * = P< 0.05 vs WT 
4.3.2 Total protein nitrosylation   
Using biotin switch assay, protein nitrosylation was measured in the control and GSNO 
treatment groups of WT and KO hearts. All bands were normalised to loading control 
(stain free gel). 
Global protein nitrosylation was observed across all groups, a representative blot is shown 
in Figure 4.2. Results from Western blotting showed that there was no significant 
difference in nitrosylated proteins in the KO GSNO treatment group compared to KO 
control (p = 0.40). There was also no significant difference in nitrosylation levels between 
WT and KO hearts in the control and GSNO treatment groups (p = 0.27). However, there 
was increased nitrosylation in the WT GSNO treatment group compared to WT control 
group (p = 0.03). These data suggest GSNO induced higher protein nitrosylation levels 
in WT compared to KO hearts. 
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Figure 4.2 Quantification of S-nitrosylation in WT and KO mouse hearts chronically 
treated with GSNO A, Representative blot showing global protein nitrosylation in WT 
and KO mouse hearts. B, Total protein nitrosylation levels. Data are expressed as mean 
± SEM. WT Control, n = 3, KO Control, n = 3 WT GSNO, n = 3, KO GSNO, n = 3. Two-
way ANOVA (uncorrected Fisher’s LSD test) was used to compare between treatment 
groups and animal models. * = p < 0.05. S-nitrosylation horseradish peroxidase (S-NO 
HRP)  
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4.3.3 Echocardiography parameters for WT and KO mice before and after GSNO 
treatment 
Echocardiography data was obtained from WT and KO mice at 13 and 18 weeks, pre- 
and post-treatment with GSNO respectively (Table 4.2). There were four groups of mice, 
WT and KO treatment and control groups. The treatment groups were given GSNO in 
drinking water for 5 weeks. I hypothesized that WT and KO mice would share similar 
baseline cardiac structure and function before GSNO treatment, since healthy animals 
were used, no significant effect of GSNO on cardiac function at 18 weeks post-treatment 
was expected. Data from echocardiography revealed no overall measurable difference 
between the WT and KO mice in LVIDd, LVPWd, EDV, ESV, SV, CO both at 13 weeks 
and 18 weeks. However, echocardiography analysis showed significant differences in 
LVIDs, IVSs, FS% and EF in WT and KO mice at 13 weeks. At 18 weeks, there was a 
significant change in IVSd, LVIDs, FS%, EF and heart rate. In the control group, KO 
mice had significantly lower fractional shortening compared to WT mice at 13 weeks (p 
= 0.02) and 18 weeks (p = 0.007). The KO GSNO treatment groups also had significantly 
reduced fractional shortening at 13 weeks (p = 0.0005) and 18 weeks (p = 0.004). Ejection 
fraction of KO mice in the control group was significantly lower at 13 weeks (p = 0.01) 
and at 18 weeks (0.007) compared to WT. This was similar to that of the treated KO mice 
compared to WT mice at 13 weeks (p = 0.0004) and 18 weeks (p = 0.007). At 18 weeks, 
heart rate in the treated KO mice was significantly reduced compared to WT (p = 0.004). 
LVPWs at 13 weeks reduced in the KO control mice compared to WT (p = 0.005). At 13 
weeks, LVIDs in the GSNO treatment group showed a significant reduction in KO mice 
compared to WT mice (p = 0.008). A significant reduction in IVSs was observed in KO 
mice compared to WT mice at 13 weeks. IVSd was also significantly reduced in the KO 
mice control group at 18 weeks (p = 0.0004). Results also showed that GSNO had no 
significant effect on any of the echocardiographic parameters after 5 weeks of treatment 
in the WT and KO groups.  
The main aim of this experiment was to measure the difference in cardiac function due to 
impact of chronic GSNO administration. Overall, there was no effect of GSNO on the 
treated WT and KO mice. The echocardiographic data showed reduced systolic function 
in the KO mice at 13 and 18 weeks of age independent of GSNO treatment. These results 
suggest that chronic GSNO treatment does not alter cardiac structure and function in 
 87 
healthy mice and deletion of CaMKIIδ reduces the functional output of the heart, 
including heart rate. These results are consistent with a known role for cardiac CaMKII 
in enhancing the chronotropic and inotropic properties of the heart.  
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Week                         Control                     GSNO Treatment 
  WT 
(n = 8) 
KO  
(n = 8) 
WT  
(n = 6) 
KO  
(n = 6) 
IVSd (mm) 13 0.91 ± 0.04 0.86 ± 0.02 0.90 ± 0.03 0.84 ± 0.03 
18 0.99 ± 0.02 0.87 ± 0.02*** 0.92 ± 0.03 0.92 ± 0.01 
IVSs (mm) 13 1.12 ± 0.04 1.05 ± 0.02 * 1.19 ± 0.07 1.05 ± 0.05* 
18 1.23 ± 0.03 1.14 ± 0.02 1.16 ± 0.07 1.15 ± 0.03 
LVIDd (mm) 13 2.74 ± 0.07 2.64 ± 0.07 2.72 ± 0.09 2.69 ± 0.06 
18 3.06 ± 0.16 3.08 ± 0.14 3.02 ± 0.20 3.00 ± 0.10 
LVIDs (mm) 13 1.62 ± 0.09 1.74 ± 0.10 1.46 ± 0.08 1.78 ± 0.10** 
18 1.88 ± 0.18 2.11 ± 0.13 1.63 ± 0.13 2.04 ± 0.09 
LVPWd (mm) 13 0.91 ± 0.02 0.89 ± 0.02 0.94 ± 0.03 0.95 ± 0.06 
 18 0.91 ± 0.02 0.89 ± 0.05 0.90 ± 0.03 0.92 ± 0.04 
LVPWs (mm) 13 1.13 ± 0.04 0.98 ± 0.02** 1.13 ± 0.05 1.01 ± 0.05 
 18 1.07 ± 0.04 1.02 ± 0.04 1.05 ± 0.02 1.03 ± 0.02 
EDV (ml) 13 0.06 ± 0.00 0.05 ± 0.00 0.05± 0.01 0.05 ± 0.01 
 18 0.08 ± 0.01 0.08 ± 0.01 0.06 ± 0.01 0.07 ± 0.01 
ESV (ml) 13 0.01 ± 0.00 0.02 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 
 18 0.02 ± 0.01 0.03 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 
FS % 13 40.79 ± 2.20 34.08 ± 1.13* 46.30 ± 2.74 33.87 ± 2.05*** 
 18 39.18 ± 2.73 31.59 ± 1.41** 42.03 ± 1.86 32.56 ± 0.47** 
EF 13 77.17 ± 2.18 69.36 ± 1.46* 82.58 ± 2.56 68.93 ± 2.65*** 
 18 74.85 ± 3.06 66.03 ± 2.06** 77.97 ± 1.80 67.81 ± 0.62** 
SV (ml) 13 0.04 ± 0.00 0.04 ± 0.00 0.04 ± 0.01 0.04 ± 0.00 
 18 0.06 ± 0.01 0.05 ± 0.01 0.05 ± 0.01 0.05 ± 0.01 
CO (ml/min) 13 24.33 ± 1.91 16.99 ± 1.46 23.21 ± 2.57 16.10 ± 2.91 
 18 26.43 ± 4.07 22.40 ± 1.64 21.72 ± 5.27 19.84 ± 2.84 
HR (bpm) 13 483.00 ± 11.36 517.92 ± 17.70 490.50 ± 9.76 473.41 ± 30.82 
 18 421.14 ± 7.32 410.04 ± 12.05 438.00 ± 8.89 379.24 ± 19.42** 
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WT= wild type; KO = knockout mice; IVSd= inter ventricular wall thickness diastole; IVSs= inter ventricular wall thickness systole; LVIDd= left 
ventricular internal diameter diastole; LVIDs= left ventricular internal diameter systole; LVPWs= left ventricle posterior wall thickness systole; 
LVPWd= left ventricle posterior wall thickness diastole; EDV= end diastolic volume; ESV= end systolic volume; FS= fractional shortening; EF= 
ejection fraction; SV= stroke volume; CO= cardiac output; HR= heart rate. Data are mean ± SEM. Two-way ANOVA (uncorrected Fisher’s LSD 
test) was used for comparison of WT and KO genotypes and the effect of GSNO treatment between groups, * = P <0.05, ** = P <0.01, *** = P 
<0.001 versus WT.  
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4.3.4 Cardiac contraction and relaxation parameters in isolated WT and KO mouse 
hearts after GSNO supplementation. 
I next determined cardiac function in isolated hearts of both animal models post treatment with 
GSNO. The hearts were isolated from WT and KO mice at 18 weeks of age, and perfused with 
Krebs-Henseleit buffer for 38 minutes before cardiac contractile parameters were measured. 
The contractile parameters in WT and KO mice at 18 weeks have been outlined in Table 4.3. I 
observed no significant difference in LVDP in the KO compared to the WT hearts (p = 0.13). 
There was a significant difference in the heart rate between the WT and KO hearts (p < 0.05). 
However, the heart rate of the WT vs KO control and WT vs KO treatment groups were 
comparable (p = 0.26; p = 0.69). The difference in max dP/dt (p = 0.30) and min dP/dt (p = 
0.13) remained insignificant in KO mice compared to WT mice. This observation in contractile 
parameters in the isolated hearts did not correspond with my data from echocardiography, in 
vivo. Both WT and KO exhibited arrhythmias at baseline, but there was no significant 
difference in the number of arrhythmic events (p = 0.83) or in arrhythmia scores (p = 0.78) 
between WT and KO hearts. Additionally, there was also no effect of GSNO supplementation 
on any of the contractile parameters or arrhythmias across all treatment groups (Table 4.3). 
Having shown that WT and KO mouse hearts had similar isolated heart function after 5 weeks 
of GSNO supplementation, the next experiment involved subjecting the isolated hearts to 
another GSNO treatment
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Table 4.3 Baseline contractile parameters and quantification of arrhythmias in isolated WT and KO mouse hearts at 18 weeks after GSNO 
supplementation 














LVDP (mmHg) 62.47 ± 10.29 54.56 ± 4.31 78.62 ± 13.45 73.30 ± 11.64 0.13 0.55 
HR (beats/min) 245.68 ± 19.95 275.91 ± 11.86 196.31 ± 28.63 221.40 ± 24.37 0.04* 0.24 
Max dP/dt (mmHg/s) 2311.02 ± 353.58 2711.09 ± 166.48 3007.53 ± 601.96 2968.40 ± 450.17 0.30 0.69 
Min dP/dt (mmHg/s) -1215.83 ± 169.59 -1147.44 ± 66.74 -1517.67 ± 
251.36 
-1449.72 ± 186.93 0.13 0.72 
Arrhythmic events 13.67 ± 3.88 8.40 ± 5.47 8.67 ± 3.46 15.20 ± 4.02 0.83 0.88 
Arrhythmia score 0.67 ± 0.21 1.0 ± 0.32 0.83 ± 0.31 1.0 ± 0.32 0.78 0.40 
WT = Wild Type; KO = CaMKIIδ-knockout; LVDP = Left ventricular developed pressure; HR = heart rate. Data are expressed as mean ± SEM. 
Two-way ANOVA (uncorrected Fisher’s LSD test) was used to compare between WT and KO genotypes and GSNO treatment effect between 




4.3.5 Effect of GSNO treatment on cardiac parameters in isolated WT and KO 
mouse hearts after in vivo GSNO supplementation 
To investigate the potential role of CaMKII during chronic NO signaling, WT and KO 
hearts were treated again with GSNO at different concentrations (100 µM, 600 µM and 
1600 µM), similar to the method in Chapter 3. I hypothesised that surplus GSNO 
treatment would alter cardiac contractility in WT and KO mouse hearts. 
Results showed that GSNO reduced LV developed pressure in the WT and KO mice 
(Figure 4.3A). There was no difference in the LVDP between WT and KO hearts (p = 
0.18). At the highest concentration of GSNO (1600 µM), there was a 16% reduction of 
LVDP in KO hearts compared to baseline, and this difference was significant (p = 0.001). 
GSNO at 600 µM also significantly depressed LVDP in the KO hearts compared to 
baseline (p = 0.03). The WT hearts exhibited a significant decrease (24.3%) in LVDP at 
the highest concentration of GSNO (p = 0.01).  
The different concentrations of GSNO had no significant effect on heart rate in WT and 
KO hearts (p = 0.26) (Figure 4.3B). In addition, there was also no overall change in heart 
rate between the WT and KO mouse hearts (p = 0.27). WT hearts subjected to 1600 µM 
GSNO  resulted in a 22.9% decrease in max dP/dt, compared to baseline and this change 
was significant (p = 0.03) (Figure 4.4A). In the KO hearts, 1600 µM GSNO caused a 
significant reduction (14.3%) in max dP/dt compared to baseline (p = 0.003). There was 
no overall significant difference in min dP/dt between WT and KO hearts (p = 0.07). 
There was a trend towards lower max dP/dt in the WT compared to the KO at the highest 
concentration of GSNO but this difference was not significant (p = 0.07). The highest 
concentration of GSNO resulted in a significant decrease in min dP/dt in WT hearts 
compared to baseline (p = 0.04). The highest concentration of GSNO had no effect on 
min dP/dt in KO hearts compared to baseline (p = 0.48) (Figure 4.4B).  
In summary, high concentrations of GSNO depressed LV developed pressure and rates 
of contraction and relaxation in WT and KO hearts. However, there was no effect of 
GSNO on cardiac chronotropy. 
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Figure 4.3 LV pressure and heart rate in WT and KO mouse hearts with GSNO 
treatment (100 µM, 600 µM and 1600 µM) A, LV developed pressure B, Heart rate. 
Data are means ± SEM. WT, blue line, n = 5 hearts; KO, red line, n = 5 hearts. Two-way 
ANOVA (uncorrected Fisher’s LSD test) was used to compare between groups. * = 
P<0.05, *** = P<0.001, GSNO treatment effect (vs baseline). 
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Figure 4.4 Rates of contraction and relaxation in WT and KO mouse hearts with 
GSNO treatment (100 µM, 600 µM and 1600 µM) A, Rate of Contraction (Max dP/dt) 
B, Rate of Relaxation (Min dP/dt). Data are means ± SEM. WT, blue line, n = 5 hearts; 
KO, red line, n = 5 hearts. Two-way ANOVA (uncorrected Fisher’s LSD test) was used 
to compare between groups. * = P<0.05, ** = P<0.01, GSNO treatment effect (vs 
baseline). 
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4.3.6 Effect of GSNO on coronary flow and pressure-time integral in isolated WT 
and KO mouse hearts 
No effect of GSNO on coronary function of isolated WT and KO hearts was observed 
after chronic treatment and subsequent perfusion with GSNO. There was no significant 
difference in coronary flow between WT and KO hearts (p = 0.65) (Figure 4.5A). 
 
The tension in the myocardium per beat measured as pressure-time integral (PTI) was 
altered in WT and KO hearts during GSNO treatment (Figure 4.5B). WT hearts showed 
significant decline in PTI after 600 µM and 1600 µM GSNO treatment compared to 
baseline (p = 0.03; p = 0.005). This effect was not pronounced in KO hearts as PTI 
declined only after 100 µM compared to baseline (p = 0.01), and remained stable with 
further increase in GSNO. There was no overall significant difference in pressure-time 
integral between WT and KO hearts (p = 0.10). 
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Figure 4.5 Cardiac response to GSNO treatment (100 µM, 600 µM and 1600 µM) in 
WT and KO mouse hearts. A, Coronary flow (ml/min) B, Pressure-time integral 
(mmHg.s). Data are means ± SEM. WT, blue line, n = 7 hearts; KO, red line, n = 5 hearts. 
Two-way ANOVA (uncorrected Fisher’s LSD test) was used to compare between groups. 




4.3.7 Effect of GSNO on cardiac arrhythmias post GSNO supplementation 
To further investigate the effect of GSNO on arrhythmias, I quantified the number of 
arrhythmic events and arrhythmia scores in WT and KO mouse hearts (Figure 4.6). WT 
and KO mouse hearts exhibited arrhythmias at baseline; however, no significant 
difference was observed in the number of arrhythmic events (p = 0.70) (Figure 4.6A). 
There was a trend towards increase in arrhythmias in both animal models with GSNO 
treatment but this did not attain a level of significance (p = 0.06). The WT and KO mouse 
hearts exhibited similar arrhythmia scores (p = 0.91). GSNO treatment did not affect the 
severity of arrhythmias in the WT and KO hearts (p = 0.40) (Figure 4.6B). There was no 
relationship between heart rate and arrhythmia score in WT hearts (r = 0.07, p = 0.79) 





        
Figure 4.6 Arrhythmias during GSNO treatment (100 µM, 600 µM and 1600 µM) in 
WT and KO mouse hearts A, Arrhythmic events B, Arrhythmia scores. Data are means 
± SEM. WT, blue line, blue bar, n = 5 hearts; KO, red line, red bar, n = 5 hearts. Two-
way ANOVA (uncorrected Fisher’s LSD test) was used to compare between groups.  
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Figure 4.7 Effect of heart rate on arrhythmia severity during GSNO treatment in 
WT and KO mouse hearts A, Wild-type hearts B, CaMKIIδ hearts. Data are means ± 
SEM. WT, n = 5 hearts; KO, n = 5 hearts.  
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4.3.8 Effect of acute and chronic GSNO treatment on arrhythmias in WT and KO 
mouse hearts 
To analyse the effect of duration of GSNO treatment on isolated WT and KO hearts, I 
compared the arrhythmic events between the baseline and highest concentration of GSNO 
used in this study during acute and chronic treatment. 
In chapter 3 (section 3.2.6), data showed that WT mice exhibited significant elevation in 
arrhythmic events in the acute GSNO treatment at the highest concentration of GSNO 
relative to baseline whereas there was no significant effect of acute GSNO treatment on 
arrhythmic events in the KO hearts at any concentration. In this chapter, there was a trend 
effect of GSNO showing an increase in arrhythmias in WT and KO in the chronic phase; 
however, this difference was not statistically significant (p = 0.06) (Figure 4.6A). 
There was an overall trend towards a difference in the amount of arrhythmias between 
the WT and KO hearts (p = 0.09) (Figure 4.8). There was a significant effect of GSNO 
treatment on number of arrhythmic events in WT and KO isolated hearts, irrespective of 
the treatment duration (p = 0.02). Post-hoc test revealed that there was a trend towards 
higher number of arrhythmias during GSNO treatment in the WT hearts during chronic 
treatment compared to acute treatment phase but level of significance was not achieved 
(p = 0.07). There was also a trend towards an increase in number of arrhythmic events in 
the KO hearts in the chronic GSNO treatment phase compared to acute GSNO treatment 
phase (p = 0.09).  
Overall, I cannot conclude that GSNO treatment influenced the number of arrhythmias in 
WT and KO hearts when duration of treatment was considered. However, though 
statistically insignificant, there was a trend indicating that chronic treatment with GSNO 
may have led to an increase in arrhythmias for the KO animals. 
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Figure 4.8 Arrhythmias during acute and chronic phases of GSNO treatment in WT 
and KO mouse hearts Data are means ± SEM. WT acute phase, broken blue line, n = 7 
hearts, KO acute phase, red broken line, n = 5 hearts, WT chronic phase, n = 5 hearts, KO 
chronic phase, n = 5 hearts. Three-way ANOVA (uncorrected Fisher’s LSD test) was 
used to compare between across groups. 
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4.4 Discussion 
The aim of this Chapter was to investigate the role of chronic GSNO treatment on cardiac 
function in WT and CaMKIIδ-KO mice. GSNO was administered to mice for 5 weeks, 
from 13 to 18 weeks of age. Echocardiography to assess LV structure and function was 
performed at week 13 and week 18. The hearts were then isolated and treated again with 
GSNO at different concentrations while cardiac contractility was measured. Protein 
nitrosylation level was quantified via Western blotting. The main findings of this study 
are as follows: (a) GSNO treatment induced protein nitrosylation, but KO mice appeared 
to be more resistant to these effects, (b) Long term GSNO treatment has no effect on in 
vivo cardiac function (c) isolated WT and KO mouse hearts that received chronic GSNO 
treatment exhibit reduced contractility and reduced rates of contraction and relaxation 
with increasing concentrations of GSNO treatment, (d) chronic GSNO treatment phase 
does not significantly enhance the number of arrhythmic events in WT and KO hearts. 
4.4.1 GSNO induces S-nitrosylation in the heart 
Cardiac tissues from WT and KO mice exposed to different concentrations of GSNO and 
further treated with GSNO after heart isolation were subjected to biotin switch assay to 
analyse levels of cardiac SNO proteins (Figure 4.2). Studies have shown that NO 
signaling can be regulated through the S-nitrosylation which involves covalent 
attachment of NO-related species to cysteine residues (Gonzalez et al., 2007; González et 
al., 2008; Cutler et al., 2012; Irie et al., 2015).  Previous studies show that GSNO mediates 
its effects through S-nitrosylation (Sun et al., 2007; Erickson et al., 2015). In this study, 
effect of GSNO was evaluated in the heart and there was upregulated S-nitrosylation in 
WT hearts compared to KO hearts. It is unclear whether the lack of change in S-
nitrosylation levels in the KO mice is due to loss of CaMKIIδ. There was no significant 
difference in GSNO water consumption between the WT and KO animals, and thus any 
differences in S-nitrosylation should not be a product of unequal exposure to GSNO. The 
level of CaMKII S-nitrosylation in the WT animals could not be directly measured due 
to difficulty in optimising this aspect of the biotin switch assay. One possibility to 
consider is that CaMKII, once activated, may interact with the nitric oxide synthase 
family of proteins to induce enhanced NO production, further increasing S-nitrosylation 
of many protein targets. This feedback loop would not occur in the CaMKIIδ KO animals, 
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which could account for why less overall S-nitrosylation was observed. Overall, my 
results suggest that the effect of GSNO observed in the isolated hearts may be mediated 
through S-nitrosylation. 
4.4.2 Effect of GSNO and deletion of CaMKIIδ on cardiac function  
Aberrant CaMKII activity has been associated with altered Ca2+ homeostasis and 
proarrhythmic remodelling (Wu et al., 2002; Erickson et al., 2013; Erickson et al., 2015; 
Grimm et al., 2015; Feng et al., 2017; Lebek et al., 2018). A previous study by Grimm et 
al. (2015) has demonstrated that genetic deletion of CaMKIIδ is protective against 
pathological signaling in the heart. The results from my study showed that KO mice had 
altered cardiac function at baseline compared to WT mice (Table 4.2). Comparing the 
WT and KO treatment groups in this Chapter, I showed that the structural and functional 
differences observed at baseline still persisted after 5 weeks. I hypothesised that deletion 
of CaMKIIδ would not affect basal cardiac structure and function. The findings from this 
Chapter reject my hypothesis. It is also contrary to other studies that have characterised 
this CaMKIIδ KO model and found no altered basal cardiac function in KO mice 
compared to the WT mice (Backs et al., 2009; Ling et al., 2009). Ling et al. (2009) 
developed the KO mouse model, measured cardiac function using echocardiography at 2 
and 10 months and found no difference in LV chamber or wall thickness. The differences 
observed in echocardiography parameters in the WT and KO mice used in this chapter 
suggest that deletion of CaMKIIδ is detrimental to mouse hearts. Despite the systolic 
dysfunction observed in the KO mice, they had no obvious alterations in phenotype 
except for significant weight gain in the control group at 13 and 18 weeks compared to 
WT mice (Table 4.1). After in vivo cardiac function assessment, the WT and KO hearts 
were isolated and cardiac contractile parameters were measured. I observed no significant 
change in cardiac function between WT and KO hearts after the 5-week GSNO 
administration. Grimm et al. (2015) found no significant differences in cardiac parameters 
of WT and KO mice using echocardiography and this result remained the same after 
isolated heart perfusion. This raises the question as to what could be happening in vivo 
that resulted in altered cardiac function while WT and KO hearts shared similar basal 
cardiac function ex vivo. The disparity in findings could be due to a factor such as level 
of anaesthesia (Gao et al., 2011).  
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Following GSNO treatment for 5 weeks, there was no difference in echocardiography 
parameters between treatment groups of each animal model (Table 4.2). My hypothesis 
was that long term GSNO treatment would upregulate NO levels and alter cardiac 
function. My data suggest that GSNO had no significant effect on cardiac structure and 
function which is not consistent with my hypothesis. To my knowledge, no study has 
measured cardiac function with chronic GSNO treatment. Other groups have reported that 
50 mg/L of a NO donor, sodium nitrite, was sufficient to improve insulin signaling and 
vascular function in mice (Jiang et al., 2014; Sindler et al., 2015). It is possible that the 
duration of GSNO treatment was not sufficient to induce significant changes in the WT 
and KO mouse hearts, and a longer duration of treatment could be required. 
4.4.3 GSNO treatment alters cardiac contractility in isolated WT and KO hearts 
after GSNO supplementation 
Another aim of this study was to investigate the effect of GSNO on the contractile 
parameters of isolated WT and KO hearts after chronic treatment with a NO donor. GSNO 
can induce S-nitrosylation which in turn modulates the activity of cardiac Ca2+-handling 
proteins (Gonzalez et al., 2007; Sun et al., 2008; Cutler et al., 2012). GSNO therapy has 
been found to have cardioprotective effects in animals and humans (Konorev et al., 1995; 
Rassaf et al., 2006; Sun et al., 2007). For example, GSNO protects cardiomyocytes from 
hypoxic damage and accelerated cardiac contractility after ischaemia/reperfusion in 
isolated rat hearts (Poluektov et al., 2019). On the other hand, GSNO exposure in 
cardiomyocytes has been found to result in pro-arrhythmic remodelling by inducing 
increased Ca2+ spark frequency in the presence of CaMKII activity (Gutierrez et al., 2013; 
Curran et al., 2014). In cardiomyocytes, SR Ca2+ leak leads to an increase in Ca2+ spark 
frequency which generates into spontaneous Ca2+ waves and suggests susceptibility of 
the heart to arrhythmias (Landstrom et al., 2017). 
First, I determined the impact of GSNO on inotropy in isolated hearts. I hypothesised that 
GSNO would increase or reduce LVDP depending on the concentration. The results 
showed reduced LVDP in WT and KO mice at high GSNO concentration (Figure 4.3A). 
Developed pressure in WT and KO mouse hearts had a similar response to GSNO which 
suggests that this observation may not be dependent on CaMKIIδ activity. These results 
add to the body of work from previous studies showing that high concentrations of NO 
 105 
result in negative inotropy (Mohan et al., 1996; Vila-Petroff et al., 1999; Brunner et al., 
2001; González et al., 2008). To my knowledge, research has focused on the effect of 
GSNO on contractility in cardiomyocytes and there is no documented literature on the 
effect of GSNO on cardiac function in isolated mouse hearts. However, the biphasic effect 
of NO donors has been established. A previous study by González et al. (2008) has 
revealed that low concentrations of the NO donor SNAP enhanced contractility in isolated 
rat hearts and high concentrations had the opposite effect. This was due to activation of 
the cAMP and cGMP pathways, depending on the concentration. Therefore, as observed 
in my study, reduced LVDP due to high GSNO concentrations suggests an activation of 
the cGMP-dependent PKG pathway which results in negative inotropy (Vila-Petroff et 
al., 1999).  
Secondly, I observed no effect of GSNO on heart rate in the WT and KO mice (Figure 
4.3B). Previous work has shown that isolated rat hearts exhibited increased heart rate with 
low concentrations of exogenous NO donors (Müller‐Strahl et al., 2000). Pabla and Curtis 
(1995) found that in isolated rat hearts, 10 mM L-arginine, a precursor of NO, had no 
effect on heart rate while 10 µM of the NO donor SNP increased heart rate prior to 
ischaemia and during reperfusion. This suggests that low concentrations of exogenous 
NO, and not endogenous NO, can enhance heart rate. In another study, high 
concentrations of NO (> 300 µM) resulted in a reduction of heart rate in isolated rat atria 
(Kennedy et al., 1994). My findings show no change in heart rate at low or high 
concentration of GSNO. It is unclear whether the treatment with GSNO before subsequent 
application of GSNO to the isolated hearts has contributed to this observation. The 
mechanism responsible for no change in heart rate, despite altered inotropy and lusitropy 
could not be identified in this study.  
GSNO treatment also decreased max dP/dt and min dP/dt at a high concentration of 
GSNO (1600 µM) (Figure 4.4). It was surprising that KO hearts did not exhibit any 
change in rate of relaxation with increasing GSNO concentration (Figure 4.4B). The 
effect of NO on rates of contraction and relaxation has been well documented. Kojda et 
al. (1997) showed that low concentration (< 1 µM) of a NO donor, DEA/NO, induced an 
increase in max dP/dt and min dP/dt in healthy isolated rat hearts. This was similar to 
what this group previously observed when investigating low concentrations of NO on 
cardiac contractility in rat cardiomyocytes (Kojda et al., 1996). The negative inotropy and 
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lusitropy due to high concentrations of GSNO as observed in the WT and KO hearts could 
be attributed to the concentration-dependent biphasic effect of NO (Mohan et al., 1996; 
Musialek et al., 1997; Preckel et al., 1997; Müller‐Strahl et al., 2000; González et al., 
2008). Therefore, the reduced max dP/dt and min dP/dt in the WT and KO hearts is 
mediated by the cGMP dependent pathway due to high levels of cGMP produced by high 
concentrations of NO donors and subsequent activation of protein kinase G, as observed 
in previous studies (Sandirasegarane & Diamond, 1999; Layland et al., 2002). 
Coronary function was unchanged during GSNO treatment in WT and KO hearts (Figure 
4.5A). Previous study showed that inhibition of NOS can modify coronary flow in 
isolated hearts and this is related to a change in developed pressure (Bouma et al., 1992). 
My data shows GSNO induced a reduction in contractile function and this did not result 
in a change in coronary flow. It was also unclear if the lack of GSNO effect on coronary 
flow was related to arrhythmic events. There was a reduction in the average developed 
pressure per beat (PTI) with increase in GSNO concentration in WT hearts, however, this 
effect was not so pronounced in the KO hearts (Figure 4.5B). This suggests that the 
amount of energy used for contraction was lower in presence of CaMKIIδ during GSNO 
treatment, and this corresponded with the LV developed pressure. 
To summarise my findings, the resultant effect of GSNO on cardiac function in this 
chapter indicates that high concentrations of NO can negatively affect cardiac 
contractility in mice even in the absence of CaMKIIδ. 
4.4.4 GSNO treatment has no effect on cardiac arrhythmias in isolated WT and 
KO hearts after GSNO supplementation 
Chapter 3 of this thesis investigated the acute effects of GSNO exposure and found 
enhanced cardiac arrhythmias with increasing GSNO concentrations in the WT mouse 
hearts while the KO hearts were protected from GSNO-induced arrhythmias. In this 
Chapter, the result is contrary and shows that after chronic GSNO treatment, increasing 
concentrations of GSNO had no effect on arrhythmias in isolated WT and KO hearts 
(Figure 4.6). Thus, my findings reject the hypothesis that GSNO would induce cardiac 
arrhythmias in WT hearts. In addition, there absence of relationship between heart rate 
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and arrhythmia scores showed that there was change in heart rate did not influence the 
severity of arrhythmias (Figure 4.7).  
The anti-arrhythmic property of NO has been documented in literature. Inhibition of NOS 
using knockout models has been used to investigate the role of NO in cardiac arrhythmias 
(Kubota et al., 2000; Rakhit et al., 2001; Burger et al., 2009). Ventricular myocytes from 
mice lacking eNOS were found to be more susceptible to arrhythmias (Kubota et al., 
2000). Previous literature has also documented a contrary report concerning NO and 
arrhythmias. Gutierrez et al. (2013) showed that CaMKII activity in guinea pig 
cardiomyocytes enhanced Ca2+ spark frequency after GSNO exposure suggesting that NO 
contributed to the susceptibility of the heart to arrhythmias during CaMKII activation. A 
similar study by Erickson et al. (2015) also implicated the activation of CaMKIIδ to be 
responsible for increased Ca2+ spark frequency in WT ventricular cardiomyocytes. 
CaMKIIδ is known to be an arrhythmogenic molecule and its inhibition has been a target 
towards protecting against proarrhythmic signaling (Sag et al., 2009; Erickson et al., 
2013; Sommese et al., 2016; Feng et al., 2017). In this Chapter, the expectation was that 
deletion of CaMKIIδ would protect the KO mouse hearts against arrhythmias, after 
exposure to GSNO. The isolated hearts from both animal models used in this chapter 
developed arrhythmias and KO hearts were not protected against ventricular arrhythmias 
regardless of GSNO concentration, suggesting that NO and CaMKIIδ may not be playing 
a role in the arrhythmogenesis. Measurement of CaMKIIδ S-nitrosylation and NOS 
activity in future studies could provide more insight into the possible underlying 
mechanism for this finding. 
In summary, GSNO may not be responsible for cardiac arrhythmias even at low 
concentrations even in the presence of CaMKIIδ. This does not correspond with data 
reported in Chapter 3 and previous reports (Gutierrez et al., 2013; Curran et al., 2014).  
4.4.5 Duration of GSNO treatment does not affect arrhythmias in WT and KO 
hearts 
Data from my study demonstrated that the duration of treatment did not significantly 
affect the response of WT hearts and KO hearts to GSNO-induced arrhythmic events 
(Figure 4.8). In acute treatment, GSNO increased arrhythmias in WT hearts and 
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chronically, there was no significant increase in arrhythmias in response to GSNO. When 
GSNO was administered to KO isolated hearts acutely, the KO hearts were protected 
from arrhythmias (Chapter 3), whereas in the chronic treatment phase, the KO hearts 
started to exhibit a trend towards increased arrhythmias with GSNO. This suggests that 
acutely, knocking out CaMKIIδ can protect the heart from GSNO-induced proarrhythmic 
remodelling. This is similar to the finding that CaMKII inhibition can prevent increase in 
Ca2+ spark frequency after GSNO treatment in cardiomyocytes (Gutierrez et al., 2013; 
Curran et al., 2014; Erickson et al., 2015). There is no published study that examines 
chronic GSNO treatment related to CaMKII inhibition. Comparing data from Chapter 3 
and Chapter 4, the presence of CaMKII during GSNO treatment induces arrhythmias as 
seen in WT hearts, whereas in long term GSNO administration, the presence or absence 
of CaMKII does not contribute to cardiac arrhythmias. The chronic administration of 
GSNO prior to heart isolation and second phase of treatment may have rendered the KO 
mice more sensitive to NO. The mechanism underlying this effect is not completely 
understood. Combined, these data provide the first evidence that chronic GSNO treatment 
does not induce arrhythmias in WT hearts and KO hearts. 
4.4.6 Conclusion 
In summary, this study shows the first evidence of the effect of chronic GSNO exposure 
on cardiac function. Data presented in this chapter show that KO mice exhibited systolic 
dysfunction at baseline and prolonged GSNO treatment can result in negative inotropy, 
however, it does not contribute to increased cardiac arrhythmias in WT and KO hearts. 
Results from this chapter also indicate that the CaMKIIδ deletion results in systolic 
dysfunction in vivo, and chronic GSNO exposure in mice is not deleterious to cardiac 
function except at a high concentration.  
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CHAPTER 5: THE ROLE OF NITRIC OXIDE AND β – 
ADRENERGIC RECEPTOR STIMULATION IN CARDIAC 
FUNCTION 
5.1 Introduction  
β-adrenergic receptor (β-AR) stimulation induces the "fight or flight" response of the 
heart to cope with stress by increasing cardiac output. β-AR signaling is an essential 
regulator of cardiac Ca2+ homeostasis and cardiac function as a whole (Yoo et al., 2009). 
β-ARs are G-protein-coupled receptors involved in regulating the heart's response to 
catecholamines (Chruscinski et al., 1999; Ferrero et al., 2007; Calvert & Lefer, 2013). 
When β-ARs are stimulated, adenylyl cyclase is activated, increasing cAMP production 
and activating PKA and other downstream mediators, including Ca2+ handling proteins. 
The heart's response to this stimulation is enhanced force and frequency of myocardial 
contraction and accelerated relaxation (Grimm & Brown, 2010). Excessive sympathetic 
stimulation has been implicated in various cardiac pathologies, such as heart failure and 
arrhythmia (Shizukuda et al., 1998; Iwai-Kanai et al., 1999; Floras, 2009; Bovo et al., 
2012; Joca et al., 2020).  
ß-AR stimulation has been shown to be an activator of CaMKII in the heart, as seen in 
Langendorff perfused mouse hearts (Grimm et al., 2015). Alongside β-AR stimulation, 
the effect of overexpression of the cardiac protein kinase CaMKII has also been observed 
in pathological cardiac conditions (Ai et al., 2005; Khoo et al., 2006; Kohlhaas et al., 
2006; Said et al., 2008). Studies have suggested that even though these two pathways can 
be independent, the β-adrenergic pathway can also modulate CaMKII activity (Wu et al., 
2002; Wang et al., 2004; Sag et al., 2009; Grimm & Brown, 2010). For example, the β-
AR agonist isoproterenol (ISO) induces spontaneous SR Ca2+ leak in cardiomyocytes and 
arrhythmias in the heart (Wu et al., 2002; Curran et al., 2007; Grimm et al., 2015). Since 
CaMKII is a downstream mediator of deleterious ß-adrenergic signaling as in heart 
failure, inhibition of CaMKII could be an effective therapeutic strategy in addressing 
heart failure (Mollova et al., 2015; Dewenter et al., 2017) and protecting the heart against 
cardiac dysfunction. Sag et al. (2009) tested the influence of CaMKII on ISO-dependent 
arrhythmias and observed that inhibition of CaMKII reduced the incidence of cardiac 
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arrhythmias in mice overexpressing CaMKIIδ. Increased Ca2+ spark frequency in 
cardiomyocytes, which is a predictor of cardiac arrhythmias, is attenuated in CaMKIIδ-
KO mouse cardiomyocytes exposed to ISO (Grimm et al., 2015). Findings from Curran 
et al. (2007) indicate that ISO-induced SR Ca2+ leak in intact rabbit ventricular cardiac 
cells was prevented by CaMKII inhibition, and this effect was not dependent on PKA. 
Taken together, these suggest that CaMKII activity contributes to cardiac pathological 
signaling during β-AR stress via a complex pathway that is not well understood.  
Interestingly, there is a link between β-adrenergic response in the heart and NO signaling. 
During basal cardiac contractility, NOS activity can induce S-nitrosylation of RyR2, 
LTCC and SERCA2 which is enhanced by β-AR stimulation (Vielma et al., 2016). 
Increased β-AR stimulation activates eNOS to increase NO bioavailability, though the 
exact mechanism is yet to be elucidated (Calvert & Lefer, 2013). NO bioavailability can 
improve vascular compliance and regulate blood pressure in hypertension (Rees et al., 
1996; Houston & Hays, 2014). NO can also modify RyR2 and protect against SR Ca2+ 
leak in cardiomyocytes (Gonzalez et al., 2007), and even prevent arrhythmias under 
elevated intracellular Ca2+ conditions in the heart (Cutler et al., 2012). 
Despite the well-established cardioprotective role of NO (Phillips et al., 2009; Houston 
& Hays, 2014; Grievink et al., 2016), evidence has emerged that shows the role of NO in 
the heart could be more complicated than described in previous studies. Recent studies 
have now identified a unique cardiac arrhythmogenesis pathway involving β-AR 
stimulation, NO and CaMKII, which induce SR Ca2+ leak in cardiomyocytes (Gutierrez 
et al., 2013). According to data reported in chapter 3, NO could potentially have an 
arrhythmogenic effect in a heart with intact CaMKIIδ. Some studies have revealed that 
even though NO can directly activate CaMKII (Erickson et al., 2015), β-AR stimulation 
can also influence CaMKII activation by NO (Gutierrez et al., 2013; Curran et al., 2014).  
Gutierrez et al. (2013) observed that CaMKII could be activated by direct NO signaling. 
In guinea-pig ventricular myocytes exposed to a NO donor, GSNO, they observed an 
increase in Ca2+ spark frequency, which mimicked the similar effect of ISO application. 
They confirmed the involvement of CaMKII using the inhibitors KN93 and AIP. 
Similarly, in rabbit ventricular myocytes, inhibition of NOS in the presence of ISO 
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ablated arrhythmogenic spontaneous Ca2+ waves and inhibition of CaMKII in the 
presence of a NO donor, SNAP, prevented increase in SR Ca2+ leak (Curran et al., 2014). 
To summarise, CaMKII plays a unique role in arrhythmogenesis in the presence of NO 
in cardiomyocytes. CaMKII activation by β-AR stimulation and NO is the pathway that 
promotes SR Ca2+ leak in cardiac cells and could be responsible for arrhythmias in the 
heart. The influence of β-AR stimulation on the NO-CaMKII pathway has only been 
tested in cardiomyocytes, and there is limited evidence to determine if the same pathway 
could be involved in cardiac arrhythmias. 
The results detailed in Chapter 3 showed that knocking out CaMKIIδ prevented cardiac 
arrhythmias associated with NO signaling. The next step was to determine the relationship 
between CaMKIIδ and NO during increased β-adrenergic stimulation. The experiments 
in this chapter focused on the effects of β-adrenergic stress and NO signaling in cardiac 
function in WT mice with intact CaMKII. 
5.1.1 Aims and hypothesis 
The aims of this chapter were; 
1) To determine if NO will also modify CaMKII via nitrosylation. I hypothesised that the 
NO donor GSNO will induce S-nitrosylation of CaMKII in WT hearts.  
2) To assess cardiac response of KO hearts to β-adrenergic stimulation and to further 
measure the effect of β adrenergic stimulation on arrhythmias. I hypothesised the 
β-adrenergic stimulation would alter cardiac contraction in KO mouse hearts and have 
no effect on arrhythmias. 
3) To determine if NO exposure and CaMKII activation via β-adrenergic stimulation 
would  alter cardiac function in WT mice. I hypothesised that β-adrenergic signaling 
would activate CaMKII and increase cardiac inotropy and chronotropy. 
4) To measure cardiac contraction and relaxation of WT hearts treated with the NO donor, 
GSNO, and β-adrenergic agonist, ISO. I hypothesised that ISO and GSNO would alter 
cardiac contractility and relaxation in WT hearts. 
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5) To investigate the effect of NO and β-adrenergic stimulation on cardiac arrhythmias 
in isolated WT mouse hearts. I hypothesised that WT hearts will be susceptible to 




5.2.1 Experimental protocol 
To measure cardiac function in WT mice, I used echocardiography (Chapter 2, section 
2.3). To determine if NO and β-adrenergic stimulation mediated CaMKII activity, I 
performed Western blotting (as described in Chapter 2, section 2.5) to measure expression 
levels of total and phosphorylated CaMKII. To determine the effect of NO and 
β-adrenergic stimulation on cardiac contractility, I isolated the hearts from healthy 12-
week old WT mice and perfused the hearts while measuring cardiac function (described 
in Chapter 2). I perfused the isolated hearts with a single dose (100 nM) of Isoproterenol 
(ISO) and a single dose (150 µM) of GSNO for 10 minutes.  
I randomly divided the isolated hearts into different groups in the following order;  
ISO-WASH group: ISO treatment before wash with KRH buffer. 
ISO-GSNO group: ISO treatment before GSNO treatment. 
GSNO-ISO group: GSNO treatment before ISO treatment.  
 
Figure 5.1 A time course protocol for the Langendorff perfusion experiment 
showing groups for ISO (100 nM) and GSNO (150 µM) treatment conditions. Groups 




5.2.2 Modified biotin switch assay 
Modified biotin switch assay is a modified method of the biotin switch assay where the 
labelling of S-nitrosylated proteins is done with a fluorophore instead of biotin. This 
experiment was performed by Dr Oby Ebenebe in Kohr Laboratory of Cardiovascular 
Redox Signaling, Johns Hopkins University, Baltimore, MD, USA. All animal handling 
and sample preparations were carried out by me in University of Otago, New Zealand 
prior to shipping to USA. 
Steps for sample preparation for S-NO detection were carried out in the dark and where 
not possible, samples were protected from direct light. Whole heart samples were 
homogenized in 1 mL cold homogenization buffer (Table 5.1) in brown tubes.  
Table 5.1 Homogenisation Buffer 
Homogenization Buffer (pH 7.7/7.8):   
for 10 mL                           
FINAL CONCENTRATIONS 
1.0269 g Sucrose (Fw342.3) 0.3 M 
2.5 mL of 1M HEPES-NaOH (pH7.7) 250 mM                                                   
20 µL of 500 mM EDTA 1 mM 
125 µL of 2 M NEM 25 mM                                           
250 µL Triton-X 100 0.5 % 
pH was adjusted to 7.7-7.8 with NaOH and solution was made up to 10 mL with 
distilled water. 
NEM was made fresh by weighing out in the dark in a brown tube with 65 mg in 250 
μL methanol. 
One tablet of EDTA-free protease-inhibitor was added to 5 µL of 0.2 M Neocuproine 
per 10 mL. 
 
Samples were homogenized and left on ice for 15 – 20 mins, followed by centrifugation 
at 14000 x g for 10 mins at 4°C. Supernatant was taken and placed in pre-labelled brown 
tube. Pellets were discarded or stored at -80°C if needed. ~10 µL of supernatant was 
aliquoted to determine protein concentration using Bradford assay (He, 2011). Remaining 
supernatants were aliquoted into brown tubes 2x 100 µL aliquots, snap frozen in liquid 
nitrogen and stored in -80oC. 
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HEN buffer was prepared (Table 5.2). Volume of sample required for 100 µg protein and 
final volume of 200 µL was prepared (Table 5.3). Samples were incubated in thermo-
shaker at 50°C for 40 mins (80 rpm) 
While samples were incubating, DyLight Malemide 800 (stock 4 mM, Thermo Fisher 
Scientific) was thawed on ice (and dissolved in 233 µL DMF, if still lyophilized) and 1% 
SDS was added to HEN buffer. After incubation, 1.2 mL of acetone was added to each 
sample and mixed with vortex mixer at lowest speed. This mixture was incubated for 20 
mins at -20°C and afterwards placed in a centrifuge to spin at 10,000 x g for 10 mins at 
4°C. Supernatant was decanted and discarded without disturbing pellet. Pellet was air 
dried using compressed air to get rid of acetone, with extra care to prevent loss of pellet 
and to prevent precipitation in subsequent steps. Pellet was resuspended in 50 µL HEN 
buffer + 1% SDS solution and a quick spin was done to get rid of bubbles. 
Table 5.2 HEN buffer 
HEN Buffer for 10 mL  
2.5 mL of 1M HEPES-NaOH (pH7.7) 250 mM                                                   
20 µL of 500 mM EDTA 1 mM 
5 µL of 0.2 M Neocuproine  
 
Table 5.3 Recipe for sample mixture 
Reagent Volume (µL) Final concentration 
25%SDS 16 µL 2% 
2 M- NEM 2 µL 20mM 
HEN 182 – Protein sample - 





For DyLight switch, 2 µL of 4mM DyLight Malemide 800 was added to sample. 1 µL of 
freshly dissolved Ascorbate (1 M, 1:50 v/v, Ascorbate = 0.198g in 1 mL Milli-Q water). 
This solution was incubated in the dark for 1hr at RT. 1.2 mL ice-cold acetone was added 
to each sample, and mixed using a vortex mixer gently at lowest speed. The mixture was 
incubated for 20mins at -20°C followed by centrifugation at 10,000xg for 10mins at 4°C. 
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Supernatant was decanted and discarded, while ensuring that pellet was not disturbed. 
Pellet was air dried using compressed air to get rid of acetone to prevent precipitation in 
subsequent steps. 
The pellet was resuspended in 50 µL of 1X sample buffer containing thiol reducing agent, 
5% beta-mercaptoethnol (BME). The mixture was boiled at 95°C for 5mins and 
subsequently 5 µL of this per sample was loaded onto a 4 – 12% SDS PAGE gel. The gel 
was run at 75 volts for 20 mins and 150 volts for 80 mins, and was then rinsed in Milli-Q 
water and visualised in iBright imaging system under fluorescence channel 800 nm 
wavelength (ThermoFisher Scientific, USA). Proteins on the gel were transferred onto a 




5.3.1 Animal Characteristics 
WT male mice shown in Table 5.4 were used for measuring effect of GSNO and ISO on 
cardiac function. There was no significant difference in body weight among the mice 
comprising each group. Measurement of CaMKII nitrosylation required another set of 
WT mouse hearts (Table 5.5). The weight of the animals in these ISO and GSNO 
treatment groups were not statistically significant compared to control (p > 0.05). KO 
mice were used to measure effect of ISO on cardiac function in the absence of CaMKIIδ 
(Table 5.6). 
Table 5.4 Animal Characteristics for 12-week old WT male mice 
Parameter Experimental Groups 
ISO-WASH ISO-GSNO GSNO-ISO 
Body Weight (g)  27.57 ± 0.30 27.90 ± 0.43 27.46 ± 1.10 
Number (n) 6 5 5 
Data are expressed as mean ± SEM 
Table 5.5 Animal Characteristics for 12-week old WT male mice for measurement 
of S-nitrosylation levels 
Parameter Experimental Groups 
CONTROL ISO-WASH ISO-GSNO GSNO-ISO 
Body Weight 
(g) 
 29.27 ± 0.48 27.80 ± 0.23 28.15 ± 0.09 29.70 ± 0.54 
Number (n) 3 4 4 4 
Data are expressed as mean ± SEM and were statistically analysed using one-way 
ANOVA. 
Table 5.6 Animal Characteristics for 12-week old KO male mice 
Parameter ISO-WASH 
Body Weight (g)  34.55 ± 1.75 
Number (n) 4 
Data are expressed as mean ± SEM 
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5.3.2 Echocardiography measurements for 12-week old WT male mice 
Table 5.7 shows the echocardiography data for WT mice of the three experimental groups 
at 12 weeks old prior to heart isolation and drug treatment. There was no significant 
difference in systolic or diastolic function parameters. Therefore, all animals used in this 
chapter had similar baseline cardiac function. 
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Table 5.7 Echocardiography parameters of 12-week old WT male mice 
Parameter ISO - WASH ISO - GSNO GSNO - ISO P value 
IVSd (mm) 1.03 ± 0.05 0.98 ± 0.04 1.01 ± 0.04 0.69 
IVSs (mm) 1.36 ± 0.07 1.24 ± 0.05 1.32 ± 0.07 0.46 
LVIDd (mm) 2.85 ± 0.07 2.82 ± 0.06 3.09 ± 0.12 0.11 
LVIDs (mm) 1.63 ± 0.15 1.29 ± 0.12 1.41 ± 0.27 0.35 
LVPWd (mm) 1.00 ± 0.08 1.41 ± 0.16 1.30 ± 0.19 0.12 
LVPWs (mm) 1.31 ± 0.03 1.28 ± 0.04 1.32 ± 0.04 0.81 
LVEDV (ml) 0.06 ± 0.00 0.06 ± 0.00 0.07 ± 0.00 0.15 
LVESV (ml) 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.98 
FS (%) 42.88 ± 0.92 42.49 ± 1.80 42.68 ± 3.45 0.99 
EF (%) 79.56 ± 0.89 79.02 ± 1.76 82.65 ± 4.16 0.57 
SV (ml) 0.05 ± 0.00 0.05 ± 0.00 0.06 ± 0.01 0.08 
CO (ml/min) 21.49 ± 0.00 24.19 ± 0.00 27.90 ± 0.00 0.21 
HR (beats/min) 412.4 ± 13.65 433.7 ± 9.63 409.2 ± 17.12 0.44 
R-R Interval (ms) 
E:A ratio 
E velocity (cm/s) 
A velocity (cm/s) 
147.1 ± 4.69 
2.24 ± 0.06 
42.4 ± 1.82 
19.20 ± 1.08 
138.9 ± 2.98 
2.44 ± 0.17 
49.23 ± 3.64 
20.25 ± 0.29 
148.3 ± 6.17 
2.33 ± 0.18 
45.91 ± 2.79 





HR, heart rate; FS, Fractional shortening; EF, Ejection Fraction; IVSD, interventricular 
septum diastolic thickness; IVSS, interventricular septum systolic thickness; LVIDD, left 
ventricular internal dimension at diastole, LVIDS, left ventricular internal dimension at 
systole; LVPWD, left ventricular posterior wall thickness at diastole; LVPWS, left 
ventricular posterior wall thickness at systole. Data are expressed as mean ± SEM. One-
way ANOVA was used to compare between ISO-WASH (n = 6), ISO-GSNO (n=5) and 
GSNO-ISO (n=5) groups. 
 120 
5.3.3 CaMKIIδ expression and activation in WT hearts 
After heart isolation and treatment with GSNO and ISO, CaMKII expression and 
activation levels in WT mouse hearts were measured in preserved cardiac tissues using 
the Western blotting method described in Chapter 2. CaMKII activation in LV tissue was 
similar across all groups (p = 0.18). CaMKII phosphorylation, which is often used as a 
proxy for CaMKII activity, was also measured in all groups (Figure 5.2). This result 
confirmed CaMKII expression and activation in WT isolated hearts. 
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Figure 5.2 Western blot for total and phosphorylated CaMKIIδ at Thr287 A, 
Representative immunoblot of total CaMKIIδ, phosphorylated CaMKIIδ at Thr287 in 
WT LV tissue and GAPDH as loading control. B, Quantification of total CaMKII levels 
in ISO-WASH (n = 5), ISO-GSNO (n = 5) and GSNO-ISO (n = 4). C, Quantification of 
P-CaMKIIδ levels in ISO-WASH (n = 5), ISO-GSNO (n = 5) and GSNO-ISO (n = 4). 
Data represented as mean ± SEM. One-way ANOVA (uncorrected Fisher’s LSD test) was 
used to compare all groups. 
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5.3.4 Quantification of S-nitrosylation levels in WT mice treated with ISO and 
GSNO 
To assess the level of CaMKII S-nitrosylation, hearts were isolated from WT animals 
(Table 5.3) and subjected to different treatment protocols, as earlier defined in this 
Chapter. The hearts were treated with single doses of 100 nM ISO and 150 µM GSNO 
for 10 minutes each. The control group received no treatment, the ISO-WASH group, 
received ISO for 10 minutes followed by a wash phase, ISO-GSNO received ISO 
followed by GSNO and the GSNO-ISO group received GSNO followed by ISO.  
To confirm if GSNO and ISO promoted S-nitrosylation in the WT hearts, a modified 
biotin switch method using sulfhydryl-reactive DyLight-maleimide fluorescent dye 
(Figure 5.3A) was performed. The results showed that was no significant difference in 
global protein nitrosylation between ISO-WASH group and control (p = 0.77), this result 
was similar to GSNO-ISO compared to control (p = 0.12). However, global protein 
nitrosylation was upregulated in the ISO-GSNO group compared to control, and this was 
significant (p < 0.01) (Figure 5.3B). DyLight fluorescence was measured relative to 
CaMKII expression to probe for CaMKII S-nitrosylation (SNO) (Figure 5.3C). The ISO-
WASH and GSNO-ISO groups had similar CaMKII SNO levels compared to control (p 
= 0.56; p = 0.78). Strikingly, there was a trend towards increased CaMKII S-nitrosylation 
in the ISO-GSNO group compared to control (p = 0.06). These data suggest that there 
was CaMKII S-nitrosylation and global protein nitrosylation under the ISO and GSNO 
conditions. 
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Figure 5.3 Quantification of CaMKII S-nitrosylation in WT mouse hearts treated 
with GSNO and ISO A, Representative images of DyLight Maleimide gel showing 
global protein nitrosylation in different groups of drug treatment and a Western blot of 
CaMKII expression in WT mouse hearts. B, Total protein nitrosylation levels. C, CaMKII 
nitrosylation levels expressed relative to the DyLight fluorescence. Data are expressed as 
mean ± SEM. Control, white bar, n = 3, ISO-WASH, black bar, n = 4, ISO-GSNO, red 
bar, n = 4, GSNO-ISO, blue bar, n = 4. One-way ANOVA (uncorrected Fisher’s LSD 
test) was used to compare groups to control: * = p < 0.05. 
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5.3.5 Effect of ß-adrenergic stimulation on contractile parameters of isolated WT 
hearts 
Studies have shown that ß-adrenergic receptor stimulation promotes inotropic and 
chronotropic effects in isolated hearts and this response could be associated with 
activation of CaMKII, one of the downstream proteins of sympathetic stimulation (Xu et 
al., 2010; Grimm et al., 2015). Data from Chapter 3 and the previous section in this 
Chapter showed that KO hearts are protected from stress-induced arrhythmias, therefore 
the aim of this section was to investigate the response of isolated WT hearts to ß-
adrenergic stress. I measured LV developed pressure, heart rate, rates of contraction and 
relaxation, arrhythmia events and severity.  
There was no significant difference in pressure development as ISO treatment failed to 
increase LVDP (p = 0.58). The wash phase that followed ISO exposure also did not alter 
LVDP compared to ISO (p = 0.39) and baseline (p = 0.76) (Figure 5.4A). As displayed 
in figure 5.4B, ISO did not significantly increase heart rate compared to baseline heart 
rate (p = 0.22). Interestingly, in the wash phase after ISO treatment, there was a 
significantly higher heart rate compared to baseline (p = 0.02), but no significant 
difference with ISO treatment (p = 0.24). There was an increase in rate of contraction, 
Max dP/dt, with ISO exposure compared to baseline (p = 0.12) although it was not 
significant and the wash phase did not cause any change compared to baseline (p = 0.46) 
and ISO treatment (0.40) (Figure 5.5A). Unlike the Max dP/dt, there was a significantly 
faster rate of relaxation, Min dP/dt, during ISO treatment (p = 0.04) and no difference in 
the wash phase (p = 0.21) (Figure 5.5B). ISO perfusion had no effect on PTI in WT hearts. 
However, there was significant decrease in PTI during the wash phase compared to 
baseline (p = 0.03) (Figure 5.6).  
Combined, the results show that ISO did induce a mild inotropic and chronotropic 
response in WT hearts.  
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Figure 5.4 LV developed pressure and heart rate in WT hearts with ISO (100 nM) 
treatment A, LV developed pressure B, Heart rate. Data are means ± SEM. Order of 
treatment; baseline, ISO, wash, n = 6 hearts. One-way ANOVA (uncorrected Fisher’s 
LSD test) was used to compare across conditions * = P < 0.05 vs baseline. 
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Figure 5.5 Rates of contraction and relaxation in WT hearts with ISO (100 nM) 
treatment. A, Max dP/dt B, Min dP/dt. Data are means ± SEM. Order of treatment; 
baseline, ISO, wash, n = 6 hearts. One-way ANOVA (uncorrected Fisher’s LSD test) was 





Figure 5.6 Pressure-Time Integral in WT hearts with ISO (100 nM) treatment. Data 
are means ± SEM. Order of treatment; baseline, ISO, wash, n = 6 hearts. One-way 
ANOVA (uncorrected Fisher’s LSD test) was used to compare across conditions * = p < 






































5.3.6 Effect of ß-adrenergic stimulation on arrhythmias in isolated WT hearts 
To test the hypothesis that ß-AR stimulation induces cardiac arrhythmias, I quantified 
arrhythmias observed in the isolated hearts. Figure 5.7A shows a representative trace of 
the parameters recorded under baseline conditions, followed by the ISO (150 μM) 
treatment phase and a wash phase.  
Figure 5.7B shows that ISO induced a significantly higher number of arrhythmic events 
in the isolated hearts compared to baseline (p < 0.0001), while the wash phase 
significantly ablated the number of arrhythmic events compared to that of ISO treatment 
(p < 0.01). There was a trend towards a higher number of arrhythmic events in the wash 
phase compared to baseline, however this was not significant (p = 0.06). These data show 
that wash phase reduced the number of arrhythmic events but not completely. I quantified 
the arrhythmia score (criteria described in Chapter 2) to determine the severity of 
arrhythmias. ISO treatment increased severity of arrhythmic events (p < 0.0001) and the 
wash phase after ISO significantly depleted the number of arrhythmic events compared 
to ISO (p = 0.0001) but remained significantly elevated compared to baseline (p < 0.001) 
(Figure 5.7C). 
In summary, these results show that ISO contributed to a significant increase in the 
number and severity of arrhythmic events. 
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Figure 5.7 Quantification of arrhythmias in WT hearts with ISO (100 nM) treatment 
A, Arrhythmic events B, Arrhythmia score. Data are means ± SEM. Order of treatment; 
baseline, ISO, wash, n = 6 hearts. One-way ANOVA (uncorrected Fisher’s LSD test) was 
used to compare across conditions *** = P < 0.001, **** = P < 0.0001 vs baseline, ### 
= P < 0.001 vs ISO. 
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5.3.7 Effect of β-AR stimulation on isolated KO mouse hearts 
To determine the effect of CaMKIIδ loss on cardiac function during β-AR stimulation, I 
used CaMKII KO hearts (Table 5.3). I perfused these hearts with 100 nM ISO followed 
with a wash phase and measured cardiac function and arrhythmias. Results in Chapter 3 
showed that loss of CaMKIIδ in isolated KO mouse hearts prevented stress-induced 
arrhythmias. I hypothesised that KO hearts would respond to β-AR stimulation but would 
also be protected from arrhythmias induced by ISO treatment. 
LV pressure development trended towards an increase after ISO treatment compared to 
baseline but remained statistically insignificant (p = 0.08) (Figure. 5.8A). After a wash, 
LV developed pressure reduced significantly compared to ISO treatment (p = 0.006) and 
became similar to baseline (p = 0.15). Heart rate remained unchanged in KO hearts 
overall, during ISO treatment and in the wash phase (p = 0.78) (Figure 5.8B). ISO 
treatment significantly elevated rate of contraction (max dP/dt) compared to baseline (p 
= 0.001) (Figure 5.9A). Max dP/dt declined in the wash phase to baseline levels (p = 
0.15), a significant difference compared to ISO treatment (p = 0.0002). Rate of relaxation 
(min dP/dt) increased significantly from baseline after ISO treatment (p = 0.004) and 
significantly declined in the wash phase compared to ISO treatment (p = 0.001) (Figure 
5.9B). PTI was unaffected by ISO perfusion in KO hearts (Figure 5.10). 
Arrhythmic events and arrhythmia scores were quantified in the KO hearts (see Figure 
5.11A for representative trace). The number of arrhythmic events was not altered during 
ISO treatment compared to baseline (p = 0.54) (Figure 5.11B). Surprisingly, the wash 
phase significantly reduced the number of arrhythmic events compared to ISO treatment 
(p = 0.04) and baseline (p = 0.01). There was no significant difference in severity of 
arrhythmias measured by arrhythmia score in KO hearts across all groups (p = 0.34) 
(Figure 5.11C).  
Taken together, these data show that response of KO mouse hearts to β-AR stimulation 
was not impaired with loss of CaMKIIδ.  However, and critically, ISO treatment did not 
promote arrhythmias in the KO hearts as it did in the WT hearts. 
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Figure 5.8 LV developed pressure and heart rate in KO hearts with ISO (100 nM) 
treatment A, LV developed pressure B, Heart rate. Data are means ± SEM. Order of 
treatment; baseline, ISO, wash, n = 4 hearts. One-way ANOVA (uncorrected Fisher’s 




             
Figure 5.9 Rates of contraction and relaxation in KO hearts with ISO (100 nM) 
treatment A, Max dP/dt B, Min dP/dt. Data are means ± SEM. Order of treatment; 
baseline, ISO, wash, n = 4 hearts. One-way ANOVA (uncorrected Fisher’s LSD test) was 
used to compare across conditions ** = P < 0.01 vs baseline, ## = P < 0.01 ### = P < 




Figure 5.10 Pressure-Time Integral in KO hearts with ISO (100 nM) treatment. Data 
are means ± SEM Order of treatment; baseline, ISO, wash, n = 4 hearts. One-way 
































                
Figure 5.11 Quantification of arrhythmias in KO hearts with ISO (100 nM) 
treatment A, Representative trace of LV contractions showing arrhythmic events in WT 
hearts in ISO and WASH phases B, Arrhythmic events C, Arrhythmia score. Data are 
means ± SEM. Order of treatment; baseline, ISO, wash, n = 4 hearts. One-way ANOVA 
(uncorrected Fisher’s LSD test for arrhythmic events and Kruskal-Wallis test for 
arrhythmia score) was used to compare across conditions * = P < 0.01, vs baseline. 
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5.3.8 Effect of GSNO treatment on cardiac contraction and relaxation before and 
after ß-adrenergic stimulation in isolated WT mouse hearts. 
Data from the previous sections established that KO hearts were protected from ISO-
induced arrhythmias compared to WT hearts when exposed to ISO. The next step was to 
investigate the effect of ISO and GSNO treatment together on isolated WT hearts.  
Treatment of the isolated hearts with ISO prior to GSNO did not alter LVDP compared 
to baseline (p = 0.25) and GSNO (p = 0.43) (Figure 5.12A). There was also no significant 
difference between baseline LVDP and LVDP during GSNO infusion (p = 0.80). In the 
GSNO-ISO group, which involved pre-treatment with GSNO, there was no significant 
difference between LVDP after GSNO perfusion (p = 0.91) and baseline. Upon addition 
of ISO, there was a trend towards increasing  LVDP compared to GSNO (p = 0.05) and 
baseline (p = 0.07). The data show that β-adrenergic stimulation did not have any 
significant effect on the force-frequency relationship, and GSNO failed to alter pressure 
development in the hearts. 
In the ISO-GSNO group, ISO perfusion significantly increased heart rate (p = 0.007) from 
baseline (Figure 5.12B). This increased chronotropy was persistent even after GSNO 
application and was significantly different from baseline (p = 0.003), but there was no 
difference in heart rate between the ISO challenge and GSNO treatment (p = 0.71). When 
the hearts were perfused with GSNO before ISO (as seen in the GSNO-ISO group), 
GSNO did not cause any change in heart rate compared to baseline (p = 0.94). However, 
after GSNO perfusion, ISO significantly increased heart rate (p = 0.002) and this was also 
significant compared to baseline (p = 0.002). 
Figure 5.13A reports the rate of contraction, max dP/dt, for the different groups. Perfusion 
of the heart with ISO before GSNO (ISO-GSNO group), significantly increased max 
dP/dt compared to baseline (p = 0.02). There was no significant change in the max dP/dt 
with GSNO infusion proceeded by ISO, compared to ISO perfusion (p = 0.71) or baseline 
(p = 0.09). In the GSNO-ISO group, GSNO did not alter max dP/dt compared to baseline 
(p = 0.94). However, ISO perfusion after GSNO treatment, significantly elevated max 
dP/dt compared to GSNO (p = 0.001) and baseline (p = 0.001). 
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As seen in Figure 5.13B, when ISO was perfused in the hearts before GSNO (ISO-GSNO 
group), min dP/dt significantly increased compared to baseline (p = 0.001). In this 
experimental group, GSNO treatment maintained high min dP/dt which was significant 
compared to baseline (p = 0.001) but not to ISO perfusion (p = 0.88). The min dP/dt 
during GSNO perfusion in the GSNO-ISO group did not significantly change when 
compared to baseline (p = 0.91); however, it significantly increased during ISO perfusion 
compared to GSNO perfusion (p = 0.0003) and baseline (p = 0.0003). 
PTI was altered following ISO and GSNO perfusion in WT hearts (Figure 5.14). ISO 
perfusion led to a decline in PTI compared to baseline in ISO-GSNO group (p = 0.03). 
This decrease was sustained after GSNO perfusion, and significantly lower compared to 
baseline (p = 0.01). In the GSNO-ISO group, GSNO pre-treatment had no effect on PTI 
compared to baseline (p = 0.75). ISO induced a significant decrease in PTI compared to 
GSNO (p = 0.02) and baseline (p = 0.01).  
 137 
          
Figure 5.12 LV Developed Pressure and Heart rate in WT mouse hearts under ISO 
(100 nM) and GSNO (150 µM) treatment conditions A, LVDP B, Heart rate. Data are 
means ± SEM. Order of treatment; left to right. ISO-GSNO, n = 5, GSNO-ISO, n = 5. 
White bar = baseline, Red bar = ISO, Blue bar = GSNO. Two-way ANOVA (uncorrected 
Fisher’s LSD test) was used to compare between groups: ** = p < 0.01, ## = p < 0.01 * 
= Drug vs baseline, # = drug 1 vs drug 2. 
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Figure 5.13 Contraction and relaxation parameters in WT mouse hearts before and 
after treatment with ISO (100 nM) and GSNO (150 µM) A, Rate of Contraction (Max 
dP/dt) B, Rate of Relaxation (Min dP/dt). Data are means ± SEM. Order of treatment; left 
to right. ISO-GSNO, n = 5, GSNO-ISO, n = 5. Two-way ANOVA (uncorrected Fisher’s 
LSD test) was used to compare between groups: * = p < 0.05, ** = p < 0.01, *** = p < 




Figure 5.14 Pressure-Time Integral in WT mouse hearts before and after treatment 
with ISO (100 nM) and GSNO (150 µM). Data are means ± SEM. Order of treatment; 
left to right. ISO-GSNO, n = 5, GSNO-ISO, n = 5. White bar = baseline, Red bar = ISO, 
Blue bar = GSNO. Two-way ANOVA (uncorrected Fisher’s LSD test) was used to 










































5.3.9 Effect of GSNO treatment and ß-adrenergic stimulation on arrhythmias in 
isolated mouse hearts. 
In Chapter 3, results showed that GSNO could induce arrhythmias with increasing 
concentration. I analysed arrhythmia count and severity in WT hearts treated with ISO 
and GSNO. I hypothesised that β-AR stimulation and exogenous NO perfusion would 
increase the number of arrhythmic events in WT hearts. 
As shown in Figure 5.15, there was a clear difference in the arrhythmia patterns in the 
different groups. In the ISO-GSNO group, ISO perfusion significantly increased the 
number of arrhythmias from baseline by 8-fold (p = 0.03) (Figure 5.16A). Infusion of 
GSNO after ISO, further increased the number of arrhythmias compared to baseline (p = 
0.002) but it was not significantly different compared to ISO (p = 0.20). In contrast to this 
finding, when GSNO was perfused through the hearts before ISO in the GSNO-ISO 
group, there was no significant increase in the number of arrhythmias compared to 
baseline (p = 0.50). Infusion of ISO after GSNO, also failed to induce arrhythmias 
compared to GSNO (p = 0.88) and baseline (p = 0.40) in the same group. 
Since the number of arrhythmias varied between hearts, I also determined the severity of 
arrhythmias in each group using arrhythmia scores. There was a significant difference in 
arrhythmia scores between ISO perfusion and baseline (p = 0.03) in the ISO-GSNO group 
(Figure 5.16B). However, the arrhythmia score with GSNO perfusion after ISO 
application did not increase as seen with arrhythmia count; instead, it was similar to 
baseline (p = 0.10) and ISO (p = 0.21). In the GSNO-ISO group, there was no significant 
change in arrhythmia severity with GSNO treatment compared to baseline (p > 0.99). ISO 
infusion also did not alter arrhythmia severity compared to GSNO treatment (p = 0.39) or 
baseline (p = 0.39).  
These data suggest that β-AR stimulation before GSNO infusion induces 
arrhythmogenesis. However, if GSNO infusion precedes β-AR stimulation, the 
arrhythmogenic effect of ISO is attenuated. 
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Figure 5.15 Representative trace of LV contractions showing arrhythmic events in 
WT hearts under ISO and GSNO conditions A, ISO followed by a wash with Krebs-
Henseleit buffer; B, ISO followed by GSNO; C, GSNO followed by ISO. 
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Figure 5.16 Quantification of arrhythmias in WT hearts under ISO (100 nM) and 
GSNO (150 µM) treatment conditions A, Arrhythmic events B, Arrhythmia score. Data 
are means ± SEM. Order of treatment; left to right. ISO-GSNO, n = 5, GSNO-ISO, n = 
5. Two-way ANOVA (uncorrected Fisher’s LSD test) was used to compare between 
groups: * = p < 0.05, ** = p < 0.01, * = Drug vs baseline. 
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5.4 Discussion 
It has been reported that CaMKII can induce SR Ca2+ leak in cardiomyocytes through the 
S-nitrosylation pathway during β-adrenergic stress (Gutierrez et al., 2013; Curran et al., 
2014) which suggests a complex role of NO in the heart. This chapter investigated the 
effect of NO donor GSNO and β-AR agonist ISO in isolated WT and KO hearts to 
understand the role of CaMKII in arrhythmogenesis. I examined the cardiac function of 
WT and KO mouse hearts during ISO treatment (100 nM). I also investigated cardiac 
function of WT mouse hearts with exogenous NO donor treatment before and after β-AR 
stimulation, using 150 µM GSNO and 100 nM ISO. I hypothesised that absence of 
CaMKIIδ would prevent stress-induced arrhythmias whereas GSNO and ISO would alter 
heart rate, cardiac contraction and relaxation and induce cardiac arrhythmias in mice with 
intact CaMKIIδ. The summary of the findings in this chapter is as follows; (a) Loss of 
CaMKIIδ does not ablate cardiac response to acute β-adrenergic stimulation (b) ISO 
induces cardiac arrhythmias in WT hearts and not KO hearts (c) ISO induced cardiac 
inotropy and chronotropy in WT hearts (d) β-AR stimulation prior to GSNO treatment 
induced and prolonged arrhythmias in WT hearts (e) GSNO treatment prior to β-AR 
stimulation prevented cardiac arrhythmias in WT hearts (f) GSNO and ISO induce 
CaMKII phosphorylation and nitrosylation in cardiac tissues.  
5.4.1 Loss of CaMKII does not affect response of KO hearts to acute β-AR 
stimulation  
Data from my studies show that β-AR stimulation affected cardiac contractility and this 
effect was attenuated by the wash phase (Figure 5.8 – 5.10). This result was consistent 
with that of Grimm et al. (2015), their study showed that acute β-AR stimulation can 
increase cardiac inotropy in isolated KO mouse hearts. In terms of arrhythmias, it was not 
surprising that ISO did not affect the number of arrhythmic events in KO hearts (Figure 
5.11). Previous studies have shown that CaMKII is one of the primary candidates 
responsible for arrhythmias, and inhibition of CaMKII is cardioprotective during 
β-adrenergic stress (Wu et al., 2002; Feng et al., 2017). Surprisingly, the wash phase 
reduced arrhythmias to below the baseline. The reason for this is not clear. However, it is 
possible that recovery of the heart from ISO-induced stress and perfusion with KH buffer 
led to further reduction in arrhythmic events in the wash phase. Taken together, these data 
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suggest that loss of CaMKII does not affect cardiac response to β-AR stimulation, 
however it reduces cardiac arrhythmias in isolated mouse hearts. 
5.4.2 S-Nitrosylation levels are altered in WT mouse hearts treated with ISO and 
GSNO 
CaMKII undergoes S-nitrosylation at a pair of cysteine residues, and therefore the protein 
activity can be modified by NO (Erickson et al., 2015). Results from my study show that 
ISO and GSNO can enhance S-nitrosylation in WT hearts (Figure 5.3B). There was an 
increase in S-nitrosylation of proteins in the ISO-GSNO group but not in the GSNO-ISO 
treatment group. CaMKII expression relative to the total protein nitrosylation showed a 
trend towards increase CaMKII SNO in the ISO-GSNO group. Surprisingly, the CaMKII 
SNO in the GSNO-ISO group remained similar to control. Previous studies have linked 
pro-arrhythmic signaling associated with NO exposure to CaMKII S-nitrosylation 
(Gutierrez et al., 2013; Curran et al., 2014). My hypothesis was that a high level of 
nitrosylation would be observed in both GSNO-ISO and ISO-GSNO groups due to NO 
exposure, and this would correspond to the incidence of cardiac arrhythmias (Figure 
5.13A). Even though, CaMKII S-nitrosylation levels in the experimental groups were not 
significant, the data reflected a nearly significant NO-mediated CaMKII activity in the 
ISO-GSNO and which suggests that effects of GSNO and ISO could be partly mediated 
via CaMKII. 
5.4.3 Acute β-adrenergic stimulation and GSNO treatment alter cardiac 
contractility in WT hearts 
One of the aims of this chapter was to examine the inotropic and chronotropic response 
of WT hearts during acute β-AR stimulation. Using echocardiography, I measured 
baseline in vivo cardiac function parameters to ensure similar function in all WT mouse 
groups (Table 5.7). To measure CaMKII activity, I investigated the presence of CaMKII 
phosphorylation at Thr 287 after ISO treatment. I found that neither the presence nor 
timing of GSNO affected either CaMKII expression or phosphorylation (Figure 5.2). 
Previous literature has shown that ISO does activate CaMKII (Yoo et al., 2009; Feng et 
al., 2017; Li et al., 2020), but ours is the first study to show that ISO-induced CaMKII 
activation is not influenced by NO availability. 
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The next aim was to investigate the effect of β-adrenergic stress and NO on the 
contractility of the heart. I hypothesised that ISO would enhance cardiac contractility as 
a response to β-AR stimulation. In contrast to other studies which have shown positive 
pressure development in WT hearts with exposure to ISO, I observed that ISO did not 
increase pressure development across all experimental groups. Developed pressure is a 
measure of the contractility of the ventricles, and it is determined by the difference 
between maximum and minimum pressure. A study by Grimm et al. (2015) using isolated 
hearts from WT and CaMKIIδ-KO mice, confirmed that 1 µM ISO increased LV 
developed pressure in the presence and absence of CaMKIIδ. In my study, the perfusion 
of ISO through the heart was done for 10 minutes, which is identical to that of Grimm et 
al. (2015). It is possible that the reason for the contrast in findings could be the difference 
in the dose, as my study used 100 nM ISO. However, this dose has been shown to be 
sufficient to increase SR Ca2+  in WT cardiomyocytes (Curran et al., 2007; Grimm et al., 
2015).  
In the ISO-GSNO and GSNO-ISO groups, GSNO also did not alter LV pressure 
development (Figure 5.12A). This was similar to the observation in Chapter 3 that there 
was no significant change in LVDP regardless of GSNO concentration. There is no study 
that has used 150 µM GSNO to measure LV developed pressure in isolated hearts. 
However, there are studies that have investigated the effect of other NO donors (Kojda et 
al., 1996; Mohan et al., 1996; Vila-Petroff et al., 1999; González et al., 2008). A common 
finding is that low concentrations of NO (< 10 µM) increase inotropy and high 
concentrations (> 10 µM) lead to negative inotropy, and the mechanisms for this effect 
could be cGMP-dependent or independent. A previous study exploring different NO 
donors on contractility has shown evidence in frog heart ventricular fibres that active 
tension, which is a measure of contractility, reduced with increased concentrations of SNP 
and SNAP (Chesnais et al., 1999).  
Despite no change in pressure development with β-AR stimulation, ISO induced a faster 
rate of contraction and relaxation in all experimental groups compared to baseline. A 
similar finding has been observed in WT cardiomyocytes treated with 4 nM ISO (Neef et 
al., 2013). The data in this study showed that positive inotropic effects were associated 
with ISO and only sustained with GSNO infusion, while GSNO prior to ISO did not 
induce any increase in rates of contraction (max dP/dt) and relaxation (min dP/dt) (Figure 
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5.13). Petroff et al. (1994) suggested that the mechanism for the positive lusitropic effect 
of ISO is via an increase in intracellular cAMP as seen in amphibian hearts. The effect of 
ISO on rates of contraction and relaxation is consistent with previous studies that have 
shown that β-AR stimulation increases inotropy and lusitropy in the heart (Kaumann et 
al., 1999; Freestone et al., 2000). Studies have shown that NOS plays a role in SR Ca2+ 
cycling which determines force frequency response in the heart (Cotton et al., 2001; Khan 
et al., 2003). The variability between results on the effect of NO donors is quite wide and 
requires a form of standardization, which is difficult due to the complex role of NO and 
the dependence of its resultant effects on many factors. In HF patients with normal LV 
function, it was found that NOS inhibition using L-NMMA, reduced baseline LV max 
dP/dt but had no effect on basal HR and basal min dP/dt, suggesting that endogenous NO 
may have little or no inotropic effect in normal human hearts (Cotton et al., 2001). With 
exogenous NO, there is evidence of augmented or depressed contractility with low or 
high levels of NO (González et al., 2008). In adult rat cardiomyocytes, 100 µM SNAP 
reduced contraction amplitude while 1 µM SNAP enhanced contraction amplitude (Vila-
Petroff et al., 1999).  
Despite perfusing the WT hearts in this study with 150 µM GSNO, it was unclear why 
there was no change in max dP/dt and min dP/dt from baseline, except when pre-treated 
with ISO in the ISO-WASH and ISO-GSNO groups. After treatment with ISO, GSNO 
seemed to sustain the increase in max dP/dt and min dP/dt, but not increase it further, as 
observed in Figure 5.13. This observation suggests that the effect of exogenous NO could 
be dependent on β-AR stimulation. It is known that β-AR stimulation activates adenylyl 
cyclase and induces large increase in cGMP, which activates PKA to increase cardiac 
contractility (Grimm & Brown, 2010), also high levels of NO stimulates the same 
pathway, but independent of PKA, and leads to a decrease in cardiac contraction (Vila-
Petroff et al., 1999). It is unclear how this sustained inotropic response after ISO 
application is mediated, as levels of intracellular cGMP before and after ISO were not 
measured. Taken together, it appears that the inotropic and lusitropic effect of NO is 
dependent on β-AR stimulation as observed in the ISO-GSNO and GSNO-ISO groups. 
ISO application induced faster heart rate in the ISO-GSNO and GSNO-ISO groups 
(Figure 5.10B), but not in the ISO-WASH group (Figure 5.4B). In the ISO-WASH group, 
the heart rate only increased during the wash phase which was after ISO infusion was 
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terminated. Even though the reason for this is unclear, the mechanism of β-AR stimulation 
and chronotropy involves cGMP production and PKA activation; therefore, one of the 
possible reasons could be sustained PKA activity during the ISO treatment or an 
incomplete washout of ISO from the isolated hearts. The duration of ISO application was 
the same in all groups. In the ISO-GSNO group, it was observed that subsequent infusion 
of GSNO after ISO did not further enhance chronotropy but maintained it within the 10 
minutes of perfusion. In the GSNO-ISO group, HR during GSNO perfusion was 
equivalent to baseline but increased with ISO perfusion. CaMKII has previously been 
shown to mediate increased HR associated with β-AR stimulation with ISO infusion in 
isolated WT hearts (Grimm et al., 2015). Since CaMKII is downstream of β-adrenergic 
signaling, there is the possibility that this protein mediated the chronotropic effect of ISO 
in this study. I earlier showed evidence of CaMKII phosphorylation in the WT hearts. 
This finding is consistent with other studies that have shown increased chronotropy and 
increased CaMKII activity are associated with β-adrenergic stress (Yoo et al., 2009; 
Grimm et al., 2015; Zhang, 2017).  
Similarly, NO did not independently induce chronotropy except after ISO infusion. This 
could either be due to the role of β-adrenergic stress or inadequate washout of ISO prior 
to NO release in the heart. Studies have shown that NO can independently induce 
increased HR through stimulation of the hyperpolarization-activated inward current If, 
preceded by cGMP activation (Musialek et al., 1997). There are contrasting findings that 
low levels of NO donor SIN 1 (< 300 µM)  induced no change in rat atrial beating rate 
(Kennedy et al., 1994) and low levels of SNP (10 µM) induced faster heart rate in isolated 
rat hearts after ischemia and reperfusion (Pabla & Curtis, 1995). Since there is a link 
between the NO-cGMP pathway, PKA and β-AR stimulation (Pereira et al., 2017), it is 
possible that this is the mechanism responsible for the chronotropic effect of GSNO seen 
in the ISO-GSNO group. Currently, there is no data to show if GSNO does increase HR 
in isolated hearts, but according to data from this study, GSNO had no direct effect on 
HR, which refutes my hypothesis that GSNO can independently induce cardiac 
chronotropy. Moreover, it appears that the decrease in PTI during ISO perfusion was due 
to the increase in heart rate (Figure 5.14). 
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5.4.4 NO can promote or prevent arrhythmogenic response to β-adrenergic 
receptor stimulation in WT hearts 
Another aim was to investigate the effect of NO on arrhythmias in isolated WT hearts. 
Previous studies show that excessive β-adrenergic stress can trigger arrhythmias in the 
heart by spontaneous Ca2+ release in cardiomyocytes through a CaMKII-mediated 
signaling pathway (Wu et al., 2002; Curran et al., 2014; Grimm et al., 2015). Data from 
this study showed that ISO infusion in WT hearts led to an increased number and severity 
of triggered arrhythmias (Figure 5.7). This effect was ablated when the hearts were in the 
wash phase, confirming the arrhythmogenic effect of β-AR stimulation. Sag et al. (2009) 
showed that CaMKII inhibition abolished ISO-induced arrhythmic events in mouse hearts 
overexpressing CaMKIIδC. They also observed that ISO treatment induced delayed 
afterdepolarization and spontaneous action potentials in cardiomyocytes from WT mice 
and in mice that overexpressed CaMKIIδC, with the latter having higher incidence of 
DADs. These data suggest that CaMKII plays a key role in determining the frequency 
and severity of cardiac arrhythmogenesis during β-AR stimulation.  
Recent studies show that NO does activate CaMKII through β-AR signaling and also 
induces SR Ca2+ leak measured as an increase in Ca2+ spark frequency (Gutierrez et al., 
2013; Curran et al., 2014). I found differences in the response of the heart to ISO and 
GSNO depending on the order of drug treatment and arrhythmias. ISO application prior 
to GSNO increased cardiac arrhythmias, and subsequent treatment with GSNO prolonged 
the arrhythmias (Figure 5.13A). Strikingly, the opposite was observed when the hearts 
were treated with GSNO before ISO. GSNO treatment did not induce cardiac arrhythmias 
and, when followed by ISO, there was no further increase in the number of arrhythmia 
events. ISO increased arrhythmia score in ISO-GSNO, whereas in the GSNO-ISO groups, 
arrhythmia score was similar across treatments (Figure 5.13B), suggesting that the 
severity of arrhythmias is also influenced by β-adrenergic stimulation. Thus, for the first 
time, I have demonstrated a dual role for NO in the whole heart, where NO prolongs 
cardiac arrhythmias after β-AR stimulation and prevent arrhythmias prior to β-AR 
stimulation.  
The findings from this study suggest that arrhythmogenesis induced by NO is dependent 
on β-AR stimulation. This is in contrast to the finding by Gutierrez et al. (2013), that NO 
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treatment in guinea pig cardiomyocytes can increase Ca2+ spark frequency directly by 
CaMKII activation, even in the absence of β-adrenergic signaling. Nevertheless, the role 
of other Ca2+ handling proteins in terms of β-AR and NO signaling have been 
investigated. In the heart, it has been found that ISO did not significantly modify SERCA2 
or LTCC but significantly enhanced RyR2 nitrosylation (Vielma et al., 2016). Studies 
have suggested that SR Ca2+ leak in cardiomyocytes caused by exogenous NO could be 
due to CaMKII nitrosylation and consequent phosphorylation of RyR2 to increase the 
opening probability of the channel (Curran et al., 2014), rather than direct RyR2 
nitrosylation. 
5.4.5 Possible dual role of NO in the heart 
It has been previously shown that CaMKIIδ nitrosylation induced by GSNO treatment in 
cardiomyocytes led to Ca2+ mishandling and triggered calcium sparks (Gutierrez et al., 
2013; Erickson et al., 2015). Thus, active CaMKII and NO can trigger arrhythmias. Even 
though the CaMKII-SNO levels observed in my study does not correlate with the 
incidence of arrhythmic events, Erickson et al. (2015) have shown that NO can modify 
CaMKIIδ by inhibiting or enhancing its activity. Their study led to the discovery that 
CaMKIIδ has two nitrosylation sites. During NO signaling, the C273 site which is 
inhibitory and prevents the deleterious effect of CaMKII while the C290 site is known to 
be the accelerator of arrhythmias. When CaMKII is in its inactive state, the C273 site is 
readily available for nitrosylation in the presence of a NO donor and this prevents 
CaMKII activation. However, upon activation of CaMKII, the C290 site becomes 
available for nitrosylation, this leads to autonomous activation of CaMKII. This relates 
to my finding in isolated WT hearts that NO release followed by β-AR stimulation 
prevents arrhythmias while β-AR stimulation which activates CaMKIIδ, followed by NO 
release, triggers arrhythmias. It is possible that prior to β-AR stimulation, nitrosylation of 
C273 acts a brake on CaMKII activity, hence the reduced number of arrhythmic events. 
Conversely, β-AR stimulation could enhance nitrosylation of the C290 and act as an 
accelerator of CaMKII activity, thereby increasing the number of arrhythmic events. This 
means that the activity state is important when it comes to the ability of CaMKIIδ to cause 
arrhythmias in the presence of exogenous NO donors.  
 150 
5.4.6 Limitations 
One of the technical limitations in this chapter was that NO release during the GSNO 
perfusion could not be measured in real time due to the complexity of the setup. To 
address this and to confirm NO release, NO concentration in the buffer solution was 
determined in a separate experiment by using a sensor to measure NO released from 
GSNO in KH buffer (Appendix A.2). Levels of cGMP, cAMP and expression of other 
calcium handling proteins aside from CaMKII were not measured; therefore, it cannot be 
concluded that the resultant effects were solely due to CaMKII activity. The dose of ISO 
and GSNO used in this chapter was based on previous experiments done in 
cardiomyocytes. There is a possibility that the dose was not sufficient to cause marked 
increase in LV developed pressure in the isolated hearts. One of the aims of this Chapter 
was to determine the level of arrhythmias in the presence of CaMKII and there was no 
significant elevation in arrhythmias in the KO mouse hearts during β-adrenergic stress. 
Therefore, further experiments with ISO and GSNO were not performed in KO hearts 
which lacked CaMKII.  
5.4.7 Conclusion 
In summary, the aim of this chapter was to determine the role of NO and CaMKII in 
cardiac arrhythmias during β-adrenergic stress. β-AR activation of CaMKII is known to 
contribute to arrhythmogenesis in pathological heart conditions by inducing abnormal 
calcium cycling. Although NO has many downstream targets which include other calcium 
handling proteins, CaMKII has been implicated as the key protein responsible for SR Ca2+ 
leak (Gutierrez et al., 2013; Curran et al., 2014). The effect of CaMKII nitrosylation has 
been established in cardiac cells and is only being investigated in the whole heart for the 
first time. From these series of experiments, results from this study show that CaMKII 
can be phosphorylated at Thr 287 in response to increased acute β-AR stimulation and 
NO signaling in the heart. Even though ISO does not enhance pressure development, it 
does increase rates of contraction and relaxation, as well as increase heart rate. The data 
from this study raises the question as to how NO can modulate CaMKII activity and 
induce cardiac arrhythmias. The different responses observed depending on treatment 
order might be explained by the NO-CaMKII signaling pathway. CaMKII can be 
activated by NO at two nitrosylation sites, C273 and C290. These sites have opposing 
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roles of inhibiting or accelerating CaMKII activity during nitrosylation. Further study will 
require the use of transgenic mice lacking either C290 or C273 nitrosylation sites to 
understand the role of each nitrosylation site in the heart. This could explain the dual role 
of NO in preventing or prolonging arrhythmias. This will be a promising approach 
towards preventing CaMKII-mediated arrhythmias during NO signaling in cardiac 





CHAPTER 6: GENERAL DISCUSSION 
6.1 Summary of key findings 
The main objective of this thesis was to investigate the effect of NO treatment on cardiac 
function. To determine the role of CaMKII in promoting arrhythmias during NO 
treatment, I used CaMKIIδ-KO mice and WT mice. This thesis describes, for the first 
time, that the NO donor S-nitrosoglutathione (GSNO) contributes to cardiac arrhythmias 
by mediating CaMKII activity through S-nitrosylation. S-nitrosylation is one of the 
mechanisms that mediates biological activity of NO in the cardiovascular system. In the 
heart, S-nitrosylation of Ca2+ handling proteins can be cardioprotective, promoting 
cardiac contractility and inotropy (Khan et al., 2003; Gonzalez et al., 2007; Murphy et al., 
2012). However, a complex role of NO has been discovered which shows that NO plays 
a role in cardiac arrhythmias. Recent studies have suggested that acute NO exposure 
contributes to pro-arrhythmic Ca2+ handling in cardiomyocytes, possibly through 
CaMKII S-nitrosylation (Gutierrez et al., 2013; Curran et al., 2014).  
To my knowledge, there is limited literature on the effect of CaMKII S-nitrosylation on 
cardiac function. Previous findings have shown that modification of CaMKII by NO 
contributes to an increase in Ca2+ spark frequency which is an indicator of proarrhythmic 
remodeling (Curran et al., 2014). However, the effect of CaMKII S-nitrosylation in the 
whole heart has not been studied prior to the findings in this thesis. The first aim of this 
thesis was to investigate the effect of loss of CaMKIIδ on basal cardiac function. One of 
the major findings from this thesis was that knocking out CaMKIIδ does not alter basal 
cardiac function. Acute GSNO treatment did not alter cardiac contractility in isolated WT 
and KO hearts; however, heart rate was increased with GSNO in WT hearts only. GSNO 
also induced arrhythmias with increasing GSNO concentrations in WT hearts; however, 
KO mouse hearts did not exhibit any change in number of arrhythmic events despite 
increasing GSNO concentration. With an increase in duration of GSNO treatment, there 
was evidence of trend towards altered susceptibility of KO mouse hearts to arrhythmias. 
The results also showed that chronic GSNO treatment reduced cardiac contractility in 
both WT and KO mouse hearts. In addition, GSNO elevated cardiac arrhythmias in WT 
and KO mice. KO hearts were responsive to β-adrenergic stimulation, however, they were 
not susceptible to stress-induced arrhythmias. Whereas, WT hearts with intact CaMKIIδ 
 153 
were susceptible to stress-induced arrhythmias. This thesis also determined the effect of 
GSNO and β-adrenergic stimulation on cardiac function in WT hearts. Surprisingly, pre-
treating the isolated hearts with GSNO before β-adrenergic stimulation prevented 
arrhythmias whereas β-adrenergic stimulation before GSNO promoted arrhythmias. This 
differential role of NO during stress suggested a new mechanism of NO in mediating 
activity in the whole heart. 
6.1.1 Loss of CaMKII prevents arrhythmias during acute GSNO treatment 
(Chapter 3) 
Western blot analysis revealed a reduced expression of CaMKIIδ in CaMKIIδ-KO mice 
compared to WT mice (Figure 3.2). This was not surprising because CaMKIIδ is the 
primary cardiac isoform which makes up about 80% of CaMKII expression in the heart. 
Furthermore, echocardiographic assessment showed that reduced expression of CaMKIIδ 
did not affect basal cardiac function, this finding is consistent with previous studies (Ling 
et al., 2009; Grimm et al., 2015). This was due to the fact that CaMKII is mostly inactive 
at baseline and only activated during stress. I found that isolated WT hearts treated with 
GSNO exhibited reduced cardiac contractility (Chapter 3, section 3.2.6). GSNO reduced 
LV developed pressure, increased heart rate and promoted arrhythmias with increasing 
concentrations in WT hearts. The decreased contraction in the WT hearts could be a result 
of S-nitrosylation and the activation of cGMP pathway which plays a role in mediating 
the contractility depending on NO concentration (González et al., 2008). The reason for 
increase in heart rate increase is not well understood but may be linked to CaMKII 
activation which in turn promotes Ca2+ flux in cardiomyocytes (Wu et al., 2009; Yaniv et 
al., 2013).  In addition, GSNO could be activation of hyperpolarisation-activated inward 
current via the cGMP pathway (Müller‐Strahl et al., 2000). No change in cardiac 
contractility was observed in the KO mouse hearts following acute GSNO treatment. 
Also, KO mouse hearts were less susceptible to arrhythmias during acute GSNO 
treatment compared to WT mouse hearts. There is a possibility that loss of CaMKIIδ in 
the heart prevented the arrhythmogenic effect associated with presence of CaMKII during 
NO treatment, therefore the KO hearts did not exhibit any change in arrhythmic events 
with increasing GSNO concentration. This thesis provides evidence to suggest that the 
presence of CaMKII contributes to the deleterious effect observed during increased NO 
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bioavailability. This corresponds to data from cardiomyocytes that show that GSNO 
promotes proarrhythmic signaling (Gutierrez et al., 2013). 
6.1.2  Chronic GSNO treatment does not promote cardiac arrhythmias (Chapter 
4) 
In acute condition, several effects of NO modulated by CaMKII presence were observed. 
The main aim of Chapter 4 was to determine the effect of chronic NO treatment on cardiac 
function. There was no change in in vivo cardiac function in WT and KO hearts after 5-
week GSNO treatment. I performed subsequent GSNO treatment on the isolated hearts 
after GSNO supplementation to WT and KO animals. Results showed there was reduced 
contractility in both the WT and KO hearts with increasing GSNO concentration 
compared to baseline. This finding was similar to studies that have shown the effect of 
increasing GSNO concentration in the heart (Sarkar et al., 2000; González et al., 2008). 
My hypothesis was that isolated WT hearts would exhibit increase susceptibility to 
arrhythmias after chronic administration of GSNO and KO hearts would have reduced 
number of arrhythmic events due to absence of CaMKIIδ. Surprising, there was a trend 
towards increased cardiac arrhythmias in both WT and KO hearts with increased GSNO 
concentration following chronic GSNO treatment. Since this observation did not reach a 
level of significance, a conclusion on the effect of CaMKIIδ can only be drawn by 
measuring CaMKIIδ nitrosylation levels. My findings do suggest that loss of CaMKIIδ 
does not prevent cardiac arrhythmias during chronic GSNO treatment, unlike during acute 
treatment. During acute GSNO treatment, NO-induced arrhythmias occur through a 
CaMKII-dependent pathway, but during chronic treatment there is the possibility that 
other signaling pathways influence the occurrence of arrhythmic events. Therefore, 
knocking out CaMKIIδ is no longer sufficient to protect the heart resulting in the trend of 
increased arrhythmias observed in WT and KO hearts in the chronic treatment phase 
compared to the acute treatment phase. 
6.1.3 NO promotes stress-induced cardiac arrhythmias (Chapter 5) 
β-adrenergic stimulation contributes to upregulation of NO production. Since 
upregulation of NO has been observed to contribute to arrhythmogenesis in WT hearts, it 
was necessary to determine how β-adrenergic stress and NO would modulate cardiac 
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function. To investigate the effect of loss of CaMKII on cardiac function during β-
adrenergic stress on cardiac function, KO mouse hearts were treated with the β-adrenergic 
receptor agonist isoproterenol (ISO). Results showed that KO hearts were protected from 
ISO-induced arrhythmias. The next step was to perform same investigation in WT mouse 
hearts. My results suggested that hearts from WT mice were susceptible to arrhythmias 
during β-adrenergic stress. Echocardiographic data showed similar in vivo cardiac 
function in all groups of WT hearts prior to drug treatment. β-adrenergic stimulation 
enhanced cardiac contractility in all groups regardless of treatment order. GSNO did not 
affect contractility except in the ISO-GSNO group pre-treated with ISO. The ISO-GSNO 
group developed cardiac arrhythmias during ISO treatment, which were prolonged by 
GSNO treatment. However, GSNO treatment followed by ISO prevented β-adrenergic 
stress. In terms of arrhythmias, the mechanism for this is not well understood and requires 
further studies but this defines a dual role of NO in the heart during stress. Western blot 
analysis showed CaMKII S-nitrosylation was upregulated in the ISO-GSNO group 
suggesting that CaMKII nitrosylation contributed to the effect seen in these hearts. Since 
nitrosylation of CaMKII is suggested to be responsible for arrhythmogenesis, this raises 
a question as to how NO modifies CaMKII during stress to induce the opposing effects 
of NO in the isolated hearts. It has been previously documented that CaMKII has two 
nitrosylation sites which influence its activity during NO signaling. This finding by 
Erickson et al. (2015) provided specific details for the nitrosylation sites of the cardiac 
isoform, CaMKIIδ. Their study also showed that exposure of CaMKIIδ to GSNO resulted 
in autonomous kinase activation via S-nitrosylation on Cys290 site, in contrast, the S-
nitrosylation on Cys273 site prevented activation of CaMKII. This led to the identification 
of a dual pathway of CaMKII activation by NO. This thesis proposes that the nitrosylation 
sites of CaMKII could mediate the response of the heart to increase in NO production 
during ß-adrenergic stress. 
6.2 Limitations 
One of the greatest challenges was working with small hearts and cannulation of these 
hearts required very steady hands, because the aorta would tear easily without extreme 
care. The aorta of the mouse is small, however it can be visualised with the naked eye. 
The cannulation time had to be kept under 5 minutes. This was a difficult task because 
after excision and arresting of the heart, the vessels around the heart had to be trimmed to 
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access the aortic root, and this had to be done quickly to avoid ischaemia in the arrested 
heart. Cutting the aorta too short or cannulating too deep would affect perfusion rate and 
thereby affect heart function. Hearts with ripped aorta were excluded from final analysis. 
The LV balloon for the heart had to be handmade and with this came the challenge of 
making balloon the right size for a mouse ventricle. This balloon had to be free of leaks, 
air bubbles which could in turn alter the LV pressure slightly. The LV balloons were made 
out of saran wrap, as they had to be thin enough to allow compliance and for pressure to 
be transmitted to the transducer, making them really susceptible to leakage. These 
balloons had to be made often, so the balloons used in the different sets of the experiments 
varied. The minimum pressure for every heart had to be > 20 mmHg to be included in 
analysis. Another reason for low pressure was due to the fact that the hearts were unpaced, 
because pacing would mask the effect of the drug treatment and the ability to detect 
arrhythmias. Despite the low baseline pressure (< 100 mmHg), the fluid volume in the 
balloon was kept constant, 10 µl to yield 5 – 10 mmHg end diastolic pressure. The final 
data was presented as fold change to present a clearer picture of the pressure change 
across each protocol. I also had time-matched controls to account for any changes in 
pressure unrelated to drug treatment. 
During my experiment, the flow probe malfunctioned therefore I could not obtain 
coronary flow for some of my Langendorff experiments. The other option was to measure 
the volume of perfusate effluent over a given time. However, the mouse heart is very tiny 
and has to remain in temperature-controlled buffer to protect the integrity of the heart 
throughout the protocol, so coronary effluent could not be obtained during that period. 
Due to the limitations mentioned, and exclusion of hearts that did not meet the criteria of 
hearts required for my data analysis, my sample size was smaller than anticipated. Some 
of my data showed trends which could have been as a result of the small sample size. For 
future studies, an increment in sample size would definitely be necessary. 
Using the biotin switch assay to measure S-nitrosylation required a lot of optimisation. 
While I was able to measure global nitrosylation, I was unable to detect nitrosylated 
CaMKII levels. It is unclear if this is due to low expression of nitrosylated CaMKII or a 
technical problem. As an alternative, the samples had to shipped for the experiment had 
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to be done by our collaborators which finally produced results. Mass spectrometry should 
have been done to measure nitrosylation at the different sites of CaMKII, however, the 
lock down due to the pandemic affected the services of the facility and that part of the 
investigation had to be suspended. Recently, I was able to probe for global protein 
nitrosylation in the heart tissues, but I am yet to obtain results from nitrosylated CaMKII. 
6.3 The role of gamma isoform of CaMKII 
As mentioned earlier in the introduction, CaMKIIγ is also expressed in the heart as a 
secondary isoform. The unique role of CaMKIIγ in cardiac dysfunction has not been fully 
explored. It is known to contributes to apoptosis of macrophages and plays a role in 
upregulation of atherosclerotic plaque which could potentially contribute to myocardial 
infarction (Timmins et al., 2009; Kreusser & Backs, 2014; Doran et al., 2017). Some 
studies have shown evidence that there is no upregulation of CaMKIIγ to compensate for 
loss of CaMKIIδ in unstressed KO mice (Backs et al., 2009) and KO mice after aorto-
caval shunt (Mohamed et al., 2019). However, a study by Kreusser et al. (2014) showed 
that CaMKIIγ and CaMKIIγ can compensate for each other in KO mice without cardiac 
dysfunction. Ling et al. (2009) showed that CaMKIIγ increased in WT and KO mice only 
after 2-week transverse aortic constriction (TAC)-induced pressure overload of the LV, 
suggesting that CaMKIIγ can be upregulated in stress conditions to compensate for loss 
of CaMKIIδ. In Chapter 3, Western blot results obtained in LV tissues of isolated heart 
after acute GSNO treatment showed that there was reduction in CaMKII expression due 
to deletion of CaMKIIδ compared to WT heart tissues. There was no evidence of 
upregulation of CaMKIIγ in the LV tissues. In the chronic study (Chapter 4), deletion of 
CaMKIIδ had no effect on cardiac arrhythmias, suggesting a possibility that some of the 
effects in the chronic experiments could be due to the compensatory role of CaMKIIγ. 
Further studies can be performed to determine the specific role of CaMKIIγ activation 
during NO exposure. 
6.4 S-Nitrosylation of Ca2+ handling proteins and cardioprotection 
An increase in S-nitrosylation of cardiac proteins is known to be cardioprotective 
(Murphy et al., 2012). Interestingly, S-nitrosylation also regulates redox signaling during 
oxidative stress where thiol groups of cysteine residues are shielded by S-nitrosylation 
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and this prevents irreversible oxidation (Sun et al., 2006b; Kohr et al., 2011). S-
nitrosylation of Ca2+ handling proteins has also been found to be beneficial. Reduced 
RyR2 nitrosylation promoted SR Ca2+ leak in cardiomyocytes (Gonzalez et al., 2007). S-
nitrosylation of L-type Ca2+ channel reduced Ca2+ entry by reducing channel activity after 
β-adrenergic stimulation (Sun et al., 2006a). S-nitrosylation of SERCA2a after GSNO 
treatment in cardiomyocytes enhances SR Ca2+ uptake (Sun et al., 2007). The evidence 
surrounding S-nitrosylation of CaMKII is still developing and the current observation is 
that CaMKII contributes to pro-arrhythmic signaling in cardiomyocytes (Gutierrez et al., 
2013; Curran et al., 2014; Erickson et al., 2015). CaMKII S-nitrosylation has been found 
to promote arrhythmias during NO treatment, which was one of the findings in this thesis. 
Another finding was that CaMKII S-nitrosylation could also be cardioprotective if S-
nitrosylation precedes β-adrenergic receptor stimulation. The mechanism for this may be 
explained by the role of the nitrosylation sites. 
6.5 Clinical relevance of CaMKII S-nitrosylation 
Consistent with previous studies, this thesis contributes to the growing body of 
knowledge that NO can modulate CaMKII activity (Gutierrez et al., 2013; Curran et al., 
2014). Studies have shown that NO is cardioprotective and decreased NO production is 
associated with cardiac decompensation in heart failure (Recchia et al., 1998; Katz et al., 
1999). Data from this thesis has shown that increase NO production can modulate cardiac 
arrhythmias through a CaMKII-dependent pathway and β-adrenergic stimulation. On the 
other hand, excessive β-adrenergic stimulation and increased CaMKII activity is 
associated with heart failure (Hoch et al., 1999; Zhang et al., 2003). In clinical settings, 
β-adrenergic receptor blockers and NO donors are administered to heart failure patients 
to suppress sympathetic activity and improve vascular flow. Since my study shows that 
NO production can contribute to pro-arrhythmic signaling independent of β-adrenergic 
stimulation, it will be necessary to investigate whether administration of NO donors will 
promote arrhythmias in heart failure patients. With evidence showing that NO promotes 
arrhythmogenesis through CaMKII in cardiomyocytes and in the whole heart, CaMKII 
S-nitrosylation may contribute to the enhancement of SR Ca2+ leak and cardiac 
arrhythmias in heart failure patients. To prevent NO-induced arrhythmias, CaMKII 
inhibitors could be a potential therapeutic target for clinical use. The findings in this thesis 
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provide initial evidence of the impact of S-nitrosylation of CaMKII on heart function 
which can serve as a foundation for further studies using human tissues. 
6.6 Future directions 
This study has provided insight on the role of NO in modifying CaMKII activity in the 
heart. Even though there were certain limitations with measurement of NO levels and 
CaMKII nitrosylation, the use of CaMKIIδ-KO mice helped to ascertain the impact of S-
nitrosylation on cardiac arrhythmias.  
One of the indicators of cardiac dysfunction is excessive sympathetic activity and in 
conditions such as diabetic heart disease or heart failure, upregulation of CaMKII 
expression has also been implicated  (Zhang et al., 2005; Erickson et al., 2013). Data from 
this thesis showed that CaMKIIδ-KO mice become susceptible to arrhythmias after 
prolonged GSNO treatment but are protected from arrhythmias in the acute phase. In 
order to understand how this evidence is relevant to the role of CaMKII and NO in heart, 
it will be necessary to investigate the long-term effect of NO treatment combined with 
adrenergic stress on cardiac function using WT and KO mice. 
According to (Erickson et al., 2015), the order of binding of NO-related species at the 
Cys273 and Cys290 sites determines the function of CaMKII during NO exposure. Pre-
treatment with NO prior to Ca2+/CaM binding caused Cys273 modification while 
treatment with NO after Ca2+/CaM activation of CaMKII modified the Cys290 site. 
Nitrosylation of Cys273 reduced Ca2+/CaM binding while nitrosylation of Cys290 
fostered Ca2+/CaM binding. This study also showed that there was persistent and 
significant increase in Ca2+ spark frequency when myocytes were treated in an order, with 
Ca2+/CaM, GSNO and egtazic acid (EGTA) (Erickson et al., 2015). These results were 
consistent with other studies in showing that autonomous activation of CaMKII by NO 
induced more frequent and spontaneous SR Ca2+ release (Ca2+ sparks) which is a predictor 
of arrhythmias. Furthermore, my study has shown that possible activation of CaMKII 
during β-adrenergic stimulation prior to GSNO treatment promoted arrhythmias while the 
reverse of treatment order prevented arrhythmias. This finding in the whole heart can 
provide a proposed mechanism for mediation of CaMKII activity by NO (Figure 6.1). It 
would be interesting to determine if there is difference in the level of nitrosylation at these 
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two sites in mice treated with GSNO. Furthermore, development of mice which lack 
either nitrosylation sites of CaMKII could provide an understanding of how NO regulates 
CaMKII activity in the whole heart. 
     
 
 
Figure 6.1 CaMKII nitrosylation enhances arrhythmia depending on the 
nitrosylation site. β-adrenergic receptor (β-AR) stimulation (which promotes Ca2+/CaM 
binding and activation), followed by NO treatment, promotes S-nitrosylation of Cys290 
site and accelerates arrhythmias. NO treatment promotes S-nitrosylation of Cys273 site 




6.7 Concluding Remarks 
This thesis provides first evidence to show that S-nitrosylation of CaMKII contributes to 
arrhythmias in isolated hearts while knocking out CaMKIIδ protected against acute 
GSNO-induced arrhythmias. Duration of GSNO exposure also determined the effect of 
CaMKII on arrhythmias. Since this concept is new, the findings from this thesis can serve 
as a foundation for further studies to investigate the mechanisms of CaMKII S-
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Curran J, Hinton MJ, Ríos E, Bers DM & Shannon TR. (2007). β-Adrenergic 
enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is 
mediated by calcium/calmodulin-dependent protein kinase. Circulation Research 
100, 391-398. 
 
Curran J, Tang L, Roof SR, Velmurugan S, Millard A, Shonts S, Wang H, Santiago D, 
Ahmad U, Perryman M, Bers DM, Mohler PJ, Ziolo MT & Shannon TR. (2014). 
Nitric Oxide-Dependent Activation of CaMKII Increases Diastolic Sarcoplasmic 
Reticulum Calcium Release in Cardiac Myocytes in Response to Adrenergic 
Stimulation. PLoS ONE 9. 
 
Currie S, Loughrey CM, Craig M-A & Smith GL. (2004). Calcium/calmodulin-dependent 
protein kinase IIdelta associates with the ryanodine receptor complex and 
regulates channel function in rabbit heart. Biochemical Journal 377, 357-366. 
 
Curtis MJ & Walker MJ. (1988). Quantification of arrhythmias using scoring systems: an 
examination of seven scores in an in vivo model of regional myocardial ischaemia. 
Cardiovascular research 22, 656-665. 
 
Cutler MJ, Plummer BN, Wan X, Sun Q-A, Hess D, Liu H, Deschenes I, Rosenbaum DS, 
Stamler JS & Laurita KR. (2012). Aberrant S-nitrosylation mediates calcium-
triggered ventricular arrhythmia in the intact heart. Proceedings of the National 
Academy of Sciences 109, 18186-18191. 
 
D’Andrea E, Nagyova I & Villari P. (2015). Cardiovascular Disease (CVD). In A 
Systematic Review of Key Issues in Public Health, ed. Boccia S, Villari P & 
Ricciardi W, pp. 33-64. Springer International Publishing, Cham. 
 
Daniels L, Bell JR, Delbridge LMD, McDonald FJ, Lamberts RR & Erickson JR. (2015). 
The role of CaMKII in diabetic heart dysfunction. Heart Failure Reviews 20, 589-
600. 
 
Daniels LJ. (2017). The role of calcium calmodulin dependent protein kinase II in type 2 
diabetic heart dysfunction (Thesis, Doctor of Philosophy). University of Otago. 
Retrieved from http://hdl.handle.net/10523/7492 
 166 
 
Daniels LJ, Wallace RS, Nicholson OM, Wilson GA, McDonald FJ, Jones PP, Baldi JC, 
Lamberts RR & Erickson JR. (2018). Inhibition of calcium/calmodulin-dependent 
kinase II restores contraction and relaxation in isolated cardiac muscle from type 
2 diabetic rats. Cardiovascular Diabetology 17, 1-15. 
 
Dewenter M, Neef S, Vettel C, Lämmle S, Beushausen C, Zelarayan LC, Katz S, von der 
Lieth A, Meyer-Roxlau S & Weber S. (2017). Calcium/calmodulin-dependent 
protein kinase II activity persists during chronic β-adrenoceptor blockade in 
experimental and human heart failure. Circulation: Heart Failure 10, e003840. 
 
Dibb K, Graham H, Venetucci L, Eisner D & Trafford A. (2007). Analysis of cellular 
calcium fluxes in cardiac muscle to understand calcium homeostasis in the heart. 
Cell Calcium 42, 503-512. 
 
Dietz NM, Rivera JM, Eggener SE, Fix RT, Warner DO & Joyner MJ. (1994). Nitric 
oxide contributes to the rise in forearm blood flow during mental stress in humans. 
The Journal of Physiology 480, 361-368. 
 
Dobrev D & Wehrens XHT. (2014). Role of RyR2 Phosphorylation in Heart Failure and 
Arrhythmias. Controversies Around Ryanodine Receptor Phosphorylation in 
Cardiac Disease 114, 1311-1319. 
 
Doran AC, Ozcan L, Cai B, Zheng Z, Fredman G, Rymond CC, Dorweiler B, Sluimer 
JC, Hsieh J & Kuriakose G. (2017). CAMKIIγ suppresses an efferocytosis 
pathway in macrophages and promotes atherosclerotic plaque necrosis. The 
Journal of Clinical Investigation 127, 4075-4089. 
 
Đorđević VB, Stojanović I, Kundalić S, Ristić T, Pavlović R, Ćosić V & Cvetković T. 
(2012). Pathophysiological importance of nitric oxide in coronary heart 
disease/Patofiziološki značaj azot-monoksida u koronarnoj bolesti srca. Journal 
of Medical Biochemistry 31, 287-294. 
 
Edman CF & Schulman H. (1994). Identification and characterization of δB-CaM kinase 
and δC-CaM kinase from rat heart, two new multifunctional Ca2+/calmodulin-
dependent protein kinase isoforms. Biochimica et Biophysica Acta (BBA)-
Molecular Cell Research 1221, 89-101. 
 
Edwards AG, Grandi E, Hake JE, Patel S, Li P, Miyamoto S, Omens JH, Brown JH, Bers 
DM & McCulloch AD. (2014). Nonequilibrium Reactivation of Na<sup>+</sup> 
Current Drives Early Afterdepolarizations in Mouse Ventricle. Circulation: 
Arrhythmia and Electrophysiology 7, 1205-1213. 
 




Erickson JR, Joiner MA, Guan X, Kutschke W, Yang J, Oddis CV, Bartlett RK, Lowe 
JS, O’Donnell S, Aykin-Burns N, Zimmerman MC, Zimmerman K, Ham AJL, 
Weiss RM, Spitz DR, Shea MA, Colbran RJ, Mohler PJ & Anderson ME. (2008). 
A dynamic pathway for calcium-independent activation of CaMKII by 
methionine oxidation. Cell 133, 462-474. 
 
Erickson JR, Nichols CB, Uchinoumi H, Stein ML, Bossuyt J & Bers DM. (2015). S-
Nitrosylation induces both autonomous activation and inhibition of 
calcium/calmodulin-dependent protein kinase II δ. Journal of Biological 
Chemistry 290, 25646-25656. 
 
Erickson JR, Patel R, Ferguson A, Bossuyt J & Bers DM. (2011). FRET-based sensor 
Camui provides new insight into mechanisms of CaMKII activation in intact 
cardiomyocytes. Circulation Research 109, 729. 
 
Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K, Copeland RJ, Despa F, Hart 
GW, Ripplinger CM & Bers DM. (2013). Diabetic Hyperglycemia activates 
CaMKII and Arrhythmias by O linked Glycosylation. Nature 502, 372-376. 
 
Fabiato A & Fabiato F. (1978). Calcium‐induced release of calcium from the 
sarcoplasmic reticulum of skinned cells from adult human, dog, cat, rabbit, rat, 
and frog hearts and from fetal and new‐born rat ventricles. Annals of the New York 
Academy of Sciences 307, 491-522. 
 
Federico M, Portiansky EL, Sommese L, Alvarado FJ, Blanco PG, Zanuzzi CN, Dedman 
J, Kaetzel M, Wehrens XH & Mattiazzi A. (2017). Calcium‐calmodulin‐
dependent protein kinase mediates the intracellular signalling pathways of cardiac 
apoptosis in mice with impaired glucose tolerance. The Journal of Physiology 
595, 4089-4108. 
 
Fei L, Baron AD, Henry DP & Zipes DP. (1997). Intrapericardial delivery of L-arginine 
reduces the increased severity of ventricular arrhythmias during sympathetic 
stimulation in dogs with acute coronary occlusion: nitric oxide modulates 
sympathetic effects on ventricular electrophysiological properties. Circulation 96, 
4044-4049. 
 
Feng Y, Cheng J, Wei B & Wang Y. (2017). CaMKII inhibition reduces isoproterenol-
induced ischemia and arrhythmias in hypertrophic mice. Oncotarget 8, 17504. 
 
Ferrero P, Said M, Sánchez G, Vittone L, Valverde C, Donoso P, Mattiazzi A & Mundiña-
Weilenmann C. (2007). Ca2+/calmodulin kinase II increases ryanodine binding 
and Ca2+-induced sarcoplasmic reticulum Ca2+ release kinetics during β-




Floras JS. (2009). Sympathetic nervous system activation in human heart failure: clinical 
implications of an updated model. Journal of the American College of Cardiology 
54, 375-385. 
 
Freestone N, Ribaric S, Scheuermann M, Mauser U, Paul M & Vetter R. (2000). 
Differential lusitropic responsiveness to β-adrenergic stimulation in rat atrial and 
ventricular cardiac myocytes. Pflügers Archiv 441, 78-87. 
 
Gao S, Ho D, Vatner DE & Vatner SF. (2011). Echocardiography in mice. Current 
Protocols in Mouse Biology 1, 71-83. 
 
Gao XM, Dart AM, Dewar E, Jennings G & Du XJ. (2000). Serial echocardiographic 
assessment of left ventricular dimensions and function after myocardial infarction 
in mice. Cardiovasc Res 45. 
 
Garreffa AM, Woodman OL, Cao AH & Ritchie RH. (2006). Sodium nitroprusside 
protects adult rat cardiac myocytes from cellular injury induced by simulated 
ischemia: role for a non-cGMP-dependent mechanism of nitric oxide protection. 
Journal of Cardiovascular Pharmacology 47, 1-8. 
 
Gaztañaga L, Marchlinski FE & Betensky BP. (2012). Mechanisms of cardiac 
arrhythmias. Revista Española de Cardiología (English Edition) 65, 174-185. 
 
Giri S, Rattan R, Deshpande M, Maguire JL, Johnson Z, Graham RP & Shridhar V. 
(2014). Preclinical therapeutic potential of a nitrosylating agent in the treatment 
of ovarian cancer. PLoS ONE 9, e97897. 
 
Gonano LA, Sepúlveda M, Rico Y, Kaetzel M, Valverde CA, Dedman J, Mattiazzi A & 
Petroff MV. (2011). Calcium-Calmodulin Kinase II Mediates Digitalis-Induced 
Arrhythmias. Circulation: Arrhythmia and Electrophysiology 4, 947-957. 
 
Gonzalez DR, Beigi F, Treuer AV & Hare JM. (2007). Deficient ryanodine receptor S-
nitrosylation increases sarcoplasmic reticulum calcium leak and 
arrhythmogenesis in cardiomyocytes. Proceedings of the National Academy of 
Sciences 104, 20612-20617. 
 
González DR, Fernández IC, Ordenes PP, Treuer AV, Eller G & Boric MP. (2008). 
Differential role of S-nitrosylation and the NO–cGMP–PKG pathway in cardiac 
contractility. Nitric Oxide 18, 157-167. 
 
Gonzalez DR, Treuer A, Sun Q-A, Stamler JS & Hare JM. (2009). S-Nitrosylation of 
cardiac ion channels. Journal of Cardiovascular Pharmacology 54, 188. 
 
Gordan R, Gwathmey JK & Xie L-H. (2015). Autonomic and endocrine control of 
cardiovascular function. World Journal of Cardiology 7, 204. 
 169 
 
Grandi E & Herren A. (2014). CaMKII-dependent regulation of cardiac Na+ homeostasis. 
Frontiers in Pharmacology 5. 
 
Gray CB & Brown JH. (2014). CaMKIIdelta subtypes: localization and function. 
Frontiers in Pharmacology 5. 
 
Grievink H, Zeltcer G, Drenger B, Berenshtein E & Chevion M. (2016). Protection by 
nitric oxide donors of isolated rat hearts is associated with activation of redox 
metabolism and ferritin accumulation. PLoS ONE 11, e0159951. 
 
Grimm M & Brown JH. (2010). β-Adrenergic receptor signaling in the heart: role of 
CaMKII. Journal of Molecular and Cellular Cardiology 48, 322-330. 
 
Grimm M, Ling H, Pereira L, Willeford A, Gray CBB, Erickson JR, Sarma S, Respress 
JL, Wehrens XHT, Bers DM & Brown JH. (2015). CaMKIIδ mediates β-
adrenergic effects on RyR2 phosphorylation and SR Ca(2+) leak and the 
pathophysiological response to chronic β-adrenergic stimulation. Journal of 
Molecular and Cellular Cardiology 85, 282-291. 
 
Grueter CE, Abiria SA, Wu Y, Anderson ME & Colbran RJ. (2008). Differential 
regulated interactions of calcium/calmodulin-dependent protein kinase II with 
isoforms of voltage-gated calcium channel β subunits. Biochemistry 47, 1760-
1767. 
 
Gutierrez DA, Fernandez-Tenorio M, Ogrodnik J & Niggli E. (2013). NO-dependent 
CaMKII activation during β-adrenergic stimulation of cardiac muscle. 
Cardiovascular Research 100, 392-401. 
 
Hancock DB, Martin ER, Vance JM & Scott WK. (2008). Nitric oxide synthase genes 
and their interactions with environmental factors in Parkinson’s disease. 
Neurogenetics 9, 249-262. 
 
Haynes WG, Noon JP, Walker BR & Webb DJ. (1993). Inhibition of nitric oxide 
synthesis increases blood pressure in healthy humans. Journal of Hypertension 
11, 1375-1380. 
 
He BJ, Joiner MLA, Singh MV, Luczak ED, Swaminathan PD, Koval OM, Kutschke W, 
Allamargot C, Yang J, Guan X, Zimmerman K, Grumbach IM, Weiss RM, Spitz 
DR, Sigmund CD, Blankesteijn WM, Heymans S, Mohler PJ & Anderson ME. 
(2011). Oxidation of CaMKII determines cardiotoxic effects of aldosterone. Nat 
Med 17, 1610-1618. 
 
He F. (2011). Bradford protein assay. Bio-protocol, e45-e45. 
 
 170 
Hegyi B, Chen-Izu Y, Jian Z, Shimkunas R, Izu LT & Banyasz T. (2015). KN-93 inhibits 
IKr in mammalian cardiomyocytes. Journal of Molecular and Cellular Cardiology 
89, 173-176. 
 
Herman AG & Moncada S. (2005). Therapeutic potential of nitric oxide donors in the 
prevention and treatment of atherosclerosis. European Heart Journal 26, 1945-
1955. 
 
Herren AW, Bers DM & Grandi E. (2013). Post-translational modifications of the cardiac 
Na channel: contribution of CaMKII-dependent phosphorylation to acquired 
arrhythmias. American Journal of Physiology - Heart and Circulatory Physiology 
305, H431-445. 
 
Hoch B, Meyer R, Hetzer R, Krause E-G & Karczewski P. (1999). Identification and 
Expression of δ-Isoforms of the Multifunctional Ca2+/Calmodulin-Dependent 
Protein Kinase in Failing and Nonfailing Human Myocardium. Circulation 
Research 84, 713-721. 
 
Hoelz A, Nairn AC & Kuriyan J. (2003). Crystal Structure of a Tetradecameric Assembly 
of the Association Domain of Ca2+/Calmodulin-Dependent Kinase II. Molecular 
Cell 11, 1241-1251. 
 
Hogan N, Casadei B & Paterson DJ. (1999). Nitric oxide donors can increase heart rate 
independent of autonomic activation. Journal of Applied Physiology 87, 97-103. 
 
Houston M & Hays L. (2014). Acute effects of an oral nitric oxide supplement on blood 
pressure, endothelial function, and vascular compliance in hypertensive patients. 
The Journal of Clinical Hypertension 16, 524-529. 
 
Hu H, Chiamvimonvat N, Yamagishi T & Marban E. (1997). Direct inhibition of 
expressed cardiac L-type Ca2+ channels by S-nitrosothiol nitric oxide donors. 
Circulation Research 81, 742. 
 
Huang X, Song Z & Qu Z. (2018). Determinants of early afterdepolarization properties 
in ventricular myocyte models. PLoS Computational Biology 14, e1006382. 
 
Hudmon A, Schulman H, Kim J, Maltez JM, Tsien RW & Pitt GS. (2005). CaMKII 
tethers to L-type Ca2+ channels, establishing a local and dedicated integrator of 
Ca2+ signals for facilitation. The Journal of Cell Biology 171, 537-547. 
 
Huggins CE, Bell JR, Pepe S & Delbridge LM. (2008). Benchmarking ventricular 




Hund TJ & Mohler PJ. (2015). Role of CaMKII in cardiac arrhythmias. Trends 
Cardiovasc Med 25, 392-397. 
 
Ignarro LJ, Napoli C & Loscalzo J. (2002). Nitric oxide donors and cardiovascular agents 
modulating the bioactivity of nitric oxide: an overview. Circulation Research 90, 
21-28. 
 
Irie T, Sips PY, Kai S, Kida K, Ikeda K, Hirai S, Moazzami K, Jiramongkolchai P, Bloch 
DB, Doulias PT, Armoundas AA, Kaneki M, Ischiropoulos H, Kranias E, Bloch 
KD, Stamler JS & Ichinose F. (2015). S-Nitrosylation of Calcium-Handling 
Proteins in Cardiac Adrenergic Signaling and Hypertrophy. Circ Res 117, 793-
803. 
 
Ishida A, Kameshita I, Okuno S, Kitani T & Fujisawa H. (1995). A novel highly specific 
and potent inhibitor of calmodulin-dependent protein kinase II. Biochemical and 
Biophysical Research Communications 212, 806-812. 
 
Iwai-Kanai E, Hasegawa K, Araki M, Kakita T, Morimoto T & Sasayama S. (1999). α-
and β-Adrenergic pathways differentially regulate cell type–specific apoptosis in 
rat cardiac myocytes. Circulation 100, 305-311. 
 
Jiang H, Torregrossa AC, Potts A, Pierini D, Aranke M, Garg HK & Bryan NS. (2014). 
Dietary nitrite improves insulin signaling through GLUT4 translocation. Free 
Radical Biology and Medicine 67, 51-57. 
 
Joca HC, Santos‐Miranda A, Joviano-Santos JV, Maia-Joca RP, Brum PC, Williams GS 
& Cruz JS. (2020). Chronic sympathetic hyperactivity triggers 
electrophysiological remodeling and disrupts excitation-contraction coupling in 
heart. Scientific Reports 10, 1-13. 
 
Johnson CN, Pattanayek R, Potet F, Rebbeck RT, Blackwell DJ, Nikolaienko R, Sequeira 
V, Le Meur R, Radwański PB, Davis JP, Zima AV, Cornea RL, Damo SM, 
Györke S, George AL & Knollmann BC. (2019). The CaMKII inhibitor KN93-
calmodulin interaction and implications for calmodulin tuning of NaV1.5 and 
RyR2 function. Cell Calcium 82, 102063. 
 
Jones SP, Greer JJ, van Haperen R, Duncker DJ, de Crom R & Lefer DJ. (2003). 
Endothelial nitric oxide synthase overexpression attenuates congestive heart 
failure in mice. Proceedings of the National Academy of Sciences 100, 4891-4896. 
 
Kalogeris T, Baines CP, Krenz M & Korthuis RJ. (2012). Cell biology of 
ischemia/reperfusion injury. In International Review of Cell and Molecular 
Biology, pp. 229-317. Elsevier. 
 
 172 
Katz SD, Khan T, Zeballos GA, Mathew L, Potharlanka P, Knecht M & Whelan J. (1999). 
Decreased activity of the L-arginine–nitric oxide metabolic pathway in patients 
with congestive heart failure. Circulation 99, 2113-2117. 
 
Kaumann A, Bartel S, Molenaar P, Sanders L, Burrell K, Vetter D, Hempel P, Karczewski 
P & Krause E-G. (1999). Activation of β2-adrenergic receptors hastens relaxation 
and mediates phosphorylation of phospholamban, troponin I, and C-protein in 
ventricular myocardium from patients with terminal heart failure. Circulation 99, 
65-72. 
 
Kennedy RH, Hicks KK, Brian Jr JE & Seifen E. (1994). Nitric oxide has no chronotropic 
effect in right atria isolated from rat heart. European Journal of Pharmacology 
255, 149-156. 
 
Khalifi S, Rahimipour A, Jeddi S, Ghanbari M, Kazerouni F & Ghasemi A. (2015). 
Dietary nitrate improves glucose tolerance and lipid profile in an animal model of 
hyperglycemia. Nitric Oxide 44, 24-30. 
 
Khan M, Dhammu TS, Qiao F, Kumar P, Singh AK & Singh I. (2019). S-
Nitrosoglutathione Mimics the Beneficial Activity of Endothelial Nitric Oxide 
Synthase-Derived Nitric Oxide in a Mouse Model of Stroke. Journal of Stroke 
and Cerebrovascular Diseases 28, 104470. 
 
Khan M & Singh I. (2019). Therapeutic exploitation of the S-nitrosoglutathione/S-
nitrosylation mechanism for the treatment of contusion spinal cord injury. Neural 
Regeneration Research 14, 973. 
 
Khan SA, Skaf MW, Harrison RW, Lee K, Minhas KM, Kumar A, Fradley M, Shoukas 
AA, Berkowitz DE & Hare JM. (2003). Nitric Oxide Regulation of Myocardial 
Contractility and Calcium Cycling. Independent Impact of Neuronal and 
Endothelial Nitric Oxide Synthases 92, 1322-1329. 
 
Khoo MS, Li J, Singh MV, Yang Y, Kannankeril P, Wu Y, Grueter CE, Guan X, Oddis 
CV & Zhang R. (2006). CLINICAL PERSPECTIVE. Circulation 114, 1352-
1359. 
 
Kim Y-M, Bergonia H & Lancaster Jr JR. (1995). Nitrogen oxide-induced autoprotection 
in isolated rat hepatocytes. FEBS letters 374, 228-232. 
 
Kirchhefer U, Schmitz W, Scholz H & Neumann J. (1999). Activity of cAMP-dependent 
protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and 
nonfailing human hearts. Cardiovascular Research 42, 254-261. 
 
Kishi T. (2012). Heart failure as an autonomic nervous system dysfunction. Journal of 
Cardiology 59, 117-122. 
 173 
 
Kohlhaas M, Zhang T, Seidler T, Zibrova D, Dybkova N, Steen A, Wagner S, Chen L, 
Heller Brown J & Bers DM. (2006). Increased sarcoplasmic reticulum calcium 
leak but unaltered contractility by acute CaMKII overexpression in isolated rabbit 
cardiac myocytes. Circulation Research 98, 235-244. 
 
Kohr MJ, Sun J, Aponte A, Wang G, Gucek M, Murphy E & Steenbergen C. (2011). 
Simultaneous measurement of protein oxidation and S-nitrosylation during 
preconditioning and ischemia/reperfusion injury with resin-assisted capture. 
Circulation Research 108, 418-426. 
 
Kojda G & Kottenberg K. (1999). Regulation of basal myocardial function by NO. 
Cardiovascular Research 41, 514-523. 
 
Kojda G, Kottenberg K, Nix P, Schlüter KD, Piper HM & Noack E. (1996). Low increase 
in cGMP induced by organic nitrates and nitrovasodilators improves contractile 
response of rat ventricular myocytes. Circulation Research 78, 91-101. 
 
Kojda G, Kottenberg K & Noack E. (1997). Inhibition of nitric oxide synthase and soluble 
guanylate cyclase induces cardiodepressive effects in normal rat hearts. European 
Journal of Pharmacology 334, 181-190. 
 
Kojda G, Laursen JB, Ramasamy S, Kent JD, Kurz S, Burchfield J, Shesely EG & 
Harrison DG. (1999). Protein expression, vascular reactivity and soluble 
guanylate cyclase activity in mice lacking the endothelial cell nitric oxide 
synthase: contributions of NOS isoforms to blood pressure and heart rate control. 
Cardiovascular Research 42, 206-213. 
 
Komukai K, O-Uchi J, Morimoto S, Kawai M, Hongo K, Yoshimura M & Kurihara S. 
(2010). Role of Ca2+/calmodulin-dependent protein kinase II in the regulation of 
the cardiac L-type Ca2+ current during endothelin-1 stimulation. American 
Journal of Physiology-Heart and Circulatory Physiology 298, H1902-H1907. 
 
Konorev E, Tarpey M, Joseph J, Baker J & Kalyanaraman B. (1995). S-nitrosoglutathione 
improves functional recovery in the isolated rat heart after cardioplegic ischemic 
arrest-evidence for a cardioprotective effect of nitric oxide. Journal of 
Pharmacology and Experimental Therapeutics 274, 200-206. 
 
Kovács M, Kiss A, Gönczi M, Miskolczi G, Seprényi G, Kaszaki J, Kohr MJ, Murphy E 
& Végh Á. (2015). Effect of sodium nitrite on ischaemia and reperfusion-induced 
arrhythmias in anaesthetized dogs: is protein S-nitrosylation involved? PLoS ONE 
10, e0122243. 
 
Koval OM, Snyder JS, Wolf RM, Pavlovicz RE, Glynn P, Curran J, Leymaster ND, Dun 
W, Wright PJ, Cardona N, Qian L, Mitchell CC, Boyden PA, Binkley PF, Li C, 
Anderson ME, Mohler PJ & Hund TJ. (2012). Ca2+/calmodulin-dependent protein 
 174 
kinase II-based regulation of voltage-gated Na+ channel in cardiac disease. 
Circulation 126, 2084-2094. 
 
Kreusser MM & Backs J. (2014). Integrated mechanisms of CaMKII-dependent 
ventricular remodeling. Frontiers in Pharmacology 5, 36. 
 
Kreusser MM, Lehmann LH, Keranov S, Hoting M-O, Oehl U, Kohlhaas M, Reil J-C, 
Neumann K, Schneider MD & Hill JA. (2014). Cardiac CaM Kinase II genes δ 
and γ contribute to adverse remodeling but redundantly inhibit calcineurin-
induced myocardial hypertrophy. Circulation 130, 1262-1273. 
 
Kruzliak P, Pechanova O & Kara T. (2014). New perspectives of nitric oxide donors in 
cardiac arrest and cardiopulmonary resuscitation treatment. Heart Failure 
Reviews 19, 383-390. 
 
Kubota I, Han X, Opel DJ, Zhao Y-Y, Baliga R, Huang P, Fishman MC, Shannon RP, 
Michel T & Kelly RA. (2000). Increased susceptibility to development of 
triggered activity in myocytes from mice with targeted disruption of endothelial 
nitric oxide synthase. Journal of Molecular and Cellular Cardiology 32, 1239-
1248. 
 
Landstrom AP, Dobrev D & Wehrens XH. (2017). Calcium signaling and cardiac 
arrhythmias. Circulation Research 120, 1969-1993. 
 
Layland J, Li JM & Shah AM. (2002). Role of cyclic GMP‐dependent protein kinase in 
the contractile response to exogenous nitric oxide in rat cardiac myocytes. The 
Journal of Physiology 540, 457-467. 
 
Lebek S, Plößl A, Baier M, Mustroph J, Tarnowski D, Lücht C, Schopka S, Flörchinger 
B, Schmid C & Zausig Y. (2018). The novel CaMKII inhibitor GS-680 reduces 
diastolic SR Ca leak and prevents CaMKII-dependent pro-arrhythmic activity. 
Journal of Molecular and Cellular Cardiology 118, 159-168. 
 
Lefer DJ, Jones SP, Girod WG, Baines A, Grisham MB, Cockrell AS, Huang PL & Scalia 
R. (1999). Leukocyte-endothelial cell interactions in nitric oxide synthase-
deficient mice. American Journal of Physiology-Heart and Circulatory 
Physiology 276, H1943-H1950. 
 
Li C, Cai X, Sun H, Bai T, Zheng X, Zhou XW, Chen X, Gill DL, Li J & Tang XD. 
(2011). The δA isoform of calmodulin kinase II mediates pathological cardiac 
hypertrophy by interfering with the HDAC4-MEF2 signaling pathway. 
Biochemical and Biophysical Research Communications 409, 125-130. 
 
Li J, Gao Q, Wang S, Kang Z, Li Z, Lei S, Sun X, Zhao M, Chen X & Jiao G. (2020). 
Sustained increased CaMKII phosphorylation is involved in the impaired 
 175 
regression of isoproterenol-induced cardiac hypertrophy in rats. Journal of 
Pharmacological Sciences 144, 30-42. 
 
Li L, Chu G, Kranias EG & Bers DM. (1998). Cardiac myocyte calcium transport in 
phospholamban knockout mouse: relaxation and endogenous CaMKII effects. 
American Journal of Physiology-Heart and Circulatory Physiology 274, H1335-
H1347. 
 
Li L, Satoh H, Ginsburg KS & Bers DM. (1997). The effect of Ca2+–calmodulin‐
dependent protein kinase II on cardiac excitation–contraction coupling in ferret 
ventricular myocytes. The Journal of Physiology 501, 17-31. 
 
Liao R, Podesser BK & Lim CC. (2012). The continuing evolution of the Langendorff 
and ejecting murine heart: new advances in cardiac phenotyping. American 
Journal of Physiology-Heart and Circulatory Physiology 303, H156-H167. 
 
Lim Y-C, Budin SB, Othman F, Latip J & Zainalabidin S. (2017). Roselle polyphenols 
exert potent negative inotropic effects via modulation of intracellular calcium 
regulatory channels in isolated rat heart. Cardiovascular Toxicology 17, 251-259. 
 
Lima B, Forrester MT, Hess DT & Stamler JS. (2010). S-nitrosylation in cardiovascular 
signaling. Circulation Research 106, 633-646. 
 
Lindberg T. (2017). Arrhythmias in older people: Focusing on atrial fibrillation. 
Epidemiology and Impact on Daily Life [dissertation] Lund: Lund University. 
 
Ling H, Zhang T, Pereira L, Means CK, Cheng H, Gu Y, Dalton ND, Peterson KL, Chen 
J & Bers D. (2009). Requirement for Ca2+/calmodulin–dependent kinase II in the 
transition from pressure overload–induced cardiac hypertrophy to heart failure in 
mice. The Journal of Clinical Investigation 119, 1230-1240. 
 
Ling WC, Mustafa MR, Vanhoutte PM & Murugan DD. (2018). Chronic administration 
of sodium nitrite prevents hypertension and protects arterial endothelial function 
by reducing oxidative stress in angiotensin II-infused mice. Vascular 
Pharmacology 102, 11-20. 
 
Liu Y, Chenhai Xia, Rutao Wang, Jinglong Zhang, Tao Yin, Yanzuo Ma, and Ling Tao. 
(2017). The opposite effects of nitric oxide donor, S‐nitrosoglutathione, on 
myocardial ischaemia/reperfusion injury in diabetic and non‐diabetic mice. 
Clinical and Experimental Pharmacology and Physiology 44, 854-861. 
 
Liu Y-H, Xu J, Yang X-P, Yang F, Shesely E & Carretero OA. (2002). Effect of ACE 
inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO 
synthase knockout mice with heart failure. Hypertension 39, 375-381. 
 
 176 
Luo M, Guan X, Luczak ED, Lang D, Kutschke W, Gao Z, Yang J, Glynn P, Sossalla S, 
Swaminathan PD, Weiss RM, Yang B, Rokita AG, Maier LS, Efimov IR, Hund 
TJ & Anderson ME. (2013). Diabetes increases mortality after myocardial 
infarction by oxidizing CaMKII. The Journal of Clinical Investigation 123, 1262-
1274. 
 
Maier LS, Zhang T, Chen L, DeSantiago J, Brown JH & Bers DM. (2003). Transgenic 
CaMKIIδC overexpression uniquely alters cardiac myocyte Ca2+ handling: 
reduced SR Ca2+ load and activated SR Ca2+ release. Circulation Research 92, 
904-911. 
 
Marionneau C, Lichti CF, Lindenbaum P, Charpentier F, Nerbonne JM, Townsend RR & 
Mérot J. (2012). Mass spectrometry-based identification of native cardiac NaV1. 
5 channel α subunit phosphorylation sites. Journal of Proteome Research 11, 
5994-6007. 
 
Marquez J, Lee SR, Kim N & Han J. (2016). Post-Translational Modifications of Cardiac 
Mitochondrial Proteins in Cardiovascular Disease: Not Lost in Translation. 
Korean Circulation Journal 46, 1-12. 
 
Massion P & Balligand JL. (2003). Modulation of cardiac contraction, relaxation and rate 
by the endothelial nitric oxide synthase (eNOS): lessons from genetically 
modified mice. The Journal of Physiology 546, 63-75. 
 
Massion P, Feron O, Dessy C & Balligand J-L. (2003). Nitric oxide and cardiac function: 
ten years after, and continuing. Circulation Research 93, 388-398. 
 
Massoudy P, Zahler S, Freyholdt T, Henze R, Barankay A, Becker BF, Braun SL & 
Meisner H. (2000). Sodium nitroprusside in patients with compromised left 
ventricular function undergoing coronary bypass: reduction of cardiac 
proinflammatory substances. The Journal of Thoracic and Cardiovascular 
Surgery 119, 566-574. 
 
Mayer P, Möhlig M, Schatz H & Pfeiffer A. (1994). Additional isoforms of 
multifunctional calcium/calmodulin-dependent protein kinase II in rat heart 
tissue. Biochemical Journal 298, 757. 
 
Mesubi OO, Rokita AG, Abrol N, Wu Y, Chen B, Wang Q, Granger JM, Tucker-Bartley 
A, Luczak ED & Murphy KR. (2020). O-GlcNAcylation, oxidation and CaMKII 
contribute to atrial fibrillation in type 1 and type 2 diabetes by distinct 
mechanisms. BioRxiv. 
 
Ministry of Health. (2017). Mortality and Demographic Data 2015 (provisional) 
[updated: January 2018]. 
 
 177 
Mohamed BA, Elkenani M, Jakubiczka-Smorag J, Buchholz E, Koszewa S, Lbik D, 
Schnelle M, Hasenfuss G & Toischer K. (2019). Genetic deletion of 
calcium/calmodulin-dependent protein kinase type II delta does not mitigate 
adverse myocardial remodeling in volume-overloaded hearts. Scientific Reports 
9, 1-11. 
 
Mohamed BA, Hartmann N, Tirilomis P, Sekeres K, Li W, Neef S, Richter C, Zeisberg 
EM, Kattner L, Didié M, Guan K, Schmitto JD, Lehnart SE, Luther S, Voigt N, 
Seidler T, Sossalla S, Hasenfuss G & Toischer K. (2018). Sarcoplasmic reticulum 
calcium leak contributes to arrhythmia but not to heart failure progression. Science 
Translational Medicine 10, eaan0724. 
 
Mohan P, Brutsaert DL, Paulus WJ & Sys SU. (1996). Myocardial contractile response 
to nitric oxide and cGMP. Circulation 93, 1223-1229. 
 
Mohler PJ & Hund TJ. (2011). Role for CaMKII in cardiovascular health, disease, and 
arrhythmia. Heart rhythm : The Official Journal of the Heart Rhythm Society 8, 
142-144. 
 
Mohri M, Egashira K, Tagawa T, Kuga T, Tagawa H, Harasawa Y, Shimokawa H & 
Takeshita A. (1997). Basal release of nitric oxide is decreased in the coronary 
circulation in patients with heart failure. Hypertension 30, 50-56. 
 
Mollova MY, Katus HA & Backs J. (2015). Regulation of CaMKII signaling in 
cardiovascular disease. Front Pharmacol 6. 
 
Moosavi M, Abbasi L, Zarifkar A & Rastegar K. (2014). The role of nitric oxide in spatial 
memory stages, hippocampal ERK and CaMKII phosphorylation. Pharmacology 
Biochemistry and Behavior 122, 164-172. 
 
Müller‐Strahl G, Kottenberg K, Zimmer HG, Noack E & Kojda G. (2000). Inhibition of 
nitric oxide synthase augments the positive inotropic effect of nitric oxide donors 
in the rat heart. The Journal of Physiology 522, 311-320. 
 
Murphy E, Kohr M, Sun J, Nguyen T & Steenbergen C. (2012). S-nitrosylation: a radical 
way to protect the heart. Journal of Molecular and Cellular Cardiology 52, 568-
577. 
 
Musialek P, Lei M, Brown HF, Paterson DJ & Casadei B. (1997). Nitric oxide can 
increase heart rate by stimulating the hyperpolarization-activated inward current, 
If. Circulation Research 81, 60-68. 
 
Neef S, Sag CM, Daut M, Bäumer H, Grefe C, El-Armouche A, DeSantiago J, Pereira L, 
Bers DM & Backs J. (2013). While systolic cardiomyocyte function is preserved, 
diastolic myocyte function and recovery from acidosis are impaired in CaMKIIδ-
KO mice. Journal of Molecular and Cellular Cardiology 59, 107-116. 
 178 
 
Neef S, Steffens A, Pellicena P, Mustroph J, Lebek S, Ort KR, Schulman H & Maier LS. 
(2018). Improvement of cardiomyocyte function by a novel pyrimidine-based 
CaMKII-inhibitor. Journal of molecular and cellular cardiology 115, 73-81. 
 
Pabla R & Curtis MJ. (1995). Effects of NO modulation on cardiac arrhythmias in the rat 
isolated heart. Circulation Research 77, 984-992. 
 
Paolocci N, Ekelund UE, Isoda T, Ozaki M, Vandegaer K, Georgakopoulos D, Harrison 
RW, Kass DA & Hare JM. (2000). cGMP-independent inotropic effects of nitric 
oxide and peroxynitrite donors: potential role for nitrosylation. American Journal 
of Physiology-Heart and Circulatory Physiology 279, H1982-H1988. 
 
Peng W, Zhang Y, Zheng M, Cheng H, Zhu W, Cao C-M & Xiao R-P. (2010). 
Cardioprotection by CaMKII-δB is mediated by phosphorylation of heat shock 
factor 1 and subsequent expression of inducible heat shock protein 70. Circulation 
Research 106, 102-110. 
 
Pereira L, Bare DJ, Galice S, Shannon TR & Bers DM. (2017). β-Adrenergic induced SR 
Ca2+ leak is mediated by an Epac-NOS pathway. Journal of Molecular and 
Cellular Cardiology 108, 8-16. 
 
Petroff MV, Mundiña-Weilenmann C, Vittone L, de Cingolani GC & Mattiazzi A. (1994). 
Lusitropic effects of α-and β-adrenergic stimulation in amphibian heart. 
Molecular and Cellular Biochemistry 141, 87-95. 
 
Phillips L, Toledo AH, Lopez-Neblina F, Anaya-Prado R & Toledo-Pereyra LH. (2009). 
Nitric oxide mechanism of protection in ischemia and reperfusion injury. Journal 
of Investigative Surgery 22, 46-55. 
 
Poluektov YM, Petrushanko IY, Undrovinas NA, Lakunina VA, Khapchaev AY, 
Kapelko VI, Abramov AA, Lakomkin VL, Novikov MS & Shirinsky VP. (2019). 
Glutathione-related substances maintain cardiomyocyte contractile function in 
hypoxic conditions. Scientific Reports 9, 1-12. 
 
Preckel B, Kojda G, Schlack W, Ebel D, Kottenberg K, Noack E & Thämer V. (1997). 
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APPENDIX A  
A.1 Nitric oxide analysis  
The nitric oxide (NO) donors used were S-nitroso-N-acetylpenicillamine (SNAP, 
Sapphire biosciences) and S-nitrosoglutathione (GSNO, Cayman chemicals). The Apollo 
1000 Free Radical analyser and the ISO-NOPF100 NO microsensor (1 mm) (WPI Florida, 
USA) were used to measure the concentration of NO released in water samples and 
plasma. Data was recorded using Powerlab 2/25 (ADInstruments, Australia). 
The microsensor was immersed in copper (II) chloride solution (0.1 M CuCl2, Merck 
Millipore) to allow for polarisation. The aim of polarisation was to create a potential 
difference between recording electrode relative to the reference electrode, which is 
amplified and recorded when NO is oxidised on the membrane of the probe (Bradley & 
Steinert, 2015). Poise voltage on the Apollo 100 was set at 865 mV, the current range was 
< 8000nA and the data was sampled at 5 Hz. The polarisation time for the microsensor 
was 1 – 2 hrs until a stable baseline was observed. The probe was immersed in a beaker 
containing 20 ml of CuCl2 (0.1 M) and a stirring bar for continuous mixing of the solution. 
For calibration, a stock solution of 100 µM SNAP and 44 µM EDTA (Merck Millipore) 
was prepared on the day. Once the microsensor was polarised and the voltage reached a 
stable baseline, different volumes (64 µl, 128 µl, 256 µl, 512 µl, 1024 µl) of SNAP + 
EDTA solution was added to the CuCl2 solution. After each volume was added, the 
voltage increased and reached a plateau, before the decay, the next volume of SNAP was 
added. The concentration of NO released from the SNAP solution was calculated 
considering the conversion efficiency of SNAP to NO in CuCl2 which is 60% (Bradley 
& Steinert, 2015). For every mole of SNAP, 0.6 mole of NO is liberated. A calibration 
curve of probe voltage against NO concentration was constructed.  
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Figure A.1 Calibration of NO microsensor with SNAP (a) Representative graph 
showing change in probe voltage with addition of SNAP in increasing concentrations. (b) 
Calibration curve for SNAP calibration. 
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A.2 Measurement of nitric oxide release from GSNO 
After calibration, the micro sensor was immersed in a beaker containing Krebs-Henseleit 
(KH) buffer. A baseline current measurement was taken. Thereafter, increasing 
concentrations of GSNO (100 µM, 150 µM, 600 µM, 1600 µM) were added to the buffer. 
Change in current was recorded and used to calculate the concentration of NO released 
from GSNO. The presence of NO was confirmed using a NO scavenger, 100 µM 2-(4-
carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide potassium salt (c-PTIO, 
Cayman Chemical Company). These experiments were repeated three times (Sample 1, 
Sample 2, Sample 3) and performed at room temperature. 
 
Figure A.2 Measurement of NO release in buffer. Results were obtained from three 
samples and NO release in KH buffer was consistent across all samples. Two-way 
ANOVA (uncorrected Fisher’s LSD test) was used to compare between groups.  
















A.3 Contraction and relaxation in WT and KO hearts with acute GSNO 
treatment 
 
Figure A.3 Basal contraction and relaxation parameters in WT and KO mouse 
hearts prior to acute GSNO treatment A, LV Developed Pressure. B, Heart rate. C, 
Maximum rate of contraction (Max dP/dt). D, Minimum rate of relaxation (Min dP/dt). 
E, Arrhythmic events F, Arrhythmia scores. Data are means ± SEM. WT, blue bar, n = 
13 hearts; KO, red bar, n = 10 hearts. Two-way ANOVA (uncorrected Fisher’s LSD test) 

































































































































Figure A.4 Contraction and relaxation parameters in WT and KO mouse hearts 
with GSNO treatment (100 µM, 600 µM and 1600 µM) A, LV developed pressure B, 
Heart rate, C, Max dP/dt, D, Min dP/dt. Data are means ± SEM. WT Control, blue line, n 
= 6 hearts; WT GSNO, green, line, n = 7 hearts; KO Control, red line, n = 5 hearts; KO 
GSNO, purple line, n = 5 hearts. Two-way ANOVA (uncorrected Fisher’s LSD test) was 
used to compare between groups.  
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Figure A.5 Arrhythmias during GSNO treatment (100 µM, 600 µM and 1600 µM) 
in in WT and KO mouse hearts A, Arrhythmic events B, Arrhythmia scores. Data are 
means ± SEM. WT Control, blue line, n = 6 hearts; WT GSNO, green, line, n = 7 hearts; 
KO Control, red line, n = 5 hearts; KO GSNO, purple line, n = 5 hearts. Two-way 
ANOVA (uncorrected Fisher’s LSD test) was used to compare between groups. ** = P < 
0.01 treatment effect ( 0 vs 1600 µM)  
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A.4 Coronary flow in WT and KO hearts during acute GSNO treatment 
 
 
Figure A.6 Coronary flow during GSNO treatment (100 µM, 600 µM and 1600 µM) 
in WT and KO mouse hearts. Data are means ± SEM. WT Control, blue line, n = 6 
hearts; WT GSNO, green, line, n = 7 hearts; KO Control, red line, n = 5 hearts; KO 
GSNO, purple line, n = 5 hearts. Two-way ANOVA (uncorrected Fisher’s LSD test) was 
used to compare between groups.  
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APPENDIX B  
B.1 NO stability in drinking water  
Water bottles were filled with ~ 300 ml of tap water and different concentrations of 
GSNO. The bottles were wrapped with aluminium foil to protect from light and placed in 
the animal cage. 50 ml of each concentration was obtained from each bottle after 1 hour 
and further after 24 and 48 hours, to measure the stability of GSNO in water. 
 
Figure B.1 NO stability in water after 1, 24 and 48 hours. Results were obtained from 
three samples and NO release in KH buffer was consistent across all samples. Two-way 
ANOVA (uncorrected Fisher’s LSD test) was used to compare between groups. * = P < 
0.05, ** = P < 0.01 concentration effect (vs 0 mg/L) 
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B.2 Detection of NO levels in plasma 
To assess NO levels, plasma was obtained after 5 weeks of GSNO treatment. It was 
expected that NO supplementation in drinking water would increase the level of plasma 
NO in the treatment groups. Blood samples (400 – 500 µl) were obtained from the chest 
cavity of the mouse after heart excision using a 1 ml syringe previously washed with 
heparin and collected in a tube. Plasma was obtained after centrifugation at 3000 rcf at 
4oC for 10 min by removing 200 – 250 µl of the supernatant using a Pasteur pipette. NO 
content was detected using a NO sensor which was placed into the tube containing the 
plasma. The current depicting the presence of NO was recorded for 30 minutes and the 
peak value was obtained and calculated as NO concentration, according to the 
manufacturer’s instructions.  
There was no significant change in plasma NO levels between WT and KO (p = 0.23). In 
addition, there was no significant change between the control or treatment group after 5 
weeks of chronic GSNO treatment (p = 0.55) (Figure 4.6B). This result suggested that 
there was no increase in circulating NO in plasma as expected despite  the 5-week GSNO 
treatment.  
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Figure B.2 Quantification of Plasma NO levels with GSNO pretreatment A, 
Representative trace of NO release in plasma B, NO concentration in WT and KO mice 
treated with GSNO. Data are means ± SEM. WT control, white bar, n = 4 hearts; WT 
treatment, black bar, n = 3 hearts; KO control, white bar, n = 7 hearts KO treatment, black 
bar, n = 4 hearts. Two-way ANOVA (uncorrected Fisher’s LSD test) was used to compare 
between animal models and treatment effect.  
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B.3 Contraction and relaxation in WT and KO hearts with chronic GSNO 
treatment 
 
Figure B.3 Basal contraction and relaxation parameters in WT and KO mouse 
hearts after in vivo GSNO supplementation A, LV Developed Pressure. B, Heart rate. 
C, Maximum rate of contraction (Max dP/dt). D, Minimum rate of relaxation (Min dP/dt). 
E, Arrhythmic events F, Arrhythmia scores. Data are means ± SEM. WT Control, n = 6 
hearts; WT GSNO, n = 5 hearts; KO Control, n = 6 hearts; KO GSNO, n = 5 hearts. Two-










































































































































Figure B.4 Contraction and relaxation parameters in WT and KO mouse hearts 
during ex vivo chronic GSNO treatment (100 µM, 600 µM and 1600 µM) A, LV 
developed pressure B, Heart rate, C, Max dP/dt, D, Min dP/dt. Data are means ± SEM. 
WT Control, blue line, n = 6 hearts; WT GSNO, green, line, n = 5 hearts; KO Control, 
red line, n = 6 hearts; KO GSNO, purple line, n = 5 hearts. Two-way ANOVA 
(uncorrected Fisher’s LSD test) was used to compare between groups. * = P<0.05, ** = 
P<0.01, treatment effect (0 vs 1600 µM). 
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B.4 Arrhythmias in WT and KO hearts with chronic GSNO treatment 
              
Figure B.5 Arrhythmias during GSNO treatment (100 µM, 600 µM and 1600 µM) 
in WT and KO mouse hearts A, Arrhythmic events B, Arrhythmia scores. Data are 
means ± SEM. WT Control, blue line, n = 6 hearts; WT GSNO, green, line, n = 6 hearts; 
KO Control, red line, n = 6 hearts; KO GSNO, purple line, n = 5 hearts. Two-way 
ANOVA (uncorrected Fisher’s LSD test) was used to compare between groups.  





















































B.5 Coronary flow in WT and KO hearts during chronic GSNO treatment 
 
 
Figure B.6 Coronary flow during chronic GSNO treatment (100 µM, 600 µM and 
1600 µM) in WT and KO mouse hearts Data are means ± SEM. WT Control, blue line, 
n = 6 hearts; WT GSNO, green, line, n = 7 hearts; KO Control, red line, n = 5 hearts; KO 
GSNO, purple line, n = 5 hearts. Two-way ANOVA (uncorrected Fisher’s LSD test) was 
used to compare between groups. 
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APPENDIX C  
C.1 Coronary flow in WT hearts during ISO treatment 
 
 
Figure C.1 Coronary flow during acute ISO treatment (100 nM) in WT and KO 
mouse hearts Data are means ± SEM. Order of treatment; left to right. ISO-GSNO, Wild-
type hearts, n = 6, CaMKIIδ-KO hearts, n = 4. Two-way ANOVA (uncorrected Fisher’s 
LSD test) was used to compare between groups: * = p < 0.05, ** = p < 0.01, *** = p < 
0.001, * = Drug vs baseline. 
 
 
